






















































































































4.2.  Agreement  between  TOAST  and  CCS  ischemic  stroke  classification:  the 
NINDS SiGN Study  64 















AF      Atrial fibrillation 
Ago      Argonaute 
BNP      Brain natriuretic peptide 
CCS      Causative classification of stroke 
CT      Computed tomography 
ESUS      Embolic stroke of undetermined source 
GWAS      Genome‐wide association study 
HC      Healthy control subject 
HS      Hemorrhagic stroke 
IS      Ischemic stroke 
miRNA     microRNA 
mRNA      messenger RNA 
MRI      Magnetic resonance imaging 
MT      Mechanical thrombectomy 
Nt      Nucleotide 
rt‐PA      Recombinant tissue plasminogen activator 
SNP      Single‐nucleotide polymorphism 
TBI      Traumatic brain injury 








biomarkers  supporting  clinical  decision‐making  in  ischemic  stroke  (IS).  Consequently, 
treatment decisions are based on delayed hospital‐based neuroimaging  in the acute phase 




as  an  early  diagnostic  marker,  2)  determine  the  agreement  between  two  established 
classification systems for stroke etiology, and 3)  identify genetic variants associated with  IS 
and its etiological subtypes. 
First,  using  RNA  sequencing  and  qRT‐PCR  in  three  independent  samples  (N=492)  we 
established a  set of  three circulating miRNAs, miR‐125a‐5p, miR‐125b‐5p and miR‐143‐3p, 






association of  large artery stroke with a  locus near TSPAN2 and confirmed  four previously 












as evidenced by either objectives  like pathology and  imaging or duration of  symptoms of 
more than 24 hours.1 Stroke, 85 % being ischemic, is the second leading cause of death and a 
major  contributor  to  long‐term  disability  and  dementia.2 Hypertension,  diabetes mellitus, 
cigarette smoking, and atrial fibrillation (AF) among others have been identified as important 
risk  factors.3  IS  is  mostly  caused  by  an  embolus  occluding  a  more  distal  vessel  with 




glucose  to  the  brain  leads  to  failure  of  ion  pumps  as  well  as  reuptake  mechanisms. 




Systemically administered recombinant  tissue plasminogen activator  (rt‐PA) represents  the 
only  approved  drug  for  patients with  IS  in  the  acute  phase.  Catalyzing  the  conversion  of 
plasminogen to plasmin, which in turn degrades fibrin, rt‐PA is intended to resolve the blood 
clot and eventually lead to reperfusion. Recently, it was shown that patients with occlusions 
of  arteries  of  the  proximal  anterior  circulation  further  benefit  from  interventional 
endovascular mechanical thrombectomy (MT) compared to standard medical care.7 
3.1.1. Genetics of IS 
In  the  general  population,  prior  stroke  in  a  first‐degree  relative  increases  stroke  risk  by 
30 %.8 Hereditary  factors contribute to stroke risk through several distinct mechanisms: 1) 
rare  single  gene  mutations  causing  familial  disorders  with  stroke  being  the  primary 
manifestation  (e.g. cerebral autosomal dominant arteriopathy with subcortical  infarcts and 
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leukoencephalopathy  (CADASIL)),  2)  single  gene mutations  causing  familial  disorders with 
stroke being one of many manifestations  (e.g. Marfan  syndrome), 3)  common  variants of 
genetic polymorphisms  associated with  an  increase  in  stroke  risk  (e.g.  rs11984041  at  the 
HDAC9  locus  for  large  artery  atherosclerosis‐related  stroke),  and  4)  genetic  variability 
associated with risk factors for IS, e.g. AF, diabetes mellitus, and hypertension (reviewed by 
Boehme et al.)9. 
Studying  associations of  genetic  variants  in  the whole  genome with  a distinct phenotype, 





European  origin  with  more  than  6.000  patients  with  IS  and  30.000  control  subjects, 
Gretarsdottir and colleagues associated  two SNPs close  to  the PITX2  locus, known  to be a 
regulator of the development of the sinoatrial node, with cardioembolic stroke.10 Next, three 
of  the  top  ten SNPs  from  this  study were  investigated  in eight  independent  samples  from 




collaboration  within  the  International  Stroke  Genetics  Consortium.12  The  METASTROKE 
consortium  identified  12q24.12,  the  first  locus  being  associated with  all  IS  rather  than  a 
specific  stroke  subtype.13  Studying  a  larger  number  of  patients  with  less  phenotypic 
heterogeneity may lead to the identification of even more loci associated with IS subtypes. 
3.1.2. Stroke etiology 
The decision  for secondary prevention of  IS patients depends on  the determination of  the 
etiology  of  the  individual  patient’s  IS.  Accordingly,  classification  systems  have  been 





brainstem  infarcts,  stroke  of  other  determined  etiology,  e.g.  arterial  dissection,  and 
undetermined  etiology.14  Using  this  classification  system,  approximately  25  %  of  IS  are 
categorized  as  large  artery  atherosclerosis,  30 %  as  cardioembolic,  10 %  as  small‐artery 
occlusion and 5 % as other defined etiology. In approximately 30 % of IS patients the etiology 
cannot  be  determined.15  The more  recent  causative  classification  of  stroke  (CCS),  a web‐
based algorithm, has adapted the TOAST criteria and assigned categorical probabilities. In a 
limited  number  of  patients,  this  tool  minimized  the  classification  into  the  category 
“undetermined”  to  4  %.16  Both,  the  agreement  between  TOAST  and  CCS  and  the 
classification performance of CCS, have not been determined in a larger sample. 
Determination of stroke etiology subsequently guides secondary prevention. In a simplified 
way, patients with  IS due  to AF,  responsible  for  the majority of cardioembolic events, are 
treated with  anticoagulating  agents, whereas  patients with  IS  due  to  non‐cardioembolic 
causes are mostly treated with antiplatelet agents. 
3.1.3. Diagnostic measures of IS 
To put  this work  in a more general  framework of diagnostics  in  IS and  to be able  to  later 
identify novel prospects for blood‐based biomarker in this context I will here introduce some 
stroke‐specific  diagnostic  questions  whose  answers  would  guide  therapeutic  decision 
making.  
In  order  to  identify  patients  eligible  for  rt‐PA:  are  currently  applied  tests  for  the 
identification  of  patients  with  hemorrhagic  stroke  (HS)  fast  and  reliable?  Computed 
tomography (CT)  is the method of choice to detect  intracranial hemorrhages.  Its sensitivity 
for  this question approximates 100 %,  its acquisition within  the hospital  is cheap and  fast.  
Magnetic  resonance  imaging  (MRI)  offers  equal  sensitivity  and  depending  on  the  chosen 
modalities the possibility to gain more information about the potentially underlying disease, 
but should only be applied in the acute phase if, compared to CT, causing no delay.17,18 Both 





CT‐angiography  is  the method  of  choice  to  visualize  supraaortic  vessels  in  patients with 
suspected acute  IS and therefore to  identify occlusions of arteries of the proximal cerebral 
circulation with a sensitivity higher than 90 %.17,18 Given the restriction of MT to specialized 
stroke  centers,  the prehospital decision process  includes  the  following question:  should  a 
patient with suspected acute IS be transferred to the nearest local stroke unit with available 
CT  and  subsequent  rt‐PA  application  and  in  case  of  a  proximal  arterial  occlusion  be 
transferred  a  second  time  to  a  specialized  stroke  center  for MT or  should  the patient be 
directly  transferred  to  the  specialized  stroke  center  with  a  resulting  delay  in  systemic 
thrombolysis and uncertainty  if MT  is needed at all? Currently,  it  is not possible to  identify 
patients with an occlusion of an artery of the proximal anterior circulation in the prehospital 
setting. 
In  order  to  guide  secondary  prevention:  are  currently  applied  tests  sensitive  and  specific 
enough  to  distinguish  patients  with  IS  from  patients  with  other  diseases  causing  acute 
neurological  dysfunction?  MRI  offers  >  90  %  sensitivity  and  high  specificity  for  the 
identification  of  cerebral  infarction  and  is  also  more  accurate  in  describing  size  and 
localization  of  infarcted  areas  compared  to  CT.17  Clinically  suspected  but  MRI  negative 
ischemic strokes are mostly assumed to be brainstem or lacunar infarctions smaller than the 
typical  3  or  5  mm  MRI  sections  (Stroke  2008,  Sylaja).  However,  MRI  is  an  expensive 
technique, not available for every patient, especially not in third‐world countries. 
In  order  to  guide  secondary  prevention:  are  currently  applied  tests  sensitive  and  specific 
enough to identify stroke etiology? Current guidelines for secondary prevention mainly pose 
two questions  to  guide  treatment decisions. 1) Does  the patient have  a  stenosis of more 
than 70 % based on  the NASCET  criteria of  the  internal  carotid artery? This question  can 
accurately  be  answered  by  duplex‐/doppler‐sonography  and  CT‐angiography.  2)  Did  the 
cerebral  vessel  occlusion  result  from  cardioembolism  or  more  specifically  AF? 
Electrocardiography  shows  almost  100 %  sensitivity  for  AF. However, many  AF  cases  are 




recent  studies  suggest  that AF  could  also  be  an  epiphenomenon  and  not  necessarily  the 
cause. For example, no temporal association was found between IS onset and subclinical AF 
episodes in patients with implantable pacemakers and defibrillators.20 Therefore, it has been 
increasingly  questioned  how  and when  the  embolus  actually  evolves  in  patients with AF. 








the  intermediate  filament  glial  fibrillary  acidic  protein  (GFAP)  increase  very  early  after 
intracerebral hemorrhage.21 Showing also increased levels in the subacute phase of IS, GFAP 
was demonstrated to have highest value  in differentiating HS  from  IS up to six hours after 
symptom onset. Although the proposed sensitivity (39 – 91 %) and specificity (96 ‐ 100 %) of 




sets  have  been  studied  regarding  their  value  in  detecting  these  occlusions  yet.  Available 
point‐of‐care‐testing  of  blood‐based  biomarkers  in  the  preclinical  setting  could  result  in 
more accurate and faster decisions, e.g. about whether the patient should be transferred to 
a  stroke  center  with  endovascular  thrombectomy  service  or  to  a  local  stroke  unit  for 
immediate thrombolysis. 
What  is  the value of blood‐based biomarkers  to distinguish patients with  IS  from patients 
with  other  diseases  causing  acute  neurological  dysfunction?  To  address  this  question, 
previous studies mainly focused on targeted protein analysis. Both, single cerebral proteins, 




What  is  the  value  of  blood‐based  biomarkers  to  identify  stroke  etiology?  Differentiating 
cardioembolic from non‐cardioembolic stroke remains the key question in guiding secondary 








proteins,  but  exert  a  posttranscriptional  regulatory  function.  Accordingly,  they  are 
categorized  as  short,  non‐coding,  regulatory  RNAs.  Canonical  multilevel  biogenesis  is 
initiated by RNA polymerase II‐transcription into primary miRNAs and subsequent liberation 
of a  stem‐loop precursor miRNA of 60‐70 nt  length  through endoribonucleolytic cleavage. 
Export to the cytoplasm is followed by a second endoribonucleolytic reaction into a ~ 22 nt 
RNA  duplex  consisting  of  the  guide  strand  (the mature miRNA)  and  a  quickly  degraded 
passenger strand (reviewed by Bartel, Mendell and Olson, and Yates et al.)33‐35.  
Mature  miRNAs  exert  their  posttranscriptional  regulatory  function  as  a  specificity 
determinant  to messenger RNAs  (mRNAs)  for Argonaute  (Ago) proteins within  the miRNA‐
induced  silencing  complex.  While  fully  complementary  mRNAs  are  cleaved,  partially 
complementary  targets  are  subject  to  a  combination  of  translational  repression, 
deadenylation,  decapping  and  5’‐to‐3’‐degradation.  The  recognition  of  partially 




have been  shown  to be  involved  in numerous pathophysiological processes and  therefore 
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lipoproteins,44  or  present  within  extracellular  vesicles,  e.g.  exosomes,45  miRNAs  exert 
remarkable stability within this RNase‐rich compartment, but also during storage and freeze‐
thaw  cycles.41  Their  use  as  diagnostic  and  prognostic  biomarkers  has  been  studied  in 




Showing  cell‐type  specific  expression  patterns,  circulating  miRNAs  may  reflect 






Up  to  50 %  of  patients with  acute  ischemic  stroke  (IS)  lack  abnormalities  on  admission 
computed  tomography  (CT)  scans.  The  diagnostic  value  of  single  protein  blood‐based 
biomarkers  in  the acute phase of  IS  is  limited. The cell‐type  specific expression pattern of 
microRNAs (miRNAs) and their high stability in blood promise potential diagnostic utility for 
multiple  disease  entities. We  hypothesized  that  a  set  of miRNAs might  better  reflect  the 
different  pathophysiological  processes  of  IS  such  as  platelet  aggregation,  endothelial 
dysfunction,  neuronal  and  glial  injury,  and  immunological  reactions  compared  to  a  single 
biomarker.  
Using  RNA  sequencing  and  qRT‐PCR  in  three  independent  patient  samples  (N=260  IS 
patients) we established a set of  three circulating miRNAs, miR‐125a‐5p, miR‐125b‐5p and 
miR‐143‐3p, which were  elevated  in  the  acute  phase  of  IS  compared  to  healthy  control 
subjects  (HC)  or  patients  with  transient  ischemic  attacks  (TIA).  Longitudinal  analysis  of 
expression levels up to 90 days after IS revealed continuously elevated levels of miR‐125a‐5p, 
while levels of miR‐125b‐5p and miR‐143‐3p normalized to control levels starting at day two. 
The  levels  of  these  miRNAs  were  unaffected  by  chemical  hypoxia  in  N2a  cells  and  in 
experimental  stroke models,  but  depended  on  platelet  numbers  in  spike‐in  experiments 









Stroke is the leading cause of long-term disability and the second most common cause of death worldwide with 
≈80% of cases attributed to ischemia.1 Currently, the diagnosis 
of ischemic stroke (IS) on hospital arrival is often reduced to 
the exclusion of hemorrhagic stroke by computed tomography 
(CT), and 40% to 50% of all acute IS cases lack abnormali-
ties on admission CT scans.2,3 The diagnostic value of blood 
biomarkers in acute IS is still limited.4 Previous attempts 
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to define markers of IS mostly focused on proteins, such as 
neuron-specific enolase,5 glial fibrillary acidic protein,6 S100 
calcium-binding protein B,7 or interleukin 6.8 However, these 
markers all either show limited specificity or substantial de-
lays in response to acute brain injury.4
Editorial, see p 905 
In This Issue, see p 893 
Meet the First Author, see p 894
MicroRNAs represent a class of small noncoding RNAs, 
which have widely been studied for their intracellular role in 
post-transcriptional modification.9 They can also be released 
into the circulation, where they are present in extracellular 
vesicles or bound to protein complexes.10,11 Because of their 
stability in peripheral blood and cell type–specific expression 
patterns, microRNAs show promise as diagnostic and prog-
nostic markers for multiple disease entities.12–14
IS might impact on expression levels of circulating mi-
croRNAs through various simultaneously occurring patho-
physiological processes, including platelet aggregation, 
endothelial dysfunction, neuronal and glial injury, as well as 
immunologic reactions.15–19 Hence, a signature of microRNAs 
resulting from different pathophysiological events could have 
higher diagnostic accuracy than single biomarkers. However, 
there is no analysis of the complete profile of microRNAs in 
the acute phase of IS immediately after hospital arrival.
The aim of the current study was to (1) identify differen-
tially regulated circulating microRNAs after acute IS using 
RNA sequencing, (2) validate and replicate findings in 2 inde-
pendent samples, (3) characterize their temporal profile during 
hospitalization and up to 90 days after IS, and (4) investigate 
their potential utility as a biomarker for acute IS. We further 
obtained data on the cellular source and the extracellular mode 
of transportation of differentially expressed microRNAs.
Methods
An expanded Methods section is available in the Online Data 
Supplement.
Study Population
Patients with suspected IS were recruited within 24 hours of symptom 
onset through the emergency department of a tertiary level university 
hospital. Blood samples (nonfasting) were collected before the receipt 
of any medication. All patients had a final diagnosis of IS as defined 
by an acute focal neurological deficit in combination with a diffusion-
weighted imaging–positive lesion on magnetic resonance imaging or a 
new lesion on a delayed CT scan. Transient ischemic attack (TIA) was 
defined as acute onset transient symptoms (lasting <24 hours) with-
out evidence of infarction on neuroimaging.20 The discovery sample 
included 20 patients with IS and 20 healthy control subjects (HCs). 
Validation was done in 40 patients with IS and 40 HCs. The replication 
sample consisted of 200 patients with IS and 100 HCs. HCs from the 
discovery and validation sample were matched to patients with IS for 
age, sex, hypertension, smoking history, hypercholesterolemia, obe-
sity, diabetes mellitus, family history, and use of antiplatelet therapy. 
We further studied 72 patients with TIA.
Discovery Analysis Using RNA Sequencing
RNA <1000 nucleotides was isolated from 2 plasma aliquots of 200 
µL using the miRCURY RNA Isolation Kit—Biofluids (Exiqon; 
Online Data Supplement). Reverse transcription was performed with 
the miScript Reverse Transcription kit (Qiagen) according to the 
manufacturer’s protocols in a 10 μL reaction. A total of 500 ng of 
RNA prepared from the plasma samples was used in the small RNA 
protocol with the TruSeq Small RNA sample prepkit v2 (Illumina) 
following the instructions of the manufacturer. For details, see Braun 
Nonstandard Abbreviations and Acronyms
AUC area under the curve
CT computed tomography
HC healthy control subject
IS ischemic stroke
TIA transient ischemic attack
Novelty and Significance
What Is Known?
• Up to 50% of patients with acute ischemic stroke (IS) lack abnormali-
ties on admission computed tomographic scans, currently the gold 
standard for diagnostic evaluation.
• Protein markers of brain injury show limited diagnostic value as blood-
based biomarkers in the acute phase of IS.
• MicroRNAs exhibit cell type–specific expression patterns and high sta-
bility in peripheral blood.
What New Information Does This Article Contribute?
• Expression levels of circulating miR-125a-5p, miR-125b-5p, and miR-
143-3p are elevated in the acute phase of IS.
• Human platelets are a major source of these microRNAs, whereas 
neuronal injury does not contribute to their levels in experimental 
paradigms.
• The combination of all 3 microRNAs shows unprecedented diagnostic 
utility for a blood-based biomarker in the acute phase of IS and outper-
forms routine multimodal computed tomography.
Previous studies have demonstrated the limited diagnostic value 
of single protein markers in the acute phase of IS. Because of 
their cell type–specific expression pattern, microRNAs show 
promise as diagnostic markers for multiple disease entities. 
We hypothesized that a set of microRNAs might better reflect 
pathophysiological processes of IS, such as platelet aggregation, 
endothelial dysfunction, neuronal and glial injury, and immuno-
logic reactions. Using RNA sequencing and quantitative real-time 
polymerase chain reaction in 3 independent patient samples, we 
established a set of 3 circulating microRNAs, which was elevated 
in the acute phase of IS. Their levels were unaffected in 2 experi-
mental stroke models and after neuronal injury in vitro but de-
pended on platelet numbers in spike-in experiments, suggesting 
a relationship to platelet aggregation or thrombus formation. The 
combination of all 3 microRNAs showed unprecedented diagnos-
tic utility for a blood-based biomarker in the acute phase of IS 
and outperformed routine multimodal computed tomography. Our 
findings encourage studies in even larger patient populations to 
determine the full potential of these microRNAs in guiding clinical 
decision making.
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et al.21 The barcoded libraries were size restricted between 140 and 
165 base pairs for additional enrichment of microRNAs, purified, and 
quantified using the Library Quantification Kit-Illumina/Universal 
(KAPA Biosystems, Woburn, MA) according to the instructions of 
the manufacturer. Libraries were pooled at a concentration of 10 
nmol/L for cluster generation using an Illumina cBot. Sequencing 
of 50 base pairs was performed with an Illumina HighScan-SQ se-
quencer at the sequencing core facility of the IZKF Leipzig (Faculty 
of Medicine, University Leipzig) using version 3 chemistry and flow 
cell following the instructions of the manufacturer.
RNA Sequencing Data Analysis
Demultiplexing of raw reads, adapter trimming, and quality filtering 
were done according to Stokowy et al.22 Further analysis was based 
on bowtie2 alignment to the sequence of the human genome (hg19) 
allowing 1 mismatch and alignments to multiple reference targets. 
MicroRNA sequences were named in concordance with miRBase 20. 
R packages DESeq223 and EdgeR24 were used to normalize counts 
and calculate differential expression of microRNAs.
Results
Characteristics of the Study Sample
Patients and control subjects included in the discovery samples 
were matched with respect to all variables except for glucose 
levels. The validation samples were matched for demographic 
and vascular risk factors, as well as previous use of antiplate-
let medication. The mean times from symptom onset to blood 
sampling in the discovery, validation, and replication sample 
were 3.9, 6.1, and 5.0 hours, respectively (Table 1). Stroke 
pathogeneses in the 260 patients with IS included large-artery 
atherosclerosis (23.5%), cardioembolism (30.4%), small-ves-
sel occlusion (6.9%), and arterial dissection (2.3%). In 36.9% 
of the patients, the pathogenesis remained undetermined.
Profiling of Circulating MicroRNAs in Acute Stroke
To determine the profile of circulating microRNAs associated 
with IS in the acute phase, we first performed RNA sequenc-
ing in the discovery sample (Figure 1A). Sequencing of small 
RNAs isolated from platelet-poor plasma revealed a median 
read count of 8.1 million both in patients with IS (interquartile 
range, 6.8–8.5 million) and in HCs (interquartile range, 5.6–9.5 
million; for individual sample characteristics, see Online Table 
I). Overall, we detected 532 mature microRNAs with a mini-
mum of 5 reads in all 40 samples. To identify differentially ex-
pressed microRNAs, we applied 2 independent strategies for the 
normalization of read counts, DESeq223 and EdgeR.24 Thirty-
two mature microRNAs showed a false discovery rate–adjusted 
P<0.05 in both normalized data sets (Figure 1B; Table 2). This 
selection was independent of microRNA abundance (Online 
Figure I). Twenty-eight of these microRNAs were downregu-
lated and 4 were upregulated in patients with IS compared with 
HCs. The microRNA reads per sample (raw and normalized) 
and microRNA statistics (EdgeR and DESeq2) are presented in 
Online Table IIa and IIb, respectively.
Validation of Differentially Expressed MicroRNAs
Next, we examined these 32 microRNAs in an independent 
validation sample using quantitative real-time polymerase chain 
reactions (Figure 1A). Twenty-two microRNAs passed pre-
specified quality criteria (Table 2). Six of these microRNAs were 
differentially regulated after stroke (P<0.00227 after Bonferroni 
correction). Three of them showed consistent directionality with 
the RNA sequencing results in the discovery sample. They were 
all upregulated in patients with IS compared with HCs: miR-143-
3p (4.77±0.70-fold, mean±SEM; P=7.8×10–9), miR-125b-5p 
(2.54±0.36-fold; P=5.6×10–6), and miR-125a-5p (1.80±0.16-
fold; P=1.5×10–6; Figure 2A; for other microRNAs, see Online 
Figure II). The results remained stable when using unadjusted 
raw values and when excluding subjects with previous major 
cardiovascular events (Online Figure III). The results were also 
stable when comparing microRNA copy numbers per microliter 
plasma from HCs and patients with IS from the combined dis-
covery and validation sample (Online Figure IVA and IVB; for 
additional control experiments, see Online Figures V and VI).
Replication of miR-125a-5p, miR-125b-5p, and 
miR-143-3p
To further solidify these results, we next examined circulating 
levels of miR-125a-5p, miR-125b-5b, and miR-143-3p in an 
independent sample of 200 patients with IS and 100 HCs with 
additional adjustment for covariates (Figure 1A). Relevant 
covariates were identified by backward stepwise regression 
analysis and included age, sex, hypertension, major cardio-
vascular events, antiplatelet therapy, and usage of calcium 
channel blockers, as well as creatinine, platelet, red blood cell, 
and white blood cell counts. All 3 microRNAs showed sig-
nificantly elevated expression levels in patients with IS com-
pared with HCs (miR-125a-5p: P=1.1×10–7; miR-125b-5p: 
P=8.2×10–9; miR-143-3p: P=2.4×10–9; Figure 2B). They were 
also elevated in patients with IS when compared with patients 
with TIA (miR-125a-5p: P=0.003; miR-125b-5p: P=0.003; 
miR-143-3p: P=0.005; n=72; Figure 2B).
Temporal Profile of miR-125a-5p, miR-125b-5p, 
and miR-143-3p During Hospitalization and up to 
90 Days After Stroke
To further explore the utility of circulating miR-125a-5p, miR-
125b-5p, and miR-143-3p as biomarkers acutely or chroni-
cally after stroke, we measured their plasma concentration at 
the first, second, third, and seventh day of hospitalization and 
at 90 days post-stroke. Thirty-two patients provided data for 
at least 4 time points and thus served as our study sample. We 
found significant changes in expression levels over time for 
all 3 microRNAs compared with 32 controls (all P<0.0001). 
In all cases, expression levels declined from admission (day 1) 
to day 2 after stroke (miR-125a-5p: P=0.0215; miR-125b-5p: 
P<0.0001; miR-143-3p: P<0.0001; Figure 3). Expression lev-
els of miR-125a-5p subsequently increased until day 90 after 
stroke and were at all time points significantly higher than in 
HCs. In contrast, expression levels of miR-143-3p remained 
low after day 2 with no significant difference compared with 
controls. Likewise, expression levels of miR-125b-5p also 
showed no significant difference compared with controls 
starting from day 2. Polynomial regression of microRNA ex-
pression levels with exact time points since symptom onset in 
hours revealed peaks of expression at 2.3 hours (miR-143-3p), 
4.6 hours (miR-125b-5p), and 6.5 hours (miR-125a-5p; Online 
Figure VII). Matched data analysis for changes in expression 
levels over time revealed significant differences for miR-
125b-5p (P=1.5×10–7) and miR-143-3p (P=3.4×10–6). In gen-
eralized linear mixed models, miR-125b-5p and miR-143-3p 
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Table 1. Demographic and Clinical Characteristics of the Discovery, Validation, and Replication Sample
Characteristics
Discovery Sample Validation Sample Replication Sample
IS Patients HCs IS Patients HCs IS Patients HCs TIA Patients
Demographic characteristics
  Total, n 20 20 40 40 200 100 72
  Age, mean (SD), y 74.7 (9.7) 72.7 (10.1) 74.7 (13.8) 69.7 (8.8) 74.1 (13.4) 65.6 (13.4) 74.8 (12.4)
  Female, n (%) 12 (60) 10 (50) 18 (45) 24 (60) 87 (43.5) 65 (65) 39 (54.2)
Vascular risk factors, n (%)
  Hypertension 16 (80) 10 (50) 34 (85) 26 (65) 157 (78.9) 35 (35) 54 (75)
  Smoking history 8 (40) 9 (45) 20 (50) 12 (30) 74 (40.4) 35 (35) 30 (44.8)
  Hypercholesterolemia 5 (25) 3 (15) 11 (27.5) 10 (25) 55 (27.8) 21 (21) 34 (47.2)
  Obesity 5 (25) 1 (5) 6 (15) 6 (15) 28 (20.9) 19 (19.2) 13 (21.7)
  Diabetes mellitus 4 (20) 0 (0) 4 (10) 2 (5) 36 (18.2) 6 (6) 18 (25.4)
  Previous TIA/stroke/MI 0 (0) 0 (0) 13 (32.5) 2 (5) 65 (32.8) 7 (7) 35 (48.6)
  Family history 5 (25) 2 (10) 6 (15) 2 (5) 23 (12.8) 9 (9) 9 (13.4)
Laboratory parameters, mean (SD)*
  Glucose, mg/dL 127.8 (30.1) 99.2 (20.1) 129.3 (38.8) 98.5 (20.7) 130.9 (41.6) 102.7 (27.5) 119.8 (34.2)
  Creatinine, mg/dL 1.0 (0.2) 1.0 (0.2) 1.1 (0.3) 1.0 (0.2) 1.2 (0.4) 1.0 (0.2) 1.1 (0.4)
  hs-CRP, mg/dL 0.7 (1.6) 0.4 (0.4) 0.5 (0.5) 0.2 (0.3) 1.3 (2.6) 0.3 (0.4) 0.7 (2.1)
  AST, U/L 24.7 (6.7) 26.2 (5.4) 31.0 (15.9) 27.6 (7.7) 26.4 (11.5) 25.6 (7.1) 23.2 (5.8)
  ALT, U/L 21.1 (9.1) 21.3 (6.6) 19.4 (12.6) 23.8 (9.6) 22.5 (16.1) 23.3 (11.7) 20.8 (12.2)
  γ-GT, U/L 42.6 (41.6) 26.1 (12.6) 24.1 (7.0) 35.3 (30.9) 45.5 (46.9) 30.8 (25.3) 44.1 (73.8)
  Total cholesterol, mg/dL 208.2 (29.7) 222.3 (36.7) 185.8 (46.1) 226.3 (48.3) 185.4 (48.0) 230.7 (49.8) 193.4 (48.6)
  Triglycerides, mg/dL 113.5 (40.3) 134.7 (66.0) 104.8 (60.7) 159.1 (71.3) 127.8 (86.1) 173.6 (195.4) 145.0 (73.3)
  LDL, mg/dL 134.8 (30.3) 136.9 (23.8) 120.9 (36.3) 144.2 (41.2) 117.9 (39.2) 143.3 (43.3) 123.1 (42.7)
  HDL, mg/dL 57.2 (14.1) 67.0 (23.8) 49.6 (12.3) 59.4 (16.8) 49.4 (13.7) 62.3 (16.4) 48.4 (14.6)
  WBC count, G/L 7.8 (2.6) 6.7 (1.8) 7.7 (2.2) 6.1 (1.6) 9.3 (3.3) 6.6 (1.6) 7.2 (1.7)
  RBC count, T/L 4.7 (0.5) 4.7 (0.4) 4.5 (0.5) 4.7 (0.5) 4.5 (0.6) 4.7 (0.4) 4.5 (0.5)
  Hemoglobin, g/dL 14.8 (1.5) 14.2 (0.9) 13.6 (1.6) 14.1 (1.0) 13.7 (1.9) 14.3 (1.1) 13.7 (1.5)
  Hematocrit 0.43 (0.04) 0.42 (0.03) 0.40 (0.05) 0.42 (0.03) 0.40 (0.05) 0.42 (0.03) 0.40 (0.04)
  Platelets, G/L 210.6 (51.2) 233.9 (60.3) 231.5 (64.8) 240.6 (57.9) 234.8 (79.8) 247.7 (53.8) 217.7 (51.2)
Medication, n (%)
  Statins 5 (25) 3 (15) 11 (27.5) 10 (25) 67 (34.2) 24 (24) 34 (47.9)
  ACE I/ARBs 10 (50) 8 (40) 23 (57.5) 15 (37.5) 110 (56.4) 23 (23) 43 (60.6)
  β-Blockers 3 (15) 3 (15) 18 (45) 15 (37.5) 91 (46.7) 19 (19) 23 (32.4)
  Diuretics 4 (20) 3 (15) 18 (45) 5 (12.5) 72 (36.9) 9 (9) 19 (26.8)
  Calcium channel blockers 8 (40) 3 (15) 10 (25) 2 (5) 38 (19.5) 3 (3) 14 (19.7)
  Antiplatelet therapy 0 (0) 0 (0) 18 (45) 16 (40)† 66 (33.5) 18 (18) 33 (46.5)
ΔT, mean (SD), h 3.9 (3.6) n/a 6.1 (4.4) n/a 5.0 (4.6) n/a 6.0 (6.4)
Infarct volumes, mean (SD), mL 18.7 (45.3) n/a 18.6 (38.9) n/a 30.8 (68.3) n/a n/a
γ-GT indicates γ-glutamyl transpeptidase; ΔT, time from symptom onset until hospital arrival; ACE I, angiotensin-converting enzyme inhibitor; ALT, alanine 
transaminase; ARBs, angiotensin II receptor blockers; AST, aspartate transaminase; HCs, healthy control subjects; HDL, high-density lipoprotein; Hs-CRP, high-
sensitivity C-reactive protein; IS, ischemic stroke; LDL, low-density lipoprotein; MI, myocardial infarction; n/a, not available; RBC, red blood cell; TIA, transient ischemic 
attack; and WBC, white blood cell.
*Blood was sampled in nonfasting condition.
†Sixteen of 40 control subjects in the validation group indicated use of aspirin (acetylsalicylic acid) on a regular basis or at least once within the last 7 days while other 
antiplatelet drugs were not used. Indications for aspirin use were coronary artery disease (n=4) and pain (n=4) while the indication was not specified in the remaining 
8 subjects.
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were associated with stroke severity during hospitalization 
(day 1–7) as assessed by the National Institutes of Health 
stroke scale (miR-125b-5p: F=7.587, P=0.007; miR-143-3p: 
F=9.636, P=0.003; miR-125a-5p: F=0.855, P=0.358).
Relationship of Circulating MicroRNA Levels With 
Stroke Pathogenesis and Infarct Volume
To determine the relationship between circulating microR-
NAs and stroke pathogenesis, patients from the combined 
discovery and validation sample (n=60) and the replication 
sample (n=200) were stratified according to the Trial of Org 
10172 in Acute Stroke Treatment classification system.25 In 
both samples, levels of miR-125a-5p, miR-125b-5p, and 
miR-143-3p were similar across etiologic subgroups. This 
particularly applied to patients with large vessel stroke 
(n=61), cardioembolic stroke (n=79), and stroke of unde-
termined pathogenesis (n=96), whereas sample sizes for 
small-vessel stroke (n=18) and stroke of other determined 
Figure 1. Study profile and RNA sequencing results. A, Workflow illustrating the 3-stage approach involving independent samples for 
discovery, validation, and replication. B, Volcano plot showing RNA sequencing results for the comparison of ischemic stroke patients vs 
healthy controls. The dashed line indicates a false discovery rate (FDR)–adjusted P value of 0.05. Individual microRNAs are displayed by 
their FDR-adjusted P value, and the corresponding fold change with the intensity of blue indicating their mean expression (normalization 
algorithm EdgeR). MicroRNAs that showed differential expression in both EdgeR and DESeq2 are marked by their names. HC indicates 
healthy control; IS, ischemic stroke; qRT-PCR, quantitative real-time polymerase chain reaction; and TIA, transient ischemic attack.
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pathogenesis (n=6) were too small to draw conclusions 
(Online Figure VIII). Next, we determined whether levels 
of miR-125a-5p, miR-125b-5p, and miR-143-3p correlated 
with infarct volumes in the replication sample (n=188). 
Infarct volumes ranged from 0.045 to 385 mL. There was no 
significant correlation between the expression levels of in-
dividual microRNAs in the acute phase and infarct volumes 
(Online Figure IX).
Cellular Source and Extracellular Transportation of 
miR-125a-5p, miR-125b-5p, and miR-143-3p
In light of previous work suggesting platelets as an important 
source of circulating microRNAs,26 we determined the ex-
tent to which platelets may contribute to circulating levels of 
miR-125a-5p, miR-125b-5p, and miR-143-3p. For this, we 
isolated platelets from platelet-rich plasma and spiked them 
back into platelet-poor plasma at increasing concentrations.27 
Table 2. Differentially Expressed Circulating MicroRNAs After Ischemic Stroke in the Discovery 
Sample
MicroRNA-ID
RNA Sequencing qRT-PCR Consistent 
Directionality 
of the FC Log
2
 (CPM) FC FDR P Value FC P Value
hsa-let-7b-3p 4.4 0.55 0.011 1.32 0.3107 …
hsa-let-7d-3p 7.8 0.60 0.014 1.83 4.9×10–6* No
hsa-let-7f-5p 11.6 0.42 <0.001 1.13 0.1767 …
hsa-let-7i-5p 10.2 0.48 0.005 1.58 0.0101 …
hsa-miR-1 4.4 0.16 <0.001 … … …
hsa-miR-16-2-3p 9.9 0.40 0.003 1.72 0.1798 …
hsa-miR-17-3p 3.0 0.40 0.011 … … …
hsa-miR-17-5p 5.0 0.37 0.003 1.77 0.0065 …
hsa-miR-18a-3p 3.5 0.38 0.004 … … …
hsa-miR-18a-5p 2.4 0.29 0.004 1.76 0.0508 …
hsa-miR-20a-5p 4.1 0.35 0.007 1.53 0.0635 …
hsa-miR-26b-5p 8.9 0.45 0.008 1.06 0.5800 …
hsa-miR-92a-3p 14.7 0.49 0.002 1.55 0.0453 …
hsa-miR-99b-5p 7.5 2.09 <0.001 1.65 0.0838 …
hsa-miR-101-3p 8.2 0.36 0.001 … … …
hsa-miR-125a-5p 7.8 2.47 <0.001 1.80 1.5×10–6* Yes
hsa-miR-125b-5p 5.0 1.69 0.026 2.54 5.6×10–6* Yes
hsa-miR-126-5p 10.1 0.46 <0.001 1.99 1.5×10–7* No
hsa-miR-130a-3p 7.5 0.57 0.022 3.73 0.0067 …
hsa-miR-140-3p 8.4 0.56 0.005 1.44 0.0678 …
hsa-miR-143-3p 10.8 1.88 0.049 4.77 7.8×10–9* Yes
hsa-miR-181a-5p 10.5 0.58 0.020 1.39 0.0113 …
hsa-miR-193a-5p 2.5 0.30 0.003 … … …
hsa-miR-378a-3p 6.8 0.58 0.026 1.23 0.0463 …
hsa-miR-423-3p 8.0 0.44 <0.001 2.14 4.2×10–6* No
hsa-miR-532-5p 5.4 0.33 <0.001 1.54 0.0119 …
hsa-miR-660-5p 5.0 0.29 <0.001 1.38 0.0582 …
hsa-miR-3158-3p 2.9 0.38 0.002 … … …
hsa-miR-3158-5p 2.9 0.38 0.002 … … …
hsa-miR-3184-5p 8.0 0.44 <0.001 … … …
hsa-miR-3688-3p 2.8 0.40 0.011 … … …
hsa-miR-3688-5p 2.8 0.40 0.011 … … …
Ten microRNAs were not detectable by qRT-PCR. Of the remaining 22 miRNAs, 6 (*) showed significant differential expression 
(P<0.00227). For 3 of them (miR-125a-5p, miR-125b-5p, and miR-143-3p), directionality of the FC was consistent between RNA 
sequencing and qRT-PCR. CPM indicates counts per million; FC, fold change; FDR, false discovery rate; and qRT-PCR, quantitative 
real-time polymerase chain reaction.
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Compared with liver-specific miR-122 (control), the levels of 
all 3 microRNAs significantly increased with increasing con-
centrations of platelets (Figure 4). To explore the possibility 
of a neuronal source of the 3 microRNAs during ischemia, 
we further challenged Neuro2a cells with increasing concen-
trations of the hypoxia-inducible factor 1-α stabilizing agent 
cobalt chloride for 2 and 6 hours and found no significant ef-
fect on the intra- and extracellular abundance of miR-125a-
5p, miR-125b-5p, and miR-143-3p (Online Figure X). Also, 
we found no change of circulating levels of miR-125a-5p, 
miR-125b-5p, and miR-143-3p in 2 different experimental 
stroke models using transient proximal or permanent distal 
occlusion of the middle cerebral artery (Online Figure XI). 
These findings suggested platelets as a major source of the 3 
microRNAs after acute IS. Next, to characterize the extracel-
lular mode of transportation of miR-125a-5p, miR-125b-5p, 
and miR-143-3p, we isolated extracellular vesicles from pa-
tients with IS and HCs and found significantly higher levels 
of miR-143-3p in vesicles from patients with IS compared 
with vesicles from controls, whereas no significant differ-
ence was found for miR-125a-5p and miR-125b-5p (Online 
Figure XII).
Figure 2. Validation and replication of miR-125a-5p, miR-125b-5p, and miR-143-3p. A, Results obtained in the independent validation 
sample (n=40/40, healthy control [HC]/ischemic stroke [IS]). miR-125a-5p, miR-125b-5p, and miR-143-3p all showed significant differential 
expression after stroke at hospital arrival (P<0.00227) with consistent directionality compared to RNA sequencing. B, Results obtained in 
the independent replication sample (n=100/72/200, HC/transient ischemic attack [TIA]/IS): miR-125a-5p, miR-125b-5p, and miR-143-3p. 
A, Mean±SEM, Mann–Whitney test; B, median±interquartile range, bars indicate 10th and 90th percentiles. Linear multivariate model after 
identification of covariates by backward stepwise regression.
Figure 3. Temporal expression profile of validated microRNAs after stroke. Results for the 32 patients with ischemic stroke with 
available data for at least 4 time points after stroke: (A) miR-125a-5p, (B) miR-125b-5p, and (C) miR-143-3p. Median±interquartile range, 
Kruskal–Wallis test followed by Dunn multiple comparison test, *P<0.05, ***P<0.001, ****P<0.0001. D indicates day; and HC, healthy control.
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Role of miR-125a-5p, miR-125b-5p, and miR-143-
3p as a Diagnostic Marker for Acute IS
In view of elevated levels of circulating miR-125a-5p, miR-
125b-5p, and miR-143-3p in the early phase after IS inde-
pendent of stroke pathogenesis and infarct volume, we next 
determined their role as diagnostic markers in the acute setting 
by calculating the receiver operating characteristics curve. 
Using the discovery sample as a training set and the validation 
sample as a test set in a random forest classification, the sig-
nature of miR-125a-5p, miR-125b-5p, and miR-143-3p differ-
entiated between HCs and patients with IS with an area under 
the curve (AUC) of 0.93 corresponding to a specificity of 
97.5% and sensitivity of 65% (replication sample: AUC=0.90; 
sensitivity: 85.6%; specificity: 76.3%; Figure 5A and 5C). 
Adding the 3 microRNAs that were differentially expressed 
in the validation step but showed no consistent directional-
ity with the discovery step resulted in no improvement of the 
receiver operating characteristics curve (Figure 5B). The AUC 
for differentiating between patients with TIA and IS was 0.66 
(sensitivity: 89.2%; specificity: 27.1%; Figure 5D). For com-
parison, the combination of noncontrast CT, CT angiography, 
and CT perfusion obtained as part of clinical routine showed 
a sensitivity for IS of 55% (pooled discovery and validation 
sample) and 72.5% (replication sample), which were lower 
than obtained with the set of microRNAs (Online Table III). 
Of note, measurements of the previously reported biomark-
ers high-sensitivity C-reactive protein,28,29 interleukin 6,8 and 
neuron-specific enolase5 yielded AUCs of 0.73, 0.82, and 
0.69, respectively, which were lower than the AUC of the 3 
microRNAs (Figure 5A and 5C). Adding interleukin 6 and 
neuron-specific enolase to the set of microRNAs further in-
creased the AUC in the replication sample to 0.92 (sensitivity: 
88.1%; specificity: 75.5%; Figure 5C) but did not improve the 
AUC for differentiating patients with IS from patients with 
TIA (AUC=0.66; Figure 5D).
Discussion
Our study establishes a set of circulating human microRNAs, 
which are differentially expressed after acute IS. Expression 
levels of miR-125a-5p, miR-125b-5p, and miR-143-3p were 
independent of infarct volume and stroke pathogenesis. When 
used to discriminate between patients with IS and HCs, this 
set showed a sensitivity of 85.6% and a specificity of 76.3% 
outperforming multimodal CT and previously reported bio-
markers in our sample. We thus consider miR-125a-5p, miR-
125b-5p, and miR-143-3p to have potential clinical utility as a 
diagnostic marker for acute IS.
To our knowledge, the receiver operating characteristics 
curve obtained for our set of microRNAs is unprecedented for 
a blood-based biomarker for stroke.30,31 Previously reported 
blood biomarkers, such as neuron-specific enolase and glial 
fibrillary acidic protein, were shown to peak at ≥24 hours after 
IS with poor discrimination in the acute phase.5,6 The potential 
of microRNAs as early diagnostic markers is illustrated by a re-
cent study showing increased levels of specific microRNAs as 
early as 15 minutes after myocardial infarction.32 Noncontrast 
CT is the imaging modality of choice for the initial assessment 
of patients with suspected stroke.33 Multimodal CT has been 
shown to increase diagnostic performance in patients present-
ing with suspected IS.2,34 However, its sensitivity in detect-
ing signs of brain ischemia is only ≈60%.2 In our sample, the 
combination of miR-125a-5p, miR-125b-5p, and miR-143-3p 
showed higher sensitivity than multimodal CT along with a 
high specificity.
Although the precise cellular sources and mechanisms 
underlying the observed elevations of miR-125a-5p, miR-
125b-5p, and miR-143-3p remain to be determined, our study 
provides important clues. Specifically, we found that all 3 mi-
croRNAs depended on platelet numbers in a platelet spike-in 
experiment. Also, platelet counts and antiplatelet therapy were 
identified as relevant covariates in the microRNA expression 
analysis in our replication sample. In contrast, levels of miR-
125a-5p, miR-125b-5p, and miR-143-3p were not affected by 
chemical hypoxia of Neuro2a cells in vitro and in 2 differ-
ent experimental stroke models. Of note, experimental stroke 
models mimic some aspects of human IS, such as ischemic 
neuronal injury, whereas the primary mechanisms underlying 
vessel occlusion in humans, in particular thromboembolism, 
are not appropriately reflected by these models.35 In fact, in 
the classical models used here, vessel occlusion was achieved 
by a filament (transient middle cerebral artery occlusion mod-
el) and thermocoagulation (permanent distal middle cerebral 
Figure 4. Platelet spike-in experiment. Levels of miR-125a-5p, miR-125b-5p, miR-143-3p, and miR-122-5p in relation to platelet-rich 
plasma (PRP) after spiking back platelets into platelet-poor plasma (PPP), n=3. Mean±SD, Friedman test.
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artery occlusion model), thus not addressing the mechanisms 
of vessel occlusion in IS, which are difficult to model in mice. 
Collectively, our data suggest platelets as a major source of 
elevated miR-125a-5p, miR-125b-5p, and miR-143-3p in our 
patients. Whether this relates to platelet aggregation or throm-
bus formation remains to be determined.
Circulating microRNA levels could result from passive re-
lease or active secretion.13 We found miR-143-3p levels to be 
significantly higher in extracellular vesicles of patients with IS 
compared with controls. Secreted microRNAs might serve as 
signaling molecules influencing systemic processes relevant 
for stroke outcome.13 miR-143-3p has been linked to the phe-
notype and function of vascular smooth muscle cells36 and 
endothelial cells.37 Exosomes and nanotubes allow for shut-
tling of miR-143 between the 2 cell types leading to modula-
tion of the angiogenic capacity of endothelial cells.38,39 The 
miR-143/-145 cluster is integral for vascular smooth muscle 
cells to sustain a contractile phenotype.40 Hence, it is tempt-
ing to speculate that elevated miR-143-3p levels may influ-
ence vessel function and structure after IS. miR-125a-5p and 
miR-125b-5p, displaying the same seed sequence, have both 
been shown to inhibit angiogenesis.41,42 However, whereas 
miR-125a-5p has been linked to supporting endothelial bar-
rier properties in the context of the blood–brain barrier43 and 
to the differentiation of inflammatory cells,44–46 miR-125b-5p 
regulates synaptic morphology and function.47 Interestingly, 
miR-125a-5p remained elevated up to day 90, whereas expres-
sion levels of miR-125b-5p rapidly returned to control levels. 
Therefore, potential biological effects of miR-125a-5p might 
have more sustained relevance after acute stroke.
Importantly, we found the expression levels of miR-125a-
5p, miR-125b-5p, and miR-143-3p to be independent of 
infarct volume and stroke pathogenesis. This finding empha-
sizes their potential utility as a broadly applicable diagnostic 
marker for acute IS. The observed absence of a correlation 
with infarct volume might seem counterintuitive but agrees 
with our experimental data, which showed that miR-125a-5p, 
miR-125b-5p, and miR-143-3p were not affected in para-
digms of ischemic neuronal injury. Our findings further agree 
with an earlier observation showing that cardiac-specific miR-
208a was elevated after myocardial infarction but did not cor-
relate with the extent of myocardial injury.32
Figure 5. Diagnostic utility of a microRNA set for acute ischemic stroke (IS). Receiver operating characteristics were calculated 
using the expression levels of specific microRNAs at hospital arrival: (A–C) for differentiating patients with IS and healthy control subjects 
(HCs). A, miR-125a-5p, miR-125b-5p, and miR-143-3p using the discovery sample as training set and the validation sample as test set in 
comparison to high-sensitivity C-reactive protein (hs-CRP), (B) adding let-7d-3p, miR-126-5p, and miR-423-3p to the initial set because 
of their differential expression in the validation step but different directionality compared with the discovery step, (C) miR-125a-5p, miR-
125b-5p, and miR-143-3p in the replication sample in comparison to and in combination with interleukin 6 (IL-6) and NSE (neuron-specific 
enolase), and (D) for differentiating patients with IS and patients with transient ischemic attack (TIA): miR-125a-5p, miR-125b-5p, and 
miR-143-3p compared with the combination of this set of miRNAs with IL-6 and NSE. 3-miR indicates the set of miR-125a-5p, miR-125b-
5p, and miR-143-3p; 6-miR, set of miR-125a-5p, miR-125b-5p, miR-143-3p, let-7d-3p, miR-126-5p, and miR-423-3p; AUC, area under 
the curve; DS, discovery sample; RS, replication sample; and VS, validation sample.
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Patients with an unknown time of symptom onset (eg, 
wake-up stroke) pose a diagnostic challenge with implications 
for therapeutic decision making. Aside from showing a higher 
sensitivity in detecting IS on hospital arrival compared with 
CT, the signature of miR-125a-5p, miR-125b-5p, and miR-
143-3p may provide information on the time interval since 
stroke onset. Specifically, elevated levels of all 3 microRNAs 
indicate the early phase after stroke and their peak of expres-
sion might be used to more accurately determine symptom 
onset and thus influence decisions on thrombolysis. However, 
this requires further investigation.
To our knowledge, the methodological rigor used in our 
study is unsurpassed in the stroke biomarker field: strengths 
include (1) the use of RNA sequencing in the discovery phase; 
(2) validation and replication in 2 independent samples; (3) 
inclusion of patients with TIA as the clinically most relevant 
differential diagnosis; (4) the exclusion of patients with prior 
antiplatelet therapy, cardiovascular events, or silent brain in-
farction in the discovery samples48; (5) consideration of other 
potential confounders of circulating microRNA levels; (6) se-
rial sampling starting immediately on hospital admission be-
fore CT and medical interventions; and (7) direct comparison 
between RNA- and protein-based biomarkers.
Our study also has limitations. First, the quantification of 
microRNAs by RNA sequencing and quantitative real-time 
polymerase chain reaction is influenced by sample prepara-
tion, in particular RNA isolation49 and cDNA preparation,50 
and dependent on the used platform.51 However, by using 2 
different methodologies, we aimed at controlling for these 
potential sources of bias and hence identifying true disease-
related microRNAs. Second, subjects were recruited from a 
single center. Moreover, we cannot exclude that the expres-
sion levels of individual microRNAs had already been elevat-
ed before stroke onset. Of note, however, expression levels 
of miR-125b-5p and miR-143-3p rapidly returned to normal 
levels after the acute phase of stroke, thus evidencing a close 
relationship with the acute event.
In conclusion, circulating miR-125a-5p, miR-125b-5p, 
and miR-143-3p associated with acute IS with high specificity 
and with higher sensitivity than multimodal CT in our sample, 
thus identifying this set of microRNAs as a promising diag-
nostic marker.
Acknowledgments
We thank all members of the emergency department team at the 
Klinikum der Universität München, especially all nurses, for assis-
tance with blood withdrawal and subsequent potential recruitment 
of patients with stroke. Also, we thank Uta Mamrak and Gemma 
Llovera for assistance with animal experiments.
Sources of Funding
M. Dichgans was supported by grants from the Deutsche 
Forschungsgemeinschaft (CRC 1123 [B3] and Munich Cluster 
for Systems Neurology [SyNergy]), the German Federal 
Ministry of Education and Research (BMBF, e:Med programme 
e:AtheroSysMed), the FP7/2007–2103 European Union project 
CVgenes@target (grant agreement No Health-F2-2013–601456), the 
European Union Horizon2020 projects SVDs@target (grant agree-
ment no 66688) and CoSTREAM (grant agreement no 667375), 
the Fondation Leducq (Transatlantic Network of Excellence on the 
Pathogenesis of Small Vessel Disease of the Brain), the Vascular 
Dementia Research Foundation, and the Jackstaedt Foundation. S. 




 1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, 
and national life expectancy, all-cause mortality, and cause-specific mor-
tality for 249 causes of death, 1980–2015: a systematic analysis for the 
Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
 2. Hopyan J, Ciarallo A, Dowlatshahi D, Howard P, John V, Yeung R, Zhang 
L, Kim J, MacFarlane G, Lee TY, Aviv RI. Certainty of stroke diagnosis: 
incremental benefit with CT perfusion over noncontrast CT and CT angi-
ography. Radiology. 2010;255:142–153. doi: 10.1148/radiol.09091021.
 3. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer 
reliability and outcome after thrombolytic treatment–systematic review. 
Radiology. 2005;235:444–453. doi: 10.1148/radiol.2352040262.
 4. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis 
of ischemic stroke: a systematic review. Stroke. 2008;39:2902–2909. doi: 
10.1161/STROKEAHA.107.511261.
 5. Anand N, Stead LG. Neuron-specific enolase as a marker for acute isch-
emic stroke: a systematic review. Cerebrovasc Dis. 2005;20:213–219. doi: 
10.1159/000087701.
 6. Wunderlich MT, Wallesch CW, Goertler M. Release of glial fibrillary acidic 
protein is related to the neurovascular status in acute ischemic stroke. Eur 
J Neurol. 2006;13:1118–1123. doi: 10.1111/j.1468-1331.2006.01435.x.
 7. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont 
R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate 
marker for long-term outcome and infarct volume in acute middle cere-
bral artery infarction. Arch Neurol. 2005;62:1130–1134. doi: 10.1001/
archneur.62.7.1130.
 8. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, 
del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ. 
Peak plasma interleukin-6 and other peripheral markers of inflammation 
in the first week of ischaemic stroke correlate with brain infarct volume, 
stroke severity and long-term outcome. BMC Neurol. 2004;4:2. doi: 
10.1186/1471-2377-4-2.
 9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. 
Cell. 2004;116:281–297.
 10. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as sta-
ble blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 
2008;105:10513–10518.
 11. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulat-
ing microRNAs: from single biomarkers to re-wired networks. Cardiovasc 
Res. 2012;93:555–562. doi: 10.1093/cvr/cvr266.
 12. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, Etheridge A, Luo Y, Ding 
Y, Wang K. Current state of circulating microRNAs as cancer biomarkers. 
Clin Chem. 2015;61:1138–1155. doi: 10.1373/clinchem.2015.241190.
 13. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel bio-
markers and extracellular communicators in cardiovascular disease? Circ 
Res. 2012;110:483–495. doi: 10.1161/CIRCRESAHA.111.247452.
 14. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within 
the continuum of postgenomics biomarker discovery. Arterioscler Thromb 
Vasc Biol. 2013;33:206–214. doi: 10.1161/ATVBAHA.112.300141.
 15. Bhalala OG, Srikanth M, Kessler JA. The emerging roles of microR-
NAs in CNS injuries. Nat Rev Neurol. 2013;9:328–339. doi: 10.1038/
nrneurol.2013.67.
 16. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, 
Jeyaseelan K. Expression profile of microRNAs in young stroke patients. 
PLoS One. 2009;4:e7689. doi: 10.1371/journal.pone.0007689.
 17. Li P, Teng F, Gao F, Zhang M, Wu J, Zhang C. Identification of circulating 
microRNAs as potential biomarkers for detecting acute ischemic stroke. 
Cell Mol Neurobiol. 2015;35:433–447. doi: 10.1007/s10571-014-0139-5.
 18. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH. Serum microR-
NA-21 and microRNA-221 as potential biomarkers for cerebrovascular 
disease. J Vasc Res. 2013;50:346–354. doi: 10.1159/000351767.
 19. Li M, Zhang J. Circulating microRNAs: potential and emerging biomark-
ers for diagnosis of cardiovascular and cerebrovascular diseases. Biomed 
Res Int. 2015;2015:730535. doi: 10.1155/2015/730535.
 20. Sacco RL, Kasner SE, Broderick JP, et al; American Heart Association 
Stroke Council, Council on Cardiovascular Surgery and Anesthesia; 
Council on Cardiovascular Radiology and Intervention; Council on 







980  Circulation Research  September 29, 2017
Cardiovascular and Stroke Nursing; Council on Epidemiology and 
Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, 
Physical Activity and Metabolism. An updated definition of stroke for the 
21st century: a statement for healthcare professionals from the American 
Heart Association/American Stroke Association. Stroke. 2013;44:2064–
2089. doi: 10.1161/STR.0b013e318296aeca.
 21. Braun J, Misiak D, Busch B, Krohn K, Hüttelmaier S. Rapid identification 
of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro 
affinity purification). Nucleic Acids Res. 2014;42:e66. doi: 10.1093/nar/
gku127.
 22. Stokowy T, Eszlinger M, Świerniak M, Fujarewicz K, Jarząb B, 
Paschke R, Krohn K. Analysis options for high-throughput sequenc-
ing in miRNA expression profiling. BMC Res Notes. 2014;7:144. doi: 
10.1186/1756-0500-7-144.
 23. Love MI, Huber W, Anders S. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. 
doi: 10.1186/s13059-014-0550-8.
 24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor pack-
age for differential expression analysis of digital gene expression data. 
Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616.
 25. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon 
DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. 
Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 
10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
 26. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr 
A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk 
PJ, Kiechl S, Mayr M. Prospective study on circulating microRNAs and 
risk of myocardial infarction. J Am Coll Cardiol. 2012;60:290–299. doi: 
10.1016/j.jacc.2012.03.056.
 27. Kaudewitz D, Skroblin P, Bender LH, et al. Association of microRNAs 
and YRNAs with platelet function. Circ Res. 2016;118:420–432. doi: 
10.1161/CIRCRESAHA.114.305663.
 28. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn 
A, Dengler R, Lichtinghagen R, Weissenborn K. The temporal profile of 
inflammatory markers and mediators in blood after acute ischemic stroke 
differs depending on stroke outcome. Cerebrovasc Dis. 2010;30:85–92. 
doi: 10.1159/000314624.
 29. Glickman SW, Phillips S, Anstrom KJ, Laskowitz DT, Cairns CB. 
Discriminative capacity of biomarkers for acute stroke in the emer-
gency department. J Emerg Med. 2011;41:333–339. doi: 10.1016/j.
jemermed.2010.02.025.
 30. Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diag-
nostic window of serum glial fibrillary acidic protein for the differentia-
tion of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis. 
2009;27:37–41. doi: 10.1159/000172632.
 31. González-García S, González-Quevedo A, Peña-Sánchez M, Menéndez-
Saínz C, Fernández-Carriera R, Arteche-Prior M, Pando-Cabrera A, 
Fernández-Concepción O. Serum neuron-specific enolase and S100 cal-
cium binding protein B biomarker levels do not improve diagnosis of 
acute stroke. J R Coll Physicians Edinb. 2012;42:199–204. doi: 10.4997/
JRCPE.2012.302.
 32. Liebetrau C, Möllmann H, Dörr O, Szardien S, Troidl C, Willmer M, Voss 
S, Gaede L, Rixe J, Rolf A, Hamm C, Nef H. Release kinetics of circu-
lating muscle-enriched microRNAs in patients undergoing transcoronary 
ablation of septal hypertrophy. J Am Coll Cardiol. 2013;62:992–998. doi: 
10.1016/j.jacc.2013.05.025.
 33. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk 
BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, 
Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart 
Association Stroke Council; Council on Cardiovascular Nursing; 
Council on Peripheral Vascular Disease; Council on Clinical Cardiology. 
Guidelines for the early management of patients with acute ischemic 
stroke: a guideline for healthcare professionals from the American Heart 
Association/American Stroke Association. Stroke. 2013;44:870–947. doi: 
10.1161/STR.0b013e318284056a.
 34. Zhu G, Michel P, Aghaebrahim A, Patrie JT, Xin W, Eskandari A, Zhang 
W, Wintermark M. Computed tomography workup of patients suspected 
of acute ischemic stroke: perfusion computed tomography adds value 
compared with clinical evaluation, noncontrast computed tomography, 
and computed tomography angiogram in terms of predicting outcome. 
Stroke. 2013;44:1049–1055. doi: 10.1161/STROKEAHA.111.674705.
 35. Sommer CJ. Ischemic stroke: experimental models and reality. Acta 
Neuropathol. 2017;133:245–261. doi: 10.1007/s00401-017-1667-0.
 36. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. 
Circ Res. 2012;110:508–522. doi: 10.1161/CIRCRESAHA.111.247445.
 37. Ramanujam D, Engelhardt S. Intercellular miRNA traffic. Circ Res. 
2015;116:1726–1728. doi: 10.1161/CIRCRESAHA.115.306519.
 38. Deng L, Blanco FJ, Stevens H, et al. MicroRNA-143 activation regu-
lates smooth muscle and endothelial cell crosstalk in pulmonary ar-
terial hypertension. Circ Res. 2015;117:870–883. doi: 10.1161/
CIRCRESAHA.115.306806.
 39. Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia 
L. TGFβ triggers miR-143/145 transfer from smooth muscle cells to 
endothelial cells, thereby modulating vessel stabilization. Circ Res. 
2015;116:1753–1764. doi: 10.1161/CIRCRESAHA.116.305178.
 40. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee 
TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate 
smooth muscle cell fate and plasticity. Nature. 2009;460:705–710. doi: 
10.1038/nature08195.
 41. Che P, Liu J, Shan Z, Wu R, Yao C, Cui J, Zhu X, Wang J, Burnett MS, 
Wang S, Wang J. miR-125a-5p impairs endothelial cell angiogenesis in 
aging mice via RTEF-1 downregulation. Aging Cell. 2014;13:926–934. 
doi: 10.1111/acel.12252.
 42. Muramatsu F, Kidoya H, Naito H, Sakimoto S, Takakura N. MicroRNA-
125b inhibits tube formation of blood vessels through translational sup-
pression of VE-cadherin. Oncogene. 2013;32:414–421. doi: 10.1038/
onc.2012.68.
 43. Reijerkerk A, Lopez-Ramirez MA, van Het Hof B, Drexhage JA, 
Kamphuis WW, Kooij G, Vos JB, van der Pouw Kraan TC, van Zonneveld 
AJ, Horrevoets AJ, Prat A, Romero IA, de Vries HE. MicroRNAs regulate 
human brain endothelial cell-barrier function in inflammation: implica-
tions for multiple sclerosis. J Neurosci. 2013;33:6857–6863. doi: 10.1523/
JNEUROSCI.3965-12.2013.
 44. Pan W, Zhu S, Dai D, et al. MiR-125a targets effector programs to stabi-
lize Treg-mediated immune homeostasis. Nat Commun. 2015;6:7096. doi: 
10.1038/ncomms8096.
 45. Banerjee S, Cui H, Xie N, Tan Z, Yang S, Icyuz M, Thannickal VJ, 
Abraham E, Liu G. miR-125a-5p regulates differential activation of mac-
rophages and inflammation. J Biol Chem. 2013;288:35428–35436. doi: 
10.1074/jbc.M112.426866.
 46. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying 
functional microRNAs in macrophages with polarized phenotypes. J Biol 
Chem. 2012;287:21816–21825. doi: 10.1074/jbc.M111.327031.
 47. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, 
Tada T, Dolan BM, Sharp PA, Sheng M. Regulation of synaptic structure 
and function by FMRP-associated microRNAs miR-125b and miR-132. 
Neuron. 2010;65:373–384. doi: 10.1016/j.neuron.2010.01.005.
 48. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel 
biomarkers for platelet activation. Circ Res. 2013;112:595–600. doi: 
10.1161/CIRCRESAHA.111.300539.
 49. McAlexander MA, Phillips MJ, Witwer KW. Comparison of methods for 
miRNA extraction from plasma and quantitative recovery of RNA from ce-
rebrospinal fluid. Front Genet. 2013;4:83. doi: 10.3389/fgene.2013.00083.
 50. Hafner M, Renwick N, Brown M, Mihailović A, Holoch D, Lin C, Pena JT, 
Nusbaum JD, Morozov P, Ludwig J, Ojo T, Luo S, Schroth G, Tuschl T. RNA-
ligase-dependent biases in miRNA representation in deep-sequenced small 
RNA cDNA libraries. RNA. 2011;17:1697–1712. doi: 10.1261/rna.2799511.
 51. Mestdagh P, Hartmann N, Baeriswyl L, et al. Evaluation of quantitative 
miRNA expression platforms in the microRNA quality control (miRQC) 
study. Nat Methods. 2014;11:809–815. doi: 10.1038/nmeth.3014.








Knut Krohn, Daniel Teupser, Arthur Liesz, Nikolaus Plesnila, Lesca Miriam Holdt and Martin
Kautzky, Ivelina Stoycheva, Julia Böck, Bernd H. Northoff, Matthias Klein, Franziska Dorn, 
Steffen Tiedt, Matthias Prestel, Rainer Malik, Nicola Schieferdecker, Marco Duering, Veronika
Biomarkers for Acute Ischemic Stroke
RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential
Print ISSN: 0009-7330. Online ISSN: 1524-4571 
Copyright © 2017 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation Research 
doi: 10.1161/CIRCRESAHA.117.311572
2017;121:970-980; originally published online July 19, 2017;Circ Res. 
 http://circres.ahajournals.org/content/121/8/970
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circres.ahajournals.org/content/suppl/2017/07/19/CIRCRESAHA.117.311572.DC1
Data Supplement (unedited) at:
  
 http://circres.ahajournals.org//subscriptions/
is online at: Circulation Research  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer about this process is available in the
located, click Request Permissions in the middle column of the Web page under Services. Further information
Editorial Office. Once the online version of the published article for which permission is being requested is 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not theCirculation Researchin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:










Ischemic stroke (IS) patients, transient ischemic attack (TIA) patients and healthy control subjects 
(HCs) were recruited at the Klinikum der Universität München (KUM), a tertiary level hospital at 
Ludwig-Maximilians-Universität, Munich, Germany. The enrolment period was January 2014 to 
January 2017. For the discovery and validation sample, we excluded IS patients and HCs with active 
malignant disease, inflammatory or infectious diseases, surgery within the last three months and prior 
medication with low-molecular or unfractionated heparin within the last month. For the discovery 
sample we further excluded IS patients and HCs with prior use of antiplatelet medication within the 
last month, a history of myocardial infarction, stroke, or transient ischemic attack, or signs for silent 
CNS infarction on neuroimaging. For the replication sample, we only excluded patients with prior 
medication with low-molecular or unfractionated heparin within the last month. No study subject 
suffered from polycythemia vera or essential thrombocythemia. The study was approved by the local 
ethics committee and was conducted in accordance with the Declaration of Helsinki as well as 
institutional guidelines. Written and informed consent was obtained from all subjects. 
Clinical assessments 
All IS patients received a comprehensive diagnostic work-up (magnetic resonance imaging: 62.3 %, 
non-contrast-enhanced computed tomography (CT): 98.5 %, CT angiography: 96.2 %, CT perfusion: 
74.2 %, 24h-electrocardiography: 31.5 %, transthoracic or transesophageal echocardiography: 57.3 %, 
extra- and transcranial ultrasound: 81.2 %). Stroke etiology was classified according to the Trial of 
Org 10172 in Acute Stroke Treatment (TOAST).1  
Patient blood sampling and processing 
Blood samples from IS and TIA patients were collected at hospital arrival in the emergency 
department. Longitudinal sampling of IS patients was additionally performed at the second, third and 
seventh day of hospitalization (or at earlier discharge) and at 90 days post-stroke. Samples from HCs 
were taken in the outpatient clinic of KUM. Whole blood was drawn into EDTA-plasma containers 
(Sarstedt) using a tourniquet and 21 gauge needles. After 30 to 45 minutes at room temperature 
separation of plasma was achieved by differential centrifugation at 2000g for 10 minutes and 2500g 
for 15 minutes at 15 °C. Samples were aliquoted in screw cap vials and kept at -80 °C. Serum 
sampling was achieved by blood collection in serum containers (Sarstedt) and subsequent 
centrifugation at 2000g for 10 minutes. 
Isolation of extracellular vesicles 
Extracellular vesicles from plasma were isolated using the miRCURY Exosome Isolation kit – Serum 
and Plasma (Exiqon) following the manufacturer’s instructions. In brief, from both groups, IS patients 
and HCs, 5 pools each consisting of 6 individual plasma samples from the validation sample, were 
used. Samples were incubated with a precipitation buffer at 4 °C for at least 60 minutes and 
centrifuged for 5 minutes at 500g. The pelleted vesicles were resuspended using a resuspension buffer. 
Platelet spike-in experiment 
The experiment was adopted from a previously published protocol.2 In short, whole blood from 3 
healthy volunteers was drawn into EDTA-plasma containers (Sarstedt) using a tourniquet and 21 
gauge needles. After 30 minutes at room temperature, samples were centrifuged at 190g for 30 
minutes at room temperature to pellet red blood cells. Next, the supernatant was centrifuged at 280g 
for 10 minutes to deplete white blood cells. The volume of the supernatant, consisting of platelet-rich 
plasma (PRP), was measured and 200 µl were kept for RNA extraction. The remainder was 
centrifuged at 1180g for 10 minutes to pellet platelets. The obtained supernatant was platelet-poor 
plasma (PPP). To further purify platelets, the pellet was washed with PBS and sorted by CD61-labeled 
beads (Miltenyi Biotec, #130-051-101) according to the manufacturer’s protocol (Miltenyi Biotec). 
The final platelet solution was again pelleted and resuspended in 1/20 of the initial PRP volume. 
S1
 Eventually, this stock solution was used to reconstitute PPP with platelet concentrations of 5 %, 50 %, 
100 %, and 200 %. Subsequently, RNA was extracted as described for plasma. 
Animal experiments 
All animal experiments were approved by the governmental committee of Upper Bavaria (protocol 
number 55.2.1.54-2532-20-14) and were performed in accordance with guidelines for the use of 
experimental animals. Wild-type C57BL/6 mice were obtained from Charles River Laboratories. 
Animals were randomized to surgery groups and subsequent experiments were performed by an 
investigator blinded with respect to the surgery group. All animal experiments were reported 
consistent with the ARRIVE guidelines (Kilkenny et al., 2010). 
Transient fMCAO 
Mice were anesthetized with isoflurane delivered in a mixture of 30 % O2 and 70 % N2O. An incision 
was made between the ear and the eye to expose the temporal bone. A laser Doppler probe was affixed 
to the skull above the middle cerebral artery (MCA) territory and the mice were placed in the supine 
position. An incision was made in the midline neck region and the common carotid artery and left 
external carotid artery were isolated and ligated; a 2 mm silicon-coated filament (Doccol, 
#701912PKRe) was inserted into the internal carotid artery and MCA occlusion was confirmed by a 
corresponding decrease in blood flow (i.e., a decrease in the laser Doppler flow signal to less than 20 
% of baseline). After 60 minutes of occlusion, the animals were reanesthetized and the filament was 
removed. For the survival period, the mice were kept in their home cage with facilitated access to 
water and food. Sham-operated mice received the same surgical procedure except the filament was 
inserted and immediately removed. Body temperature was maintained at 37 °C throughout surgery 
using a feedback-controlled heating pad. The overall mortality rate in mice subjected to MCAo was 10 
%. Exclusion criteria were as follows: insufficient MCA occlusion (a reduction in cerebral blood flow 
to > 20% of the baseline value; n=0) and mortality during surgery (n=0).  
Permanent distal MCA occlusion model 
Focal cerebral ischemia was induced as described previously by permanent occlusion of the MCA 
distal of the lenticulostriate arteries (Llovera et al., 2014). In brief, the mice were anesthetized with 
isoflurane delivered in a mixture of 30 % O2 and 70 % N2O. The skull was exposed by a lateral skin 
incision between eye and ear, a burr hole was drilled in the temporal bone, and the MCA was 
permanently occluded using high-frequency electrocoagulation forceps (ERBE Erbotome). After 
recovery, mice were returned to their home cages with ad libitum access to water and food. Sham 
surgery was performed by the same surgical procedures without coagulation of the exposed MCA. 
Throughout the surgical procedure, body temperature was maintained at 37 °C using a feedback-
controlled heating pad. The overall mortality rate in this experimental group was 5 %. Exclusion 
criteria were subarachnoid hemorrhage or death during surgery (n=1). 
Animal blood sampling and processing 
Under deep anethesia with ketamine (120 mg/kg) and xylazine (16 mg/kg), whole blood from mice 
was collected by cardiac puncture of the right ventricle using 25 gauge needles and drawn into EDTA-
plasma containers (Sarstedt). After 30 to 45 minutes at room temperature separation of plasma was 
achieved by differential centrifugation at 2000g for 10 minutes and 2500g for 15 minutes at 15 °C. 
Samples were kept at -80 °C.  
RNA isolation from plasma and reverse transcription 
RNA < 1000 nucleotides was isolated from 200 µl plasma using the miRCURY RNA Isolation Kit – 
Biofluids (Exiqon) according to the manufacturer’s recommendations with additional use of 3 µg 
glycogen as carrier.3 The process was monitored by using the manufacturer’s spike-in mix (UniSp2, 
UniSp4 and UniSp5). Starting from day 2 most IS patients received low-molecular-weight heparin. 
Hence, all samples included into the longitudinal analyses were treated with heparinase for one hour at 
room temperature prior to RNA isolation.4,5 The reverse transcription reaction was performed using 
the Universal cDNA Synthesis Kit II (Exiqon) following the manufacturer’s instructions.  
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 qPCR assay 
ExiLENT SYBR® Green and microRNA LNA™ PCR primer sets (Exiqon) were used to determine 
microRNA (miRNA) expression levels in a LightCycler 480/II (Roche). All samples were run in 
duplicates. The spiked-in UniSp2, UniSp4 and UniSp5 were used for normalization. Cq-values from 
miRNAs of interest were normalized using a median normalization method (discovery and validation 
step) or the ΔΔCq normalization method (replication step). Replicates of individual samples with Cq 
values > 35 were set to 40. miRNAs were excluded if more than half of the samples within each group 
showed Cq values > 35. miRNA copy numbers were calculated using recombinant miRNAs 
(Metabion) as standards.  
Quantification of infarct volumes 
Infarct volumes were quantified on images from diagnostic scans, either CT or magnetic resonance 
imaging (diffusion-weighted, T2 or fluid-attenuated inversion recovery). The modality and image with 
the largest infarct size was used for volumetry. Trained raters segmented infarcts manually slice-by-
slice. The inter-rater reliability for this procedure showed an intraclass correlation coefficient of 0.993. 
Statistics 
Data for continuous variables are expressed as mean +/- standard error of the mean or median +/- 
interquartile range, if not stated otherwise. For group-wise comparisons (n > 2 groups) ANOVA or 
Kruskal–Wallis test followed by Dunn’s multiple comparison test were used as appropriate. For n = 2 
groups Mann–Whitney test or Student’s t test were used as appropriate. Outliers were identified by the 
ROUT method. Matched data were analyzed using the Durbin-Skillings-Mack-test or Friedman test. 
For categorical variables, we used the Fisher’s exact test or the Chi-squared test. All tests were 
performed 2-sided. A p-value < 0.05 was considered statistically significant. If indicated, Bonferroni 
correction for multiple testing was applied. Random forest classification (R package ‘randomForest’)6 
was used for constructing receiver operating characteristic statistics. We used standard parameters and 
grew 100,001 trees per run. Linear and polynomial regressions as well as generalized linear mixed 
models were used to characterize the relationship of miRNA expression levels with infarct volumes, 
time since symptom onset and stroke severity (as measured by the NIH stroke scale (NIHSS)). For 
multivariate linear regression, we used a backward stepwise approach in order to identify covariates 
building the model with the best fit as indicated by the Akaike information criterion (AIC) (‘StepAIC’ 
function from the ‘MASS’ package in ‘R’).7 Statistical analyses were done using GraphPad Prism 6.0 




























































Online Figure I. Scatter plot of RNA sequencing results. Individual miRNAs are displayed by their FDR-adjusted p-value 
(for the comparison of ischemic stroke patients vs. healthy controls) and the corresponding CPM (normalization algorithm 
EdgeR). The dashed line indicates an FDR-adjusted p-value of 0.05. miRNAs that showed differential expression in both 







































































































































































































































































































































































Online Figure II. Validation experiment results of miRNAs that were selected via RNA sequencing but not confirmed via 
qRT-PCR. 16 miRNAs were not significantly differentially expressed: (A) let-7b-3p, (C) let-7f-5p, (D) let-7i-5p, (E) miR-16-2-3p, 
(F) miR-17-5p, (G) miR-18a-5p, (H) miR-20a-5p, (I) miR-26b-5p, (J) miR-92a-3p, (K) miR-99b-5p, (M) miR-130a-5p, (N) 
miR-140-3p, (O) miR-181a-5p, (P) miR-378a-3p, (R) miR-532-3p, and (S) miR-660-5p. Three circulating miRNAs were signifi-
cantly differentially expressed (p < 0.00227) but did not show consistent directionality with RNA sequencing: (B) let-7d-3p, (L) 
miR-126-5p, and (Q) miR-423-3p. Mean ± SEM, N=40, Mann-Whitney test. miRNA, microRNA; qRT-PCR, quantitative real-time 













































































**** **** **** ****
**** **** **** ******** **** **** ****
Online Figure III. Alternative analyses for the validation of miR-125a-5p, miR-125b-5p and miR-143-3p. The validati-
on results for (A) miR-125a-5p, (B) miR-125b-5p, and (C) miR-143-3p remained stable (compared to the established 
analysis (std + cut-off)) when not correcting qRT-PCR data with Cq values > 35 (std / no cut-off), when excluding subjects 
with previous major cardiovascular events (std / no PE) and when using non-standardized qRT-PCR data (without correc-
tion by Spike-Ins; no std). Mean ± SEM, N=40, Mann-Whitney test, **** p < 0.0001. qRT-PCR, quantitative real-time 
polymerase chain reaction; SEM, standard error of the mean; groups are indicated by: IS, ischemic stroke; and HC, 



















































Online Figure IV. Standard curves and qRT-PCR validation for miR-125a-5p, miR-125b-5p and miR-143-3p. (A) 
Different copy number inputs of recombinant miRNAs were used to generate standard curves for miR-125a-5p, miR-125b-
5p, and miR-143-3p. (B) Copy numbers per microliter plasma obtained in the combined discovery and validation samples 
(N=60): miR-125a-5p, miR-125b-5p, and miR-143-3p. Median ± IQR; Mann-Whitney test. qRT-PCR, quantitative real-time 
polymerase chain reaction; RT, reverse transcription reaction; miRNA, microRNA; IQR, interquartile range; groups are 
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Online Figure V. Serum expression levels of miR-125a-5p, miR-125b-5p and miR-143-3p. To exclude plasma-
specific differential miRNA expression, 10 IS patients and HCs were randomly selected from the validation sample and 
their serum samples analyzed for the expression levels of (A) miR-125a-5p, (B) miR-125b-5p, and (C) miR-143-3p. 






































































Online Figure VI. No expression bias by sequence similarity of miR-125a-5p and miR-125b-5p. (A) hsa-miR-125a-5p 
and hsa-miR-125b-5p have similar sequences. (B) Recombinant miR-125a-5p is not detected by the primers of miR-
125b-5p and (C) vice versa. Mean ± SD. SD, standard deviation.
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Online Figure VII. Relationship of miRNA expression 
levels with time since symptom onset. Fourth grade 
polynomial equations were used to plot expression levels 
of (A) miR-125a-5p, (B) miR-125b-5p, and (C) miR-143-3p 
from the 32 IS patients included in the longitudinal analy-
sis at day one and two after symptom onset. For patients 
with unknown time from symptom onset, the difference 
between last seen healthy and first seen symptoms was 
calculated. The dashed line indicates the global maximum. 
Note that the second slight increase beyond 32 hours with 
few available measurements may result from statistical 
overfitting due to the use of fourth-grade polynomial 
equations. Polynomial regression analysis. miRNA, 






















Online Figure VIII. Relationship of miRNA expression levels 
with stroke etiology. The plasma concentrations of miR-125a-5p, 
miR-125b-5p, and miR-143-3p from IS patients from (A) the 
combined discovery and validation samples (N=60) and (B) the 
replication sample (N=200) (see also Figure 2A and B) were 
segregated into the TOAST categories large vessel disease (LVD), 
cardioembolism (CE), small vessel disease (SVD), other determi-
ned etiology (Other) and undetermined etiology (Und.). miRNA, 
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p = 0.392 p = 0.986
p = 0.795
Online Figure IX. Relationship of miRNA expres-
sion levels with infarct volume. The transformed 
infarct volumes of ischemic stroke patients (N=188) 
were correlated with expression levels of (A) miR-
125a-5p, (B) miR-125b-5p, and (C) miR-143-3p. 
Linear regression analysis. miRNA, microRNA.
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Online Figure X. miRNA expression analyses after CoCl   challenge of N2a cells. (A) Cellular and (B) extracellular abun-
dance of miR-125a-5p, miR-125b-5p and miR-143-3p did not change significantly after 2 and 6 hours of treatment with increa-
sing concentrations (100 - 600 μM) of the HIF1α stabilizing agent CoCl  compared to control (H O) treated cells. (C) Expression 
of HIF1α is increased after CoCl  treatment. A and B: mean ± SD, Kruskal-Wallis-Test; C: western blot analysis. N2a, Neuro2a; 
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Online Figure XI. miRNA levels in 
experimental stroke models. (A) 
Expression of miR-125a-5p, miR-
125b-5p and miR-143-3p at 6 hours 
after induction of stroke in two 
experimental models. (B) miRNA 
expression at 2, 6, 24, and 72 hours 
after filament occlusion of the middle 
cerebral artery (MCA) or sham 
surgery. Mean ± SD, N=8-9, Mann-
Whitney test and Bonferroni correc-
tion. Sh, sham; fMo, filament occlusi-
on of the MCA; dMo, distal occlusion 
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Online Figure XII. Extracellular vesicle miRNA levels in IS patients compared to HCs. Expression levels of miR-125a-5p, 
miR-125b-5p, and miR-143-3p were analyzed in extracellular vesicles isolated from IS patients and HCs (in each group from 
5 pools consisting each of 6 individual samples). Mean ± SEM, N=5 pools, Mann-Whitney test. Groups are indicated by: IS, 
ischemic stroke; and HC, healthy control subjects. miRNA, microRNA; SEM, standard error of the mean.
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 SUPPLEMENTAL TABLES 
Online Table I: Individual sample characteristics 





reads [miR-486 + miR-16-5p + 
miR-92a-3p] of miRNA reads  (%) 
1 stroke 6.644.136 889.364 13.4 43.5 
2 stroke 7.151.832 409.431 5.7 47.7 
3 stroke 6.500.093 142.132 2.2 42.3 
4 stroke 8.318.539 2.796.547 33.6 50.1 
5 stroke 8.960.549 2.155.168 24.1 47.1 
6 stroke 8.019.565 247.076 3.1 41.9 
7 stroke 6.967.596 1.075.369 15.4 47.0 
8 stroke 15.279.030 446.267 2.9 44.0 
9 stroke 6.720.124 428.881 6.4 45.9 
10 stroke 7.672.286 582.012 7.6 46.7 
11 stroke 5.999.103 122.117 2.0 40.7 
12 stroke 8.086.114 152.341 1.9 43.9 
13 stroke 8.512.960 223.141 2.6 39.2 
14 stroke 8.518.381 204.232 2.4 43.2 
15 stroke 6.839.795 137.378 2.0 48.3 
16 stroke 4.282.503 228.649 5.3 45.5 
17 stroke 9.878.416 1.458.512 14.8 48.9 
18 stroke 8.638.248 193.398 2.2 43.5 
19 stroke 9.051.766 189.795 2.1 41.3 
20 stroke 8.161.355 122.554 1.5 44.6 
21 control 9.530.966 1.165.867 12.2 49.4 
22 control 9.450.249 816.919 8.6 48.9 
23 control 8.894.061 4.513.161 50.7 49.6 
24 control 11.508.674 4.603.933 40.0 49.6 
25 control 9.601.776 1.730.942 18.0 51.4 
26 control 9.161.124 4.517.736 49.3 52.0 
27 control 8.553.193 880.956 10.3 47.5 
28 control 8.797.517 378.127 4.3 45.5 
29 control 7.680.805 770.032 10.0 47.2 
30 control 7.471.164 923.621 12.4 47.8 
31 control 7.731.336 48.057 0.6 43.7 
32 control 6.419.856 392.607 6.1 44.6 
33 control 6.771.409 98.856 1.5 47.2 
34 control 2.430.061 88.400 3.6 48.5 
35 control 3.220.558 307.606 9.6 51.4 
36 control 2.061.139 51.510 2.5 50.0 
37 control 377.400 17.409 4.6 43.7 
38 control 1.452.484 25.602 1.8 44.8 
39 control 11.030.262 1.025.496 9.3 45.7 
40 control 10.834.234 1.336.697 12.3 47.3 
The proportion of miRNA counts of total reads was 5.9 % (2.4 – 12.3 %; median and IQR). miRNA, 
microRNA; IQR, interquartile range.   
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 Online Table III: Matching of initial evaluation of multimodal CT upon hospital arrival and delayed imaging 
Patient_ID     
Initial multimodal CT imaging upon hospital arrival  Delayed imaging resulting in final diagnosis 
Non-contrast CT CT angiography CT perfusion  Modality Final diagnosis 
DS_01 Focal swelling in left  
frontoparietal lobe 
Left MCA M2 segment      
occlusion 
Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
DS_02 Unremarkable Unremarkable Unremarkable  MRI Left pons ischemic infarct 
DS_03 Unremarkable Unremarkable Mismatch in right cerebellar 
hemisphere 
 MRI Right cerebellar ischemic 
infarct 
DS_04 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
DS_05 Unremarkable Unremarkable Unremarkable  MRI Right MCA territory 
ischemic infarct 
DS_06 Unremarkable Unremarkable Unremarkable  MRI Right thalamus ischemic 
infarct 
DS_07 Parenchymal hypoattenuation in 
right MCA territory 
Right MCA M2 segment    
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory 
ischemic infarct 
DS_08 Unremarkable Unremarkable Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
DS_09 Unremarkable Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
DS_10 Unremarkable Unremarkable Unremarkable  MRI Left  PCA territory ischemic 
infarct 
DS_11 Unremarkable Unremarkable Unremarkable  MRI Right MCA territory 
ischemic infarct 
DS_12 Parenchymal hypoattenuation in  
left MCA territory 
Unremarkable Matched perfusion defect in left 
MCA territory 
 MRI Left MCA territory 
ischemic infarct 
DS_13 Unremarkable Unremarkable Unremarkable  MRI Right ACA territory 
ischemic infarct 
S18
 DS_14 Unremarkable Left VA V3 occlusion  Unremarkable  MRI Left/right VA/MCA 
territory ischemic infarcts 
DS_15 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
DS_16 Parenchymal hypoattenuation in  
left MCA territory 
Left MCA M1 segment      
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
DS_17 Unremarkable Unremarkable -  MRI Left  PCA territory ischemic 
infarct 
DS_18 Hypoattenuation of the left    
caudate nucleus 
Unremarkable Perfusion defect between left 
MCA/ACA and left MCA/PCA 
 CT Left MCA territory 
ischemic infarct 
DS_19 Unremarkable Unremarkable Mismatch in left MCA territory  MRI Left MCA and right PCA 
ischemic infarcts 
DS_20 Unremarkable Right MCA M2 segment    
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory 
ischemic infarct 
VS_01 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct
VS_02 Parenchymal hypoattenuation in 
right MCA territory 
Right ICA and MCA          
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
VS_03 Unremarkable Unremarkable Matched perfusion defect in left 
MCA territory 
 CT Left MCA territory 
ischemic infarct 
VS_04 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_05 Unremarkable Possible left MCA M4          
segment occlusion 
Mismatch in left MCA territory  MRI Left/right MCA territory 
ischemic infarcts 
VS_06 Unremarkable Unremarkable Unremarkable  MRI Left pons ischemic infarct 
VS_07 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_08 Unremarkable Left MCA M2 segment      
occlusion 
Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
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 VS_09 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_10 Unremarkable Unremarkable Unremarkable  MRI Right ACA territory 
ischemic infarct 
VS_11 Unremarkable Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
VS_12 Unremarkable Left VA V2 segment          
occlusion 
Unremarkable  MRI Right SCA territory 
ischemic infarct 
VS_13 Parenchymal hypoattenuation in 
right ACA/MCA territories 
Unremarkable Unremarkable  MRI Right MCA territory 
ischemic infarct 
VS_14 Unremarkable Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
VS_15 Parenchymal hypoattenuation in  
left MCA territory 
Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
VS_16 Unremarkable Unremarkable Unremarkable  MRI Right pons ischemic infarct 
VS_17 Unremarkable Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
VS_18 Unremarkable Unremarkable -  CT Left MCA territory 
ischemic infarct 
VS_19 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
VS_20 Parenchymal hypoattenuation in  
left PCA territory 
Unremarkable Matched perfusion defect within 
the left PCA territory 
 MRI Left PCA territory ischemic 
infarct 
VS_21 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
VS_22 Unremarkable Left MCA M1/2 segment    
occlusion   
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
VS_23 Unremarkable Right MCA M2 segment    
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
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 VS_24 Unremarkable Unremarkable Unremarkable  MRI Left thalamus ischemic 
infarct 
VS_25 Hyperdense MCA sign (left) Left MCA M2 segment         
stenosis 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
VS_26 Unremarkable Right PCA P1/2 segment    
occlusion    
Mismatch in right PCA territory  MRI Right PCA territory 
ischemic infarct 
VS_27 Unremarkable Left MCA M1 segment         
stenosis 
Mismatch in left MCA territory  CT Left MCA territory 
ischemic infarct 
VS_28 Parenchymal hypoattenuation in 
right MCA territory 
Right MCA M1 segment       
stenosis 
-  MRI Right MCA territory 
ischemic infarct 
VS_29 Unremarkable Unremarkable Unremarkable  MRI Right thalamus ischemic 
infarct 
VS_30 Unremarkable Unremarkable Unremarkable  MRI Right PICA territory 
ischemic infarct 
VS_31 Parenchymal hypoattenuation of 
right inferior frontal gyrus 
Possible right MCA M3       
segment occlusion 
Matched perfusion defect in right 
MCA territory 
 MRI Right MCA territory 
ischemic infarct 
VS_32 Unremarkable Left ICA stenosis Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_33 Unremarkable Left ICA stenosis Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_34 Unremarkable - Matched perfusion defect in right 
PICA territory 
 CT Right PICA territory 
ischemic infarct 
VS_35 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
VS_36 Unremarkable Unremarkable -  MRI Right MCA territory 
ischemic infarct 
VS_37 Unremarkable Unremarkable Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
VS_38 Unremarkable Left MCA M1 segment      
occlusion 
Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
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 VS_39 Unremarkable Left ICA occlusion Perfusion defect in left PCA 
territory 
 CT Left MCA/PCA territory 
ischemic infarcts 
VS_40 Parenchymal hypoattenuation in 
right parietal lobe 
Unremarkable Matched perfusion defect in right 
parieto-occipital region 
 MRI Right MCA territory 
ischemic infarct 
RS_1 Unremarkable Right VA V3 segment 
occlusion
-  MRI Right SCA territory 
ischemic infarct
RS_2 Unremarkable Unremarkable -  MRI Left pontine ischemic 
infarct 
RS_3 Hyperdense MCA sign (right) - -  CT Right MCA territory 
ischemic infarct 
RS_4 Parenchymal hypoattenuation of  
the left basal ganglia 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_5 Parenchymal hypoattenuation of  
the left insula and basal ganglia 
Left ICA occlusion Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_6 Parenchymal hypoattenuation in  
the left frontal lobe 
Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_7 Parenchymal hypoattenuation in  
the right temporal lobe 
Right ICA occlusion Unremarkable  MRI Right MCA territory 
ischemic infarct 
RS_8 Parenchymal hypoattenuation of  
the left insula and basal ganglia 
Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_9 Focal swelling in left  
parietal lobe 
Left ICA thrombus Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_10 Unremarkable Unremarkable Unremarkable  MRI Left and right MCA 
territory ischemic infarcts 
RS_11 Unremarkable Unremarkable Perfusion defect in right ACA 
territory 
 CT Right ACA territory 
ischemic infarct 
RS_12 Unremarkable Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_13 Parenchymal hypoattenuation of  
the left internal capsule 
Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
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 RS_14 Unremarkable Left ICA occlusion Unremarkable  MRI Left ACA and MCA 
territory ischemic infarcts 
RS_15 Parenchymal hypoattenuation of  
the left insula and basal ganglia 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_16 Unremarkable Unremarkable -  MRI Right MCA territory 
ischemic infarct 
RS_17 Unremarkable Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA and PICA 
territory ischemic infarcts 
RS_18 Unremarkable Right PCA P2 segment 
occlusion 
Perfusion defect in right PCA 
territory 
 CT Right PCA territory 
ischemic infarct 
RS_19 Unremarkable Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI  Right MCA, left MCA/PCA 
territory ischemic infarcts 
RS_20 Unremarkable Bilateral PCA stenoses -  MRI Right PCA territory 
ischemic infarct 
RS_21 Unremarkable Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_22 Unremarkable Right (older) ICA occlusion Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_23 Unremarkable Left PCA stenosis -  MRI Left thalamic ischemic 
infarct 
RS_24 Unremarkable Right ICA occlusion -  MRI Right ACA territory 
ischemic infarct 
RS_25 Unremarkable Left ICA occlusion Perfusion defect in right MCA 
territory 
 MRI  Right/left MCA and ACA 
territory ischemic infarcts 
RS_26 Unremarkable Right MCA M2 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_27 Hyperdense MCA sign (left) Left MCA M1 segment 
occlusion 
-  CT Left MCA territory 
ischemic infarct 
RS_28 Unremarkable Left MCA M2 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
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 RS_29 Parenchymal hypoattenuation of  
the left insula 
- -  CT Left MCA territory 
ischemic infarct 
RS_30 Unremarkable Right ICA stenosis -  MRI Right MCA territory 
ischemic infarct 
RS_31 Unremarkable Right ICA and MCA   
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_32 Parenchymal hypoattenuation of  
the left parietal lobe 
Left ICA stenosis Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_33 Parenchymal hypoattenuation of  
the left insula 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_34 Parenchymal hypoattenuation of  
the left basal ganglia 
Left MCA M1 stenosis Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_35 Unremarkable - -  MRI Right MCA territory 
ischemic infarct 
RS_36 Unremarkable Unremarkable Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_37 Unremarkable Unremarkable Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_38 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
RS_39 Unremarkable Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
RS_40 Unremarkable Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_41 Parenchymal hypoattenuation in  
the right SCA territory 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA and SCA 
territory ischemic infarcts 
RS_42 Unremarkable Unremarkable Unremarkable  MRI Right pontine ischemic 
infarct 
RS_43 Parenchymal hypoattenuation of  
the right insula 
Right MCA M2 segment 
occlusion 
-  CT Right MCA territory 
ischemic infarct 
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 RS_44 Parenchymal hypoattenuation of  
the left MCA territory 
Left ICA and MCA M1 
segment occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_45 Unremarkable - -  CT Right MCA territory 
ischemic infarct 
RS_46 Parenchymal hypoattenuation of  
the right basal ganglia 
- -  CT Right MCA territory 
ischemic infarct 
RS_47 Unremarkable Unremarkable Unremarkable  MRI Right MCA territory 
ischemic infarct 
RS_48 Parenchymal hypoattenuation in  
the right temporal lobe 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_49 Parenchymal hypoattenuation of  
the left insula 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_50 Parenchymal hypoattenuation in  
the right MCA territory 
Right ICA occlusion Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_51 Parenchymal hypoattenuation of  
the left MCA territory 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_52 Unremarkable Unremarkable Unremarkable  MRI Left thalamic/capsule 
ischemic infarct 
RS_53 Parenchymal hypoattenuation of  
the left frontal lobe 
Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_54 Parenchymal hypoattenuation of  
the right frontal lobe 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_55 Parenchymal hypoattenuation of  
the right temporal lobe 
Unremarkable Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_56 Unremarkable Unremarkable Unremarkable  MRI Left pontine ischemic 
infarct 
RS_57 Parenchymal hypoattenuation of  
the right temporal lobe 
Right MCA M2 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_58 Parenchymal hypoattenuation of  
the left frontal lobe 
Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
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 RS_59 Parenchymal hypoattenuation in  
the right MCA territory 
Right ICA occlusion Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_60 Parenchymal hypoattenuation of  
the left insula 
Left ICA occlusion Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_61 Parenchymal hypoattenuation in  
the right MCA territory 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_62 Parenchymal hypoattenuation of  
the right basal ganglia 
Unremarkable Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_63 Unremarkable Unremarkable -  MRI Right MCA territory 
ischemic infarct 
RS_64 Parenchymal hypoattenuation in  
the right PCA territory 
Right PCA P4 segment 
occlusion 
-  MRI Right PCA territory 
ischemic infarct 
RS_65 Unremarkable Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA and PICA 
territory ischemic infarcts 
RS_66 Parenchymal hypoattenuation in  
the right MCA territory 
Unremarkable Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_67 Parenchymal hypoattenuation of  
the right MCA territory 
Right ICA occlusion Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_68 Parenchymal hypoattenuation in  
the left MCA territory 
Left ICA stenosis Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_69 Unremarkable Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_70 Hyperdense MCA sign (left) Left MCA M2 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_71 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M1 segment 
occlusion 
-  CT Left MCA territory 
ischemic infarct 
RS_72 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
RS_73 Parenchymal hypoattenuation in  
the right MCA territory 
Right MCA M2 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
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 RS_74 Parenchymal hypoattenuation in  
the left basal ganglia  
Unremarkable Unremarkable  CT Left MCA territory 
ischemic infarct 
RS_75 Parenchymal hypoattenuation in  
the right MCA territory 
Right ICA occlusion Perfusion defect in right MCA 
territory 
 MRI Right MCA territory 
ischemic infarct 
RS_76 Unremarkable Left MCA M2 segment 
stenosis 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_77 Parenchymal hypoattenuation in  
the right MCA territory 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_78 Unremarkable Unremarkable -  MRI Left MCA territory 
ischemic infarct 
RS_79 Unremarkable Unremarkable Unremarkable  MRI Bilateral thalamic ischemic 
infarcts 
RS_80 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_81 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_82 Unremarkable - -  MRI Left PCA territory ischemic 
infarct 
RS_83 Hyperdense MCA sign (left) Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_84 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M3 segment 
occlusion 
-  CT Left MCA territory 
ischemic infarct 
RS_85 Parenchymal hypoattenuation in  
the right MCA territory 
Right MCA M2 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_86 Unremarkable Left PCA P1 segment 
occlusion 
Perfusion defect in left PCA 
territory 
 CT Left PCA and SCA territory 
ischemic infarcts 
RS_87 Parenchymal hypoattenuation in  
the left temporal lobe 
Left ICA and MCA     
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA and PCA 
territory ischemic infarcts 
RS_88 Parenchymal hypoattenuation in  
the left MCA territory 
- -  CT Left MCA territory 
ischemic infarct 
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 RS_89 Parenchymal hypoattenuation in  
the left frontal lobe 
Left CCA, ICA and MCA     
occlusion 
Perfusion defect in left ACA and 
MCA territories 
 CT Left MCA and ACA 
territory ischemic infarcts 
RS_90 - (external MRI acquisition) - -  MRI Left MCA territory 
ischemic infarct 
RS_91 Parenchymal hypoattenuation in  
the left basal ganglia 
Left MCA M1 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory 
ischemic infarct 
RS_92 Parenchymal hypoattenuation in  
the left MCA territory 
Left ICA occlusion Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_93 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
RS_94 Parenchymal hypoattenuation in  
the right PCA territory 
Unremarkable -  MRI Right PCA territory 
ischemic infarct 
RS_95 Parenchymal hypoattenuation in  
the right frontal lobe 
Right MCA M2 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory 
ischemic infarct 
RS_96 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_97 Unremarkable Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory 
ischemic infarct 
RS_98 Parenchymal hypoattenuation in  
the left cerebellar hemipshere 
Right and left VA V4    
segment occlusion 
Perfusion defect in left AICA and 
PICA territories 
 MRI Left PICA territory 
ischemic infarct 
RS_99 Unremarkable Left PCA P2 segment 
occlusion 
Perfusion defect in left PCA 
territory 
 MRI Left PCA territory   
ischemic infarct 
RS_100 Parenchymal hypoattenuation in  
the left pulvinar 
Left PCA P1 segment 
occlusion 
Perfusion defect in left PCA 
territory 
 MRI Left PCA territory   
ischemic infarct 
RS_101 Unremarkable Unremarkable Perfusion defect in left MCA 
territory 
 MRI Left MCA territory   
ischemic infarct 
RS_102 Unremarkable Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI Right MCA territory   
ischemic infarct 
RS_103 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory   
ischemic infarct 
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 RS_104 Unremarkable Basilar artery thrombosis Mismatch in left cerebellar 
hemisphere 
 MRI Bilateral PCA and left SCA 
territory ischemic infarcts 
RS_105 Unremarkable Unremarkable -  CT Left pontine ischemic 
infarct 
RS_106 Unremarkable Left MCA M1 segment 
occlusion 
-  MRI Left MCA territory   
ischemic infarct 
RS_107 Unremarkable Unremarkable -  MRI Right MCA territory   
ischemic infarct 
RS_108 Unremarkable Left VA V4 segment     
stenosis 
Unremarkable  MRI Left medulla oblongata 
ischemic infarct 
RS_109 Unremarkable Unremarkable -  CT Left MCA territory   
ischemic infarct 
RS_110 Unremarkable Unremarkable -  MRI Left PCA territory   
ischemic infarct 
RS_111 Unremarkable Right ICA occlusion Mismatch in right ACA territory  CT Right ACA territory 
ischemic infarct 
RS_112 Unremarkable - -  MRI Right MCA territory 
ischemic infarct 
RS_113 Parenchymal hypoattenuation in  
the right MCA territory 
Right ICA occlusion Matched perfusion defect in right 
MCA territory 
 CT Right MCA territory 
ischemic infarct 
RS_114 Unremarkable Unremarkable -  CT Right MCA territory 
ischemic infarct 
RS_115 Unremarkable Unremarkable -  MRI Left MCA and PCA 
territory ischemic infarcts 
RS_116 Unremarkable Right MCA M2 segment 
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory 
ischemic infarct 
RS_117 Parenchymal hypoattenuation in  
the left basal ganglia 
Left MCA M2 segment 
occlusion 
Mismatch in left MCA territory  MRI Left MCA territory   
ischemic infarct 
RS_118 Unremarkable Left ICA occlusion/           
high-grade stenosis 
Mismatch in left MCA territory  CT Left MCA territory   
ischemic infarct 
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 RS_119 Unremarkable - -  MRI Left MCA territory   
ischemic infarct 
RS_120 Unremarkable Right VA V4 segment 
occlusion 
Matched perfusion defect in right 
PICA territory 
 MRI Right PICA territory   
ischemic infarct 
RS_121 Parenchymal hypoattenuation in  
the right MCA territory 
Right MCA M2 segment 
occlusion 
-  CT Right MCA territory 
ischemic infarct 
RS_122 Unremarkable Unremarkable Unremarkable  MRI Right thalamic ischemic 
infarct 
RS_123 Unremarkable Right MCA M1 segment 
occlusion 
Mismatch in right MCA territory  CT Right MCA territory 
ischemic infarct 
RS_124 Unremarkable Unremarkable -  MRI Bilateral PCA territory 
ischemic infarcts 
RS_125 Infarction of left basal ganglia    
with hemorrhagic transformation  
Unremarkable -  MRI Bilateral MCA territory   
ischemic infarcts 
RS_126 Unremarkable Unremarkable Unremarkable  CT Left MCA territory   
ischemic infarct 
RS_127 Parenchymal hypoattenuation of  
the left insula 
Left ICA and MCA M1 
segment occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory   
ischemic infarct 
RS_128 Unremarkable Left MCA M2 segment 
occlusion 
Mismatch in left MCA territory  CT Left MCA territory   
ischemic infarct 
RS_129 Unremarkable - -  MRI Left MCA territory   
ischemic infarct 
RS_130 Unremarkable Unremarkable Unremarkable  MRI Right MCA territory   
ischemic infarct 
RS_131 Unremarkable Right MCA M2 segment 
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory   
ischemic infarct 
RS_132 Unremarkable Unremarkable Perfusion defect in left MCA 
territory  
 MRI Left MCA territory   
ischemic infarct 
RS_133 Unremarkable Left MCA M3 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 MRI Left MCA territory   
ischemic infarct 
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 RS_134 Unremarkable Unremarkable Unremarkable  MRI Left thalamic ischemic 
infarct 
RS_135 Unremarkable Left MCA M2 segment 
occlusion 
Mismatch in left MCA territory  CT Left MCA territory   
ischemic infarct 
RS_136 Unremarkable Unremarkable -  CT Left MCA territory   
ischemic infarct 
RS_137 Parenchymal hypoattenuation of  
the right frontal lobe 
Unremarkable Perfusion defect in right MCA 
territory 
 MRI Right MCA territory   
ischemic infarct 
RS_138 Unremarkable Unremarkable Unremarkable  MRI Right MCA territory   
ischemic infarct 
RS_139 Unremarkable Unremarkable Unremarkable  MRI Right medulla oblongata 
ischemic infarct 
RS_140 Parenchymal hypoattenuation in  
the left MCA territory 
Unremarkable -  MRI Left MCA territory   
ischemic infarct 
RS_141 Parenchymal hypoattenuation in  
the right frontal lobe 
Right MCA M3 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory   
ischemic infarct 
RS_142 Unremarkable Right MCA M2 segment 
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory   
ischemic infarct 
RS_143 Parenchymal hypoattenuation in  
the left PCA territory 
Unremarkable -  CT Left PCA and MCA 
territory ischemic infarcts 
RS_144 Unremarkable Left MCA M2 segment 
occlusion 
Perfusion defect in left MCA 
territory 
 CT Left MCA territory   
ischemic infarct 
RS_145 Parenchymal hypoattenuation in  
the left insula 
Left ICA and MCA M1 
segment occlusion 
Matched perfusion defect in left 
ACA and MCA territory 
 CT Left ACA and MCA 
territory ischemic infarcts 
RS_146 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M1 segment 
occlusion 
Mismatch in left MCA territory  CT Left MCA territory   
ischemic infarct 
RS_147 Unremarkable Right MCA M1 segment 
occlusion 
Mismatch in right MCA territory  MRI Right MCA territory   
ischemic infarct 
RS_148 Parenchymal hypoattenuation in  
the right occipital lobe 
Right PCA P3 segment 
occlusion 
Perfusion defect in right PCA 
territory 
 MRI Right PCA territory   
ischemic infarct 
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 RS_149 Parenchymal hypoattenuation of  
the right MCA territory 
Right MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 CT Right MCA territory   
ischemic infarct 
RS_150 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M1 segment 
occlusion 
Perfusion defect in right MCA 
territory 
 MRI Left MCA territory   
ischemic infarct 
RS_151 Parenchymal hypoattenuation of  
the left insula 
Left MCA M1 segment 
occlusion 
Matched perfusion defect in left 
MCA territory 
 CT Left MCA territory   
ischemic infarct 
RS_152 Unremarkable Unremarkable -  MRI Left MCA territory   
ischemic infarct 
RS_153 Parenchymal hypoattenuation of  
the left occipital lobe 
Unremarkable Matched perfusion defect in left 
PCA territory 
 CT Left PCA territory   
ischemic infarct 
RS_154 Parenchymal hypoattenuation of  
the right basal ganglia 
Right MCA M1 segment 
occlusion 
Mismatch in right MCA territory  CT Right MCA territory   
ischemic infarct 
RS_155 Unremarkable Unremarkable -  MRI Right thalamic ischemic 
infarct 
RS_156 Parenchymal hypoattenuation of  
the left temporal lobe 
Left MCA M1 segment 
occlusion 
-  MRI Left MCA territory   
ischemic infarct 
RS_157 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory   
ischemic infarct 
RS_158 Unremarkable Unremarkable -  CT Left MCA territory   
ischemic infarct 
RS_159 Unremarkable Unremarkable -  MRI Left pontine ischemic 
infarct 
RS_160 Unremarkable Left MCA M3 segment 
occlusion 
Mismatch in left MCA territory  CT Left MCA territory   
ischemic infarct 
RS_161 Parenchymal hypoattenuation of  
the left PCA territory 
Left PCA P1 segment 
occlusion 
-  CT Left PCA territory   
ischemic infarct 
RS_162 Unremarkable Unremarkable Mismatch in right MCA territory  MRI Right PCA and MCA 
territory ischemic infarcts 
RS_163 Parenchymal hypoattenuation in  
the right frontal lobe 
Right ICA occlusion -  MRI Right MCA territory   
ischemic infarct 
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 RS_164 Parenchymal hypoattenuation in  
the left temporal lobe 
Unremarkable -  CT Left MCA territory   
ischemic infarct 
RS_165 Unremarkable Basilar artery thrombosis Perfusion defect in right PCA and 
bilateral SCA territories 
 CT Right PCA and bilateral 
SCA territory ischemic inf. 
RS_166 Parenchymal hypoattenuation in  
the left temporal lobe 
Unremarkable -  MRI Left MCA territory   
ischemic infarct 
RS_167 Parenchymal hypoattenuation in  
the right basal ganglia 
Right MCA M1 segment 
occlusion 
Mismatch in right MCA territory  CT Right MCA territory 
ischemic infarct 
RS_168 Unremarkable Right MCA M2 segment 
occlusion 
Mismatch in right MCA territory  CT Right MCA territory 
ischemic infarct 
RS_169 Parenchymal hypoattenuation in  
the left frontal lobe 
Unremarkable Mismatch in right MCA territory  MRI Left MCA territory   
ischemic infarct 
RS_170 Unremarkable Unremarkable Mismatch in right MCA territory  MRI Right MCA territory 
ischemic infarct 
RS_171 Unremarkable Right PCA P3 segment 
occlusion 
Perfusion defect in right parietal 
lobe 
 MRI Right MCA and PCA 
territory ischemic infarcts 
RS_172 Unremarkable Unremarkable -  MRI Right PICA territory 
ischemic infarct 
RS_173 Unremarkable Right ICA stenosis -  MRI Right MCA territory 
ischemic infarct 
RS_174 Unremarkable Unremarkable -  MRI Left MCA territory 
ischemic infarct 
RS_175 Parenchymal hypoattenuation in  
the right frontal lobe 
Unremarkable -  CT Right MCA territory 
ischemic infarct 
RS_176 Parenchymal hypoattenuation in  
the right MCA territory 
Unremarkable -  MRI Right MCA territory 
ischemic infarct 
RS_177 Unremarkable Left MCA M2 segment 
occlusion 
Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
RS_178 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
S33
 RS_179 Unremarkable Unremarkable Mismatch in right MCA territory  MRI Right MCA territory 
ischemic infarct 
RS_180 Parenchymal hypoattenuation of  
the right basal ganglia 
Right MCA M1 segment 
occlusion 
-  CT Right MCA territory 
ischemic infarct 
RS_181 Unremarkable Left PCA stenosis -  MRI Bilateral mesencephalic 
ischemic infarcts 
RS_182 Unremarkable Unremarkable -  MRI Right MCA territory 
ischemic infarct 
RS_183 Unremarkable Left MCA M2 segment 
occlusion 
Mismatch in left ACA and MCA 
territories 
 MRI Left ACA and MCA 
territory ischemic infarcts 
RS_184 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
RS_185 Parenchymal hypoattenuation in  
the left frontal lobe 
Unremarkable Perfusion defect in left ACA 
territory 
 CT Left ACA territory ischemic 
infarct 
RS_186 Parenchymal hypoattenuation in  
the left MCA territory 
Left CCA occlusion Matched perfusion defect in left 
MCA territory 
 CT Left ACA and MCA 
territory ischemic infarcts 
RS_187 Unremarkable Unremarkable Unremarkable  MRI Left pontine ischemic 
infarct 
RS_188 Parenchymal hypoattenuation in  
the left basal ganglia 
Left ICA occlusion -  MRI Left MCA territory 
ischemic infarct 
RS_189 Parenchymal hypoattenuation in  
the right ACA territory 
Right ACA A2 segment 
occlusion 
Mismatch in right ACA territory  CT Right ACA territory 
ischemic infarct 
RS_190 Parenchymal hypoattenuation in  
the left MCA territory 
Left ICA occlusion Mismatch in left MCA territory  MRI Left MCA territory 
ischemic infarct 
RS_191 Parenchymal hypoattenuation in  
the left temporal lobe 
Left ICA stenosis -  MRI Bilateral MCA territory 
ischemic infarcts 
RS_192 Unremarkable Basilar artery thrombosis -  MRI Right PCA territory 
ischemic infarct 
RS_193 Unremarkable Unremarkable Unremarkable  MRI Left MCA territory 
ischemic infarct 
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 RS_194 Unremarkable Unremarkable Matched perfusion defect in right 
MCA territory 
 MRI Right MCA territory 
ischemic infarct 
RS_195 - (immediate MRI acquisition) - -  MRI Right MCA territory 
ischemic infarct 
RS_196 Unremarkable Unremarkable -  MRI Left medulla oblongata 
ischemic infarct 
RS_197 - (external MRI acquisition) - -  MRI Right MCA territory 
ischemic infarct 
RS_198 Unremarkable Left MCA M1 segment 
occlusion 
-  MRI Bilateral MCA territory 
ischemic infarcts 
RS_199 Parenchymal hypoattenuation in  
the left MCA territory 
Left MCA M1 segment 
occlusion 
-  MRI Left MCA territory 
ischemic infarct 
RS_200 Parenchymal hypoattenuation in  
the left MCA territory 
Unremarkable -  MRI Left MCA territory 
ischemic infarct 
CT, computed tomography; MRI, magnetic resonance imaging; ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, 
posterior cerebral artery; VA, vertebral artery; PICA, posterior inferior cerebellar artery; SCA, superior cerebellar artery; unremarkable, no signs for infarction; 
mismatch/match, with reference to blood flow and blood volume. Light grey indicates signs of infarction in at least one CT modality matching the final diagnosis.
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95  %  CI,  0.58  –  0.60).  The  agreement  on  specific  subtypes  was  higher  for  large‐artery 
atherosclerosis  (κ  =  0.71)  compared  to  small‐artery  occlusions  (κ  =  0.56).  Although  both 
systems idenfied a nearly identical number of patients as undeterminable (CCS: 4.673 cases; 
TOAST: 4.664 cases), the agreement was only κ = 0.44 (95 % CI 0.43 – 0.46). 
In  conclusion,  the  agreement between TOAST  and CCS  is  lower  than previously  reported. 
Both  classification  systems  leave more  than  25  %  of  IS  patients  undetermined.  Further 




Agreement between TOAST and CCS
ischemic stroke classification
The NINDS SiGN Study
ABSTRACT
Objective: The objective of this study was to assess the level of agreement between stroke sub-
type classifications made using the Trial of Org 10172 Acute Stroke Treatment (TOAST) and
Causative Classification of Stroke (CCS) systems.
Methods: Study subjects included 13,596 adult men and women accrued from 20 US and Euro-
pean genetic research centers participating in the National Institute of Neurological Disorders
and Stroke (NINDS) Stroke Genetics Network (SiGN). All cases had independently classified
TOAST and CCS stroke subtypes. Kappa statistics were calculated for the 5 major ischemic
stroke subtypes common to both systems.
Results: The overall agreement between TOAST and CCS was moderate (agreement rate, 70%;
k 5 0.59, 95% confidence interval [CI] 0.58–0.60). Agreement varied widely across study sites,
ranging from 28% to 90%. Agreement on specific subtypes was highest for large-artery ather-
osclerosis (k 5 0.71, 95% CI 0.69–0.73) and lowest for small-artery occlusion (k 5 0.56, 95%
CI 0.54–0.58).
Conclusion: Agreement between TOAST and CCS diagnoses wasmoderate. Caution is warranted
when comparing or combining results based on the 2 systems. Replication of study results, for
example, genome-wide association studies, should utilize phenotypes determined by the same
classification system, ideally applied in the same manner. Neurology® 2014;83:1653–1660
GLOSSARY
CI 5 confidence interval; CCS 5 Causative Classification of Stroke; NINDS 5 National Institute of Neurological Disorders
and Stroke; SiGN 5 Stroke Genetics Network; TOAST 5 Trial of Org 10172 Acute Stroke Treatment.
Trial of Org 10172 in Acute Stroke Treatment (TOAST)1 and the Causative Classification of
Stroke (CCS)2–4 are 2 well-established systems for classifying ischemic stroke. They use broadly
similar categories of stroke diagnoses, e.g., large-vessel, small-vessel, and cardioembolic stroke,
but may not necessarily be interchangeable. TOAST and CCS require different data and use
different classification criteria and decision-making rules. It is therefore critical to understand the
agreement rate between these 2 systems in diverse clinical and research settings. Delineation of
the level of agreement between TOAST and CCS would be important to assess the validity of
combining ischemic stroke subtyping using these 2 systems.
This report investigates the agreement between TOAST and CCS within the Stroke
Genetics Network (SiGN), a collaborative study involving a network of international genetic
research centers. This analysis is a retrospective pooled analysis of several independent
research efforts, each of which enrolled patients under different research protocols.5 TOAST
and CCS were compared by assessing identical subtype assignment and accounting for
agreement by chance by using a k statistic. Because there is no gold standard in etiologic
stroke classification, we make no qualitative judgments regarding which system is “better” at
subtype assignment, rather report agreement to help inform whether the 2 systems make
similar assignments.
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METHODS The Stroke Genetics Network (SiGN) is a multi-
national collaboration with the goal of finding genetic determi-
nants of stroke.5 The SiGN Study standardized the
phenotyping of the cases across all genetic research centers. The
CCS system was chosen to facilitate study administration because
of the Web-based, semiautomated, and evidence- and rule-based
nature of the system (https://ccs.mgh.harvard.edu).2 In addition
to classifying stroke cases by subtype, the CCS system also has the
practical benefit for large consortia of standardizing and
centralizing all individual data points that underlie subtype
classification.2 A centralized committee of 4 expert neurologists
met weekly to monitor subtype data quality and site performance.
This panel aimed to ensure consistency of CCS assignments
across all SiGN centers but did not contribute to subtype
classifications directly.
CCS subtyping of stroke cases for this report was performed
based on reviews of data available in study-specific case report forms
and medical records by 41 adjudicators from 10 European and 10
US sites. Adjudicators included neurology residents (n5 10), neu-
rologists (n 5 17), stroke fellows (n 5 12), one nurse, and one
student. Adjudicators completed an interactive online training
module and a certification module available at the CCS Web site
(https://ccs.mgh.harvard.edu). Data adjudication began in June
2011 and was still ongoing at the time of data analysis for this
report. This study included 13,596 cases adjudicated as of July 7,
2013. A centralized committee of 4 expert neurologists met weekly
to monitor data quality and site performance. Feedback was pro-
vided during subtyping to ensure quality of data.
TOAST subtypes were determined locally by site investiga-
tors following individual study protocols without benefit of cen-
tral oversight. Of note, TOAST subtypes were determined using
the same data sources that were available for the CCS classifica-
tions. TOAST and CCS classifications were done by different
physicians and at different time points in the majority of study
sites but using the same study or site-specific case report forms.
CCS adjudicators were required to confirm that they were fully
blind to TOAST results before they began to enter patient data
into CCS.
Two deviations from the above-mentioned protocol warrant
acknowledgment. One center (STGEORGE) had completed case
phenotyping using the CCS system before the initiation of the
SiGN Study. Therefore, this center did not conduct CCS subtyp-
ing under the oversight of the expert panel. One other study
(BASICMAR) utilized a computer algorithm rather than a certified
adjudicator to extract data from a study data source to populate the
required fields in CCS for 389 cases of their total of 1,088 cases.
For the purposes of this report, a complete investigation was
defined as having head imaging (CT, MRI, or both), vascular
imaging of both the intracranial and extracranial vasculature,
and a cardiac evaluation consisting of echocardiography (either
transthoracic or transesophageal) unless cardiac source of embo-
lism was identified by medical history, physical examination, or
ECG. Cranial imaging (either CT or MRI) was required for
inclusion in the SiGN case set.
Statistical analysis was performed using SAS 9.2 (SAS Insti-
tute, Cary, NC). Percent of absolute agreement in subtype assign-
ments is reported. Agreement was also estimated by k statistics,
and 95% confidence intervals (CIs) are provided for interpreta-
tion. Nonweighted k values were calculated for 5 major stroke
subtypes common to both systems: large-artery atherosclerosis,
cardioaortic embolism, small-artery occlusion, other causes,
and undetermined causes (i.e., cryptogenic causes, unclassifiable
cases because of multiple competing etiologies, and incomplete
evaluation).
RESULTS In total, 16,267 cases were enrolled in
SiGN via the Web-based CCS system as of July 7,
2013. Of those, 13,596 stroke cases had subtypes
classified using the TOAST system by the individual
studies. Sample characteristics varied considerably by
study design among the participating sites (table 1).
For example, GEOS (Genetics of Early Onset
Stroke)6 targeted recruitment among young stroke
patients. WHI, the Women’s Health Initiative,
recruited women only and reported low levels of
current smoking. The diversity of study designs and
populations allows for evaluation of the agreement
between TOAST and CCS across a variety of clinical
and research settings.
The overall agreement between CCS and TOAST
was moderate (table 2) (k 5 0.59, 95% CI 0.58–
0.60), although the agreement varied across study sites
(x2 [df 5 19] 5 782; p , 0.0001) (table 2). Agree-
ment on specific subtypes was highest for large-artery
atherosclerosis (k 5 0.71) and lowest for small-artery
occlusions (k 5 0.56). Table 3 provides the cross-
tabulation for subtype agreement. The 2 systems
identified approximately equal number of cases as
undetermined (CCS 4,673 cases and TOAST 4,664
cases), but did not show much agreement on which
those undetermined cases were (table 3). The agree-
ment of TOAST and CCS for undetermined cases was
only k 5 0.44 (95% CI 0.43–0.46). Agreement
between TOAST and CCS regarding undetermined
cases was primarily based on cases CCS determined
to be “incomplete evaluations” (k5 0.30). Cases clas-
sified by CCS as either “cryptogenic embolism” or
“unclassified” had no agreement with the TOAST cat-
egory of “undetermined” (k , 0.05).
Stroke subtype agreement varied substantially
across genetic research centers (see table 2). Part of
this variability across study sites could be attributable
to the variable process used to implement TOAST
subtyping across sites. Additional variability could be
attributable to the presence or absence of certain diag-
nostic evaluations available to each center (table 4).
Agreement was slightly higher in the presence of ves-
sel imaging, but slightly lower when a cardiac evalu-
ation was performed. Agreement between TOAST
and CCS was slightly lower when a complete evalu-
ation was conducted (defined as the presence of brain
imaging, cardiac evaluation, vascular imaging of the
intra- and extracranial circulations). Regardless, the
slight variation in agreement in the presence or
absence of certain diagnostic evaluations (table 4) is
not sufficient to account for the large variation seen
across genetic research centers (table 2). The overall
agreement reported here (k 5 0.59) belies the fact
that in any particular center agreement ranged from
excellent (STGEORGE k5 0.85) to poor (BRAINS
k 5 0.12).
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A sensitivity analysis was performed removing the 2
centers that deviated from the network protocol.
Removing the STGEORGE and relevant BASICMAR
cases resulted in lower overall agreement (k 5 0.57).
DISCUSSION To accelerate advances in stroke treat-
ment, prevention, and discovery of genetic and other
novel risk factors, the heterogeneity of ischemic stroke
must be addressed. Identifying the genetic determi-
nants of many complex diseases has proven challeng-
ing7; stroke is no exception. Success is more likely to
occur in large studies and active consortia of individ-
ual studies.8 Standardization and harmonization of
phenotypes will reduce misclassification error when
combining analysis efforts in consortia. In the study
of stroke, this often means the standardization of
subtyping among cases.
Previously reported levels of agreement between
the TOAST and CCS classification systems were
high.9,10 In a prospective cohort study of North
Dublin, a single physician performed data abstraction
and classification in both TOAST and CCS in 381
patients with first-ever ischemic stroke. An overall
agreement was not reported, but agreement between
the 2 systems on specific subtypes ranged from excel-
lent (k5 0.95 for cardioembolism) to moderate (k5
0.69 for other and undetermined causes). Another
study of 690 ischemic stroke patients from a single
center (also included in this report, STGEORGE)
reported excellent overall agreement (k 5 0.85).
We report a lower overall agreement between the 2
systems, with some centers witnessing much less
agreement between TOAST and CCS. This could
be attributable to differences among the studies in
their ability to take into account the whole spectrum
Table 1 Descriptive characteristics of the cases in the SiGN Study with both CCS and TOAST classifications, by genetic research center
Study No. Age, y (SD) % Female % Vascular imaging % Cardiac evaluation % Head CT % Brain MRI %Complete investigationa
SiGN 13,596 66.6 (15.2) 48.1 65.1 79.2 92.5 57.0 54.8
BASICMAR 1,088 74.8 (11.7) 47.2 96.3 67.6 99.5 41.8 64.2
BRAINS 346 70.3 (13.8) 46.5 23.4 42.5 93.4 35.8 12.7
EDIN 620 71.0 (11.8) 45.5 1.3 46.3 79.0 25.5 0.7
GASROS 613 64.7 (14.9) 36.4 98.7 92.7 86.3 83.2 91.8
GCNKSS 642 67.3 (14.3) 50.2 54.8 84.6 93.3 58.3 47.8
GEOS 891 41.3 (6.9) 41.3 81.8 91.5 90.6 85.3 76.1
GRAZ 512 67.9 (14.3) 39.3 93.0 77.0 97.5 58.6 70.7
ISGS 675 63.6 (14.9) 43.1 91.4 80.4 91.0 84.3 73.9
KRAKOW 1,486 68.7 (14.0) 48.2 20.7 85.5 99.0 19.7 19.1
LEUVEN 524 67.6 (14.6) 41.8 91.0 96.9 92.4 84.9 88.4
MCISS 876 69.6 (14.7) 49.4 90.3 94.4 92.9 82.0 86.2
MIAMISR 314 62.6 (14.4) 35.0 97.8 99.4 99.0 85.7 97.1
MUNICH 524 66.7 (14.4) 40.8 99.8 92.4 86.8 82.3 92.4
NOMAS 438 69.3 (12.7) 54.3 77.9 95.9 98.2 48.2 77.4
OXVASC 2002–2008 554 74.2 (12.6) 50.9 23.6 56.7 93.5 24.4 15.0
REGARDS 489 71.7 (8.5) 46.8 52.4 74.8 90.6 65.4 43.6
SAHLSIS 1,083 55.6 (11.0) 35.5 50.5 79.0 98.7 58.1 41.1
STGEORGE 678 75.2 (12.9) 47.2 98.5 71.1 — — 70.4
SWISS 407 62.9 (12.8) 46.7 67.1 70.0 64.6 47.7 51.4
WHI 836 74.0 (6.7) 100.0 36.8 73.2 89.2 55.5 28.6
Abbreviations: BASICMAR 5 BASe de datos de ICtus del hospital del MAR (Spain); BRAINS 5 Bio-Repository of DNA in Stroke (England); CCS 5 Causative
Classification of Stroke; EDIN 5 Edinburgh stroke study (Scotland); GASROS 5 Genes Affecting Stroke Risk and Outcome Study (Boston); GCNKSS 5
Greater Cincinnati Northern Kentucky Stroke Study (Cincinnati); GEOS 5 Genetics of Early-Onset Stroke (Baltimore); GRAZ 5 Graz Stroke Study (Austria);
ISGS 5 Ischemic Stroke Genetics Study (Jacksonville); KRAKOW 5 Krakow stroke study (Poland); LEUVEN 5 Leuven stroke study (Belgium); MCISS 5
Middlesex County Ischemic Stroke Study (New Jersey); MIAMISR 5 Miami Stroke Registry (Miami); MUNICH 5 Munich stroke study (Germany); NOMAS 5
Northern Manhattan Aging Study (New York); OXVASC5 Oxford Vascular Study (England); REGARDS5 Reasons for Geographic And Racial Differences in
Stroke (Birmingham); SAHLSIS 5 Sahlgrenska Academy Study on Ischemic Stroke (Sweden); SiGN 5 Stroke Genetics Network; STGEORGE 5 St. George’s
Stroke Study (England); SWISS 5 Siblings With Ischemic Stroke Study (Jacksonville); TOAST 5 Trial of Org 10172 Acute Stroke Treatment; WHI 5
Women’s Health Initiative (Boston).
a Complete investigation 5 head imaging (either CT or MRI or both), vascular imaging (requires both intracranial and extracranial arterial imaging), and
cardiac evaluation (echocardiography performed unless cardiac source of embolism identified on physical examination and ECG).
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Table 2 Agreement statistics, k (95% confidence interval), between CCS and TOAST for the SiGN Study
Study No. % Agreed Overall k CE k LAA k SAO k Other k Undetermined k
SiGN 13,596 0.70 0.59 (0.58–0.60) 0.68 (0.67–0.70) 0.71 (0.69–0.73) 0.56 (0.54–0.58) 0.64 (0.61–0.67) 0.44 (0.43–0.46)
BASICMAR 1,088 0.87 0.81 (0.78–0.84) 0.85 (0.82–0.88) 0.82 (0.78–0.87) 0.89 (0.86–0.92) — —
BRAINS 346 0.28 0.12 (0.07–0.17) 0.30 (0.19–0.42) 0.14 (0.05–0.24) 0.09 (0.02–0.17) — 0.03 (20.06 to 0.11)
EDIN 620 0.69 0.47 (0.41–0.53) 0.64 (0.55–0.72) 0.76 (0.67–0.84) 0.31 (0.21–0.40) — 0.36 (0.29–0.43)
GASROS 613 0.69 0.59 (0.54–0.64) 0.62 (0.55–0.68) 0.69 (0.62–0.76) 0.57 (0.46–0.67) 0.67 (0.58–0.77) 0.42 (0.33–0.51)
GCNKSS 642 0.78 0.69 (0.65–0.74) 0.78 (0.72–0.84) 0.81 (0.74–0.87) 0.65 (0.58–0.73) 0.70 (0.45–0.95) 0.59 (0.52–0.65)
GEOS 891 0.66 0.53 (0.49–0.58) 0.61 (0.55–0.68) 0.70 (0.62–0.78) 0.69 (0.63–0.76) 0.42 (0.34–0.51) 0.39 (0.33–0.44)
GRAZ 512 0.78 0.70 (0.66–0.75) 0.74 (0.68–0.80) 0.87 (0.81–0.92) 0.64 (0.54–0.74) 0.84 (0.72–0.96) 0.54 (0.45–0.62)
ISGS 675 0.63 0.51 (0.46–0.56) 0.55 (0.48–0.62) 0.64 (0.57–0.71) 0.40 (0.31–0.50) 0.78 (0.67–0.90) 0.36 (0.29–0.43)
KRAKOW 1,486 0.75 0.62 (0.59–0.65) 0.67 (0.63–0.71) 0.83 (0.79–0.87) 0.22 (0.12–0.32) 0.83 (0.73–0.92) 0.52 (0.47–0.56)
LEUVEN 524 0.67 0.54 (0.49–0.60) 0.62 (0.55–0.68) 0.67 (0.58–0.75) 0.49 (0.36–0.62) 0.79 (0.67–0.91) 0.33 (0.25–0.42)
MCISS 876 0.61 0.50 (0.46–0.54) 0.56 (0.50–0.62) 0.57 (0.51–0.63) 0.74 (0.67–0.81) 0.60 (0.49–0.71) 0.22 (0.16–0.28)
MIAMISR 314 0.68 0.58 (0.52–0.65) 0.66 (0.57–0.74) 0.63 (0.53–0.73) 0.68 (0.58–0.79) 0.48 (0.31–0.65) 0.34 (0.20–0.48)
MUNICH 524 0.63 0.51 (0.45–0.56) 0.65 (0.58–0.72) 0.53 (0.45–0.62) 0.42 (0.27–0.57) 0.67 (0.55–0.79) 0.30 (0.22–0.39)
NOMAS 438 0.65 0.54 (0.48–0.60) 0.55 (0.47–0.64) 0.76 (0.67–0.84) 0.65 (0.56–0.73) 0.36 (0.00–0.72) 0.31 (0.22–0.40)
OXVASC 2002–2008 554 0.76 0.66 (0.61–0.71) 0.83 (0.78–0.88) 0.88 (0.81–0.95) 0.39 (0.30–0.49) 1.00 (1.00–1.00) 0.57 (0.50–0.63)
REGARDS 489 0.62 0.47 (0.41–0.53) 0.47 (0.37–0.56) 0.65 (0.56–0.75) 0.45 (0.34–0.56) 0.56 (0.41–0.72) 0.37 (0.28–0.45)
SAHLSIS 1,083 0.68 0.56 (0.52–0.60) 0.70 (0.65–0.76) 0.73 (0.66–0.79) 0.31 (0.23–0.38) 0.84 (0.79–0.89) 0.41 (0.35–0.46)
STGEORGE 678 0.90 0.85 (0.82–0.89) 0.91 (0.87–0.94) 0.89 (0.85–0.94) 0.85 (0.79–0.90) — 0.78 (0.72–0.83)
SWISS 407 0.54 0.38 (0.32–0.44) 0.45 (0.33–0.56) 0.65 (0.56–0.74) 0.13 (0.06–0.20) 0.53 (0.34–0.72) 0.27 (0.18–0.36)
WHI 836 0.64 0.50 (0.45–0.54) 0.66 (0.59–0.72) 0.61 (0.52–0.70) 0.46 (0.39–0.53) 0.45 (0.30–0.60) 0.38 (0.32–0.45)
Abbreviations: BASICMAR 5 BASe de datos de ICtus del hospital del MAR (Spain); BRAINS 5 Bio-Repository of DNA in Stroke (England); CCS 5 Causative Classification of Stroke; CE 5 cardiac embolism; EDIN 5
Edinburgh stroke study (Scotland); GASROS 5 Genes Affecting Stroke Risk and Outcome Study (Boston); GCNKSS 5 Greater Cincinnati Northern Kentucky Stroke Study (Cincinnati); GEOS 5 Genetics of Early-
Onset Stroke (Baltimore); GRAZ 5 Graz Stroke Study (Austria); ISGS 5 Ischemic Stroke Genetics Study (Jacksonville); KRAKOW 5 Krakow stroke study (Poland); LAA 5 large-artery atherosclerosis; LEUVEN 5
Leuven stroke study (Belgium); MCISS 5 Middlesex County Ischemic Stroke Study (New Jersey); MIAMISR 5 Miami Stroke Registry (Miami); MUNICH 5 Munich stroke study (Germany); NOMAS 5 Northern
Manhattan Aging Study (New York); OXVASC 5 Oxford Vascular Study (England); REGARDS 5 Reasons for Geographic And Racial Differences in Stroke (Birmingham); SAHLSIS 5 Sahlgrenska Academy Study on
Ischemic Stroke (Sweden); SAO 5 small-artery occlusion; SiGN 5 Stroke Genetics Network; STGEORGE 5 St. George’s Stroke Study (England); SWISS 5 Siblings With Ischemic Stroke Study (Jacksonville); TOAST
5 Trial of Org 10172 Acute Stroke Treatment; WHI 5 Women’s Health Initiative (Boston).

















of variance in determining etiologic stroke sub-
types. The present study, in our opinion, offers less
bias because of its larger sample size, higher number
of raters, multicenter design, and methodology that
required a blinded assessment of CCS and TOAST
subtypes. The current report provides agreement
statistics stratified by study center and demonstrates
variability in agreement rates with many genetic
research centers having poor agreement (14 of 20
have k , 0.60). One could interpret our results to
indicate that in many research settings, the agree-
ment between the 2 systems is quite low and data
from standardized chart abstractions studies may
not reflect the complexities of many practical
implementations.
The lack of good agreement between TOAST and
CCS is not surprising because these 2 systems use
different classification criteria, definitions for subtypes,
and diagnostic investigation requirements (table 5).
Furthermore, their internal reliability also differs; exist-
ing studies by independent investigators demonstrate a
moderate interrater reliability for the TOAST classifi-
cation system with k values ranging between 0.42 and
0.54.11–15 In contrast, interrater reliability of the CCS
ranges between 0.8 and 0.9.2–4 These studies tended
to be small and with varying methodologies. Well-
powered reliability studies of both systems are still
needed. While TOAST and CCS differ from each
other in several ways, they both are subject to variabil-
ity because of differences in adjudicators’ ability to
Table 3 Cross-classification of 13,596 cases by TOAST and CCS
TOAST
LAA CE SAO Other Undetermined Total
CCS
LAA 1,691 113 83 18 453 2,358
CE 103 3,063 155 27 761 4,109
SAO 27 68 1,297 12 296 1,700
Other 42 59 22 439 203 765
Undetermined 246 485 902 71 2,960 4,664
Total 2,109 3,788 2,459 567 4,673 13,596
Abbreviations: CCS 5 Causative Classification of Stroke; CE 5 cardiac embolism; LAA 5 large-artery atherosclerosis;
SAO 5 small-artery occlusion; TOAST 5 Trial of Org 10172 Acute Stroke Treatment.
Table 4 Agreement statistics, k (95% confidence interval), between CCS and TOAST for the SiGN Study by the presence of diagnostic
evaluations
No. Overall k CE k LAA k SAO k Other k Undetermined k
Vascular imaging
Present 8,846 0.61 (0.60–0.62) 0.67 (0.65–0.68) 0.70 (0.68–0.72) 0.67 (0.65–0.69) 0.67 (0.64–0.70) 0.40 (0.37–0.42)
Absent 4,750 0.54 (0.52–0.56) 0.72 (0.70–0.74) 0.69 (0.65–0.73) 0.34 (0.30–0.37) 0.51 (0.43–0.59) 0.45 (0.43–0.48)
Cardiac evaluation
Present 10,768 0.57 (0.56–0.58) 0.66 (0.64–0.67) 0.68 (0.66–0.70) 0.56 (0.54–0.59) 0.61 (0.58–0.65) 0.40 (0.38–0.42)
Absent 2,828 0.61 (0.59–0.64) 0.35 (0.23–0.46) 0.80 (0.77–0.83) 0.53 (0.50–0.57) 0.74 (0.69–0.80) 0.54 (0.51–0.57)
Head CT
Present 11,948 0.58 (0.57–0.59) 0.67 (0.66–0.69) 0.70 (0.68–0.72) 0.55 (0.53–0.57) 0.65 (0.62–0.68) 0.43 (0.41–0.45)
Absent 970 0.51 (0.47–0.55) 0.59 (0.53–0.65) 0.68 (0.61–0.74) 0.47 (0.40–0.54) 0.58 (0.47–0.69) 0.37 (0.31–0.43)
Brain MRI
Present 7,358 0.57 (0.56–0.59) 0.62 (0.60–0.65) 0.69 (0.66–0.71) 0.61 (0.59–0.63) 0.66 (0.63–0.70) 0.40 (0.37–0.42)
Absent 5,560 0.58 (0.56–0.60) 0.71 (0.69–0.73) 0.72 (0.69–0.75) 0.43 (0.39–0.46) 0.55 (0.49–0.62) 0.46 (0.44–0.49)
Complete evaluation
Present 7,451 0.58 (0.56–0.59) 0.65 (0.63–0.66) 0.67 (0.65–0.69) 0.64 (0.61–0.67) 0.63 (0.59–0.67) 0.37 (0.34–0.39)
Absent 6,145 0.60 (0.58–0.61) 0.73 (0.71–0.75) 0.77 (0.75–0.80) 0.48 (0.45–0.51) 0.66 (0.61–0.71) 0.49 (0.47–0.51)
Abbreviations: CCS 5 Causative Classification of Stroke; CE 5 cardiac embolism; LAA 5 large-artery atherosclerosis; SAO 5 small-artery occlusion;
SiGN 5 Stroke Genetics Network; TOAST 5 Trial of Org 10172 Acute Stroke Treatment.
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interpret diagnostic test findings as well as variability in
the completeness and quality of available diagnostic
investigations. Regarding the latter point, we found
that agreement for a subtype was generally higher when
diagnostic investigations were complete for that partic-
ular subtype. For instance, in patients with complete
cardiac evaluation, the agreement for cardiac embolism
was almost twice as high compared to those with
incomplete cardiac investigation (k 5 0.66 vs 0.35;
table 4). Likewise, agreement for small-artery occlusion
was higher in the presence of brain MRI (k 5 0.61 vs
0.43). In contrast to cardiac embolism and small-artery
occlusion, there was no difference in agreement for
large-artery atherosclerosis between cases with and with-
out complete vascular evaluation. This may be attrib-
utable to diagnosis of large-artery atherosclerosis being
contingent on extracranial carotid artery stenosis—the
most common site for large-artery atherosclerosis—
which does not require a complete assessment of both
extracranial and intracranial vessels.
These findings suggest that availability of objec-
tive diagnostic information reduces the subjective
component in decision-making for stroke subtypes
regardless of the classification system used. Never-
theless, too much diagnostic information provides
the opportunity for differential investigator inter-
pretation in the absence of rule-based criteria and
this may in turn reduce agreement between CCS
and TOAST. In line with this, we found that overall
agreement rate was lower, albeit slightly, when all
investigations (brain imaging, brain vascular imag-
ing, and cardiac evaluation) were complete than
when they were incomplete (k 5 0.58 vs 0.60).
We also found that the agreement rate for the unde-
termined group was lower than rates in other etio-
logic categories. The undetermined group is a
heterogeneous category consisting of cryptogenic
stroke (undetermined-unknown), multiple compet-
ing etiologies (undetermined-unclassified), and
missing diagnostic tests (incomplete evaluation).
Lower agreement rate in the undetermined category
reflects differences between TOAST and CCS in
dealing with multiple potential causes and missing
diagnostic tests. CCS takes into account the com-
pleteness of diagnostic investigations and strength
of evidence favoring one mechanism over others in
the presence of multiple mechanisms in identifying
stroke subtypes. In contrast, TOAST provides lim-
ited guidance on these issues leading to room for
opinion in many practical implementations and
hence variance in subtype assignments.
The present study required a uniform Web-based
training and certification of investigators to be able to
perform CCS. The same standardization was not
applied to the TOAST classification. The TOAST
classification was done locally, using local interpreta-
tions of the TOAST classification system, and before
the formation of the SiGN collaboration. This differ-
ential application of TOAST is likely responsible for
the variability in agreement seen between the centers.
Thus, the overall agreement captures both differences
in the subtyping systems and differences in their ap-
plications. The optimal test to compare the 2 classifi-
cations would have included prospective data-quality
assessment and centrally trained certified investigators
for performing also the TOAST classification at the
same time as the CCS. However, we address this lim-
itation by assessing agreement separately within each
genetic research center, and the agreement between
the 2 systems was modest at best for a majority of
them. In only 2 of the 20 studies can agreement
between TOAST and CCS be classified as excellent
(k . 0.80). Of note, both of those studies used pro-
tocols for CCS assignment that deviated from the
Table 5 Characteristics of the TOAST and CCS classification systems
TOAST CCS
Year of publication 1993 2005
Diagnosis of LAA Requires imaging of a limited portion of
the extracranial circulation
Result influenced by intracranial
imaging (if performed)
Diagnosis of SAO Does not require imaging confirmation Does require imaging
confirmation
Size limit for lacunar infarct 15 mm 20 mm
Imaging of the parent artery in lacunar infarcts
required
No Yes
Threshold to separate high- and low-risk cardiac
sources
No 2% absolute primary risk
threshold
Criteria to identify the most likely etiology in the
presence of multiple etiologies
No Yes
Criteria to identify a known subtype in patients
with missing tests
No Yes
Abbreviations: CCS 5 Causative Classification of Stroke; LAA 5 large-artery atherosclerosis; SAO 5 small-artery occlu-
sion; TOAST 5 Trial of Org 10172 Acute Stroke Treatment.
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recommended consortium design. In addition, a
computerized tool for TOAST classification has also
been made available12 and an additional question of
interest may be how well the computerized TOAST
agrees with CCS.
The agreement between CCS and TOAST reported
here is lower than previously reported. The low agree-
ment between the 2 systems described here simply
means that the 2 systems classify stroke cases in differ-
ent categories, although perhaps unfortunately, the
names of the categories are similar. The practical impli-
cation of this finding is that combining or comparing
classifications across systems should proceed with cau-
tion, and where possible, rephenotyping should be
encouraged before combining data. For example, repli-
cation of results from genetic association studies should
be made using phenotypes from the same classification
system. A large benefit of the CCS system is the stan-
dardization of input and output data across cases from
different sites. This feature allows for flexible analysis
and further stratification of stroke phenotypes and
hence promises utility in genetic studies such as SiGN.
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4.3. Loci  associated  with  ischaemic  stroke  and  its  subtypes  (SiGN):  a 
genome‐wide association study 
The identification of disease‐associated genetic variants represents an important strategy for 
the  discovery  of  disease‐causing molecular  pathways  and  eventually  the  development  of 
new diagnostic tests and therapies. Genome‐wide association studies (GWAS) serve as a tool 
to  link  these  single‐nucleotide  polymorphisms  (SNP)  with  a  phenotype,  but  have  been 
limited by small sample sizes and phenotypic heterogeneity in the context of IS. 
In a  first step, 16.851  IS cases and 32.473 controls  from different ancestries were enrolled 
for genome‐wide analysis. 1372 SNPs in 268 loci linked to IS or any etiological subgroup were 
identified.  The  second  step  included  an  additional  set  of  20.941  IS  cases  and  364.736 
controls from 18 independent studies enabling in silico analysis of overall 37.893 IS cases and 
397.209  controls  of  the  SNPs  identified  in  the  first  step.  By  this,  we  identified  a  novel 
association  of  large  artery  atherosclerosis‐related  stroke with  a  locus  near  TSPAN2  (joint 
odds ratio 1.19, 95 % CI 1.12 – 1.26, p=1.3x10‐9). Four previously established loci, PITX2 and 
ZFHX3  for cardioembolic stroke, HDAC9  for  large artery atherosclerosis‐related stroke, and 
12q24 near ALDH2 with small‐artery stroke, were confirmed. 
In addition to the identification of a novel locus associated with large artery atherosclerosis‐
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Loci associated with ischaemic stroke and its subtypes 
(SiGN): a genome-wide association study
NINDS Stroke Genetics Network (SiGN) and International Stroke Genetics Consortium (ISGC)*
Summary
Background The discovery of disease-associated loci through genome-wide association studies (GWAS) is the leading 
genetic approach to the identiﬁ cation of novel biological pathways underlying diseases in humans. Until recently, 
GWAS in ischaemic stroke have been limited by small sample sizes and have yielded few loci associated with 
ischaemic stroke. We did a large-scale GWAS to identify additional susceptibility genes for stroke and its subtypes.
Methods To identify genetic loci associated with ischaemic stroke, we did a two-stage GWAS. In the ﬁ rst stage, we 
included 16 851 cases with state-of-the-art phenotyping data and 32 473 stroke-free controls. Cases were aged 16 to 
104 years, recruited between 1989 and 2012, and subtypes of ischaemic stroke were recorded by centrally trained and 
certiﬁ ed investigators who used the web-based protocol, Causative Classiﬁ cation of Stroke (CCS). We constructed case-
control strata by identifying samples that were genotyped on nearly identical arrays and were of similar genetic ancestral 
background. We cleaned and imputed data by use of dense imputation reference panels generated from whole-genome 
sequence data. We did genome-wide testing to identify stroke-associated loci within each stratum for each available 
phenotype, and we combined summary-level results using inverse variance-weighted ﬁ xed-eﬀ ects meta-analysis. In the 
second stage, we did in-silico lookups of 1372 single nucleotide polymorphisms identiﬁ ed from the ﬁ rst stage GWAS in 
20 941 cases and 364 736 unique stroke-free controls. The ischaemic stroke subtypes of these cases had previously been 
established with the Trial of Org 10 172 in Acute Stroke Treatment (TOAST) classiﬁ cation system, in accordance with 
local standards. Results from the two stages were then jointly analysed in a ﬁ nal meta-analysis.
Findings We identiﬁ ed a novel locus (G allele at rs12122341) at 1p13.2 near TSPAN2 that was associated with large 
artery atherosclerosis-related stroke (ﬁ rst stage odds ratio [OR] 1·21, 95% CI 1·13–1·30, p=4·50 × 10–⁸; joint OR 1·19, 
1·12–1·26, p=1·30 × 10–⁹). Our results also supported robust associations with ischaemic stroke for four other loci that 
have been reported in previous studies, including PITX2 (ﬁ rst stage OR 1·39, 1·29–1·49, p=3·26 × 10–¹⁹; joint OR 1·37, 
1·30–1·45, p=2·79 × 10–³²) and ZFHX3 (ﬁ rst stage OR 1·19, 1·11–1·27, p=2·93 × 10–⁷; joint OR 1·17, 1·11–1·23, 
p=2·29 × 10–¹⁰) for cardioembolic stroke, and HDAC9 (ﬁ rst stage OR 1·29, 1·18–1·42, p=3·50 × 10–⁸; joint OR 1·24, 
1·15–1·33, p=4·52 × 10–⁹) for large artery atherosclerosis stroke. The 12q24 locus near ALDH2, which has previously 
been associated with all ischaemic stroke but not with any speciﬁ c subtype, exceeded genome-wide signiﬁ cance in the 
meta-analysis of small artery stroke (ﬁ rst stage OR 1·20, 1·12–1·28, p=6·82 × 10–⁸; joint OR 1·17, 1·11–1·23, 
p=2·92 × 10–⁹). Other loci associated with stroke in previous studies, including NINJ2, were not conﬁ rmed.
Interpretation Our results suggest that all ischaemic stroke-related loci previously implicated by GWAS are subtype 
speciﬁ c. We identiﬁ ed a novel gene associated with large artery atherosclerosis stroke susceptibility. Follow-up studies 
will be necessary to establish whether the locus near TSPAN2 can be a target for a novel therapeutic approach to stroke 
prevention. In view of the subtype-speciﬁ city of the associations detected, the rich phenotyping data available in the 
Stroke Genetics Network (SiGN) are likely to be crucial for further genetic discoveries related to ischaemic stroke.
Funding US National Institute of Neurological Disorders and Stroke, National Institutes of Health.
Introduction
Worldwide, stroke is the second leading cause of death1 and 
a major contributor to dementia and age-related cognitive 
decline. About 15 million people have a stroke each year.1 
Most survivors are left with a permanent disability, which 
makes stroke the world’s leading cause of adult incapacity.2 
Strokes result from the sudden occlusion or rupture of a 
blood vessel supplying the brain, and so are categorised 
accordingly as ischaemic (vessel occlusion) or haemorrhagic 
(vessel rupture) on the basis of neuroimaging results. Up 
to 85% of all strokes are ischaemic.
Although hypertension, atrial ﬁ brillation, diabetes 
mellitus, and cigarette smoking are known risk factors 
for stroke,3 a substantial proportion of the risk remains 
unexplained and might be attributable to inherited 
genetic variation. Discovery of genetic variants that 
predispose to stroke is a crucial ﬁ rst step toward the 
development of improved diagnostic tests for stroke and 
novel therapies that might reduce the disease burden. 
Genome-wide association studies (GWAS) have thus far 
identiﬁ ed only a few conﬁ rmed loci,4–7 which together 
account for a small proportion of the heritable risk.8
Ischaemic stroke occurs when the blood ﬂ ow to a region 
of the brain is interrupted because of blockage of a blood 
vessel. Because vessel occlusion can occur through 
diﬀ erent mechanisms, ischaemic stroke can be subtyped 
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on the basis of the presumed mechanism: large artery 
atherosclerosis, cardioembolism, or small artery occlusion. 
With one exception, all associations for ischaemic stroke 
detected in GWAS have been subtype-speciﬁ c, suggesting 
the need for studies that are powered to detect subtype-
speciﬁ c associations. The National Institute of Neurological 
Disorders and Stroke (NINDS) Stroke Genetics Network 
(NINDS-SiGN)9 is the largest and most comprehensive 
GWAS of stroke and its subtypes to date. We sought to 
detect new associations of polymorphisms with risk of 
ischaemic stroke and its subtypes and to provide evidence 
for previously reported associations.
Methods
Study design
We did a two-stage joint association analysis of ischaemic 
stroke and its subtypes. The ﬁ rst stage consisted of a 
GWAS, and the second stage was an in-silico association 
analysis of the top single nucleotide polymorphisms 
(SNPs) identiﬁ ed in the ﬁ rst stage in a set of independent 
samples of cases and controls. We then analysed both 
stages together to identify loci that exceeded the threshold 
for genome-wide signiﬁ cance (1 × 10–⁸). Compared with 
separate discovery and replication analyses, this two-stage 
approach has been shown to improve the power for 
discovery without altering the type I error.10
Study sample
For the ﬁ rst stage, we assessed 31 existing collections that 
included cases of ischaemic stroke with either available 
genotypic data or DNA for genotyping, neuroimaging 
conﬁ rmation of stroke, and adequate clinical data to 
enable phenotypic classiﬁ cation. The cases of ischaemic 
Research in context
Evidence before this study
We searched PubMed with the search terms “stroke” and “genome 
wide association study” for reports published before Oct 19, 2015. 
We only included peer-reviewed reports in English. Compared with 
the rapid pace of genetic discovery for other common disorders, 
only four loci (PITX2, HDAC9, ZFHX3, and 12q24.2) have been 
convincingly implicated by genome-wide association studies 
(GWAS) in ischaemic stroke. GWAS of stroke have been limited by 
small sample sizes and concerns about phenotypic heterogeneity.
Added value of this study
To our knowledge, the National Institute of Neurological 
Disorders and Stroke (NINDS)-Stroke Genetics Network (SiGN) 
project is the largest and most comprehensive study of ischaemic 
stroke so far. Discovery analyses were done in 16 851 cases and 
32 473 controls and ﬁ ndings were followed up in an additional 
20 941 cases and 364 736 controls. Furthermore, the project 
implemented the Causative Classiﬁ cation of Stroke (CCS) system 
to subtype cases and generated a rich phenotypic database. Trial 
of Org 10 172 in Acute Stroke Treatment (TOAST)-based 
subtypes were also available, allowing for the ﬁ rst ever analysis of 
the genetic overlap between TOAST and CCS subtypes.
Implications of all the available evidence
Our data show that increasing sample size and applying a 
standardised subtyping method can reveal additional 
information about the underlying genetic architecture of stroke. 
Because we had access to phenotype information generated by 
two diﬀ erent subtyping methods, we also showed that there is 
moderate to strong genetic correlation between the CCS and 
TOAST subtyping methods, suggesting that future studies 
might beneﬁ t from liberal inclusion of cases, regardless of 
subtyping approach. Also, our results show that all discovered 
loci, including the 12q24.12 locus, which was previously 
implicated in all ischaemic stroke, are speciﬁ c to a single 
subtype, suggesting that these subtypes will have at least partly 
distinct genetic signatures. Because of the subtype-speciﬁ city of 
genetic associations in stroke, substantially larger samples of 
stroke subtypes will probably be needed to expand the number 
of identiﬁ ed stroke loci to that of other common diseases. 
See Online for appendix
stroke in the second stage met similar requirements, 
except that we used pre-existing Trial of Org 10 172 in 
Acute Stroke Treatment (TOAST)11 subtyping data for the 
phenotypic classiﬁ cation. The appendix contains details 
about each collection, including their study design.
For each collection, approval for inclusion in the SiGN 
analysis complied with local ethical standards and with 
local institutional review board and ethics committee 
oversight. All people included as cases and controls 
provided written informed consent for genetic studies 
either directly or by a legally authorised representative.
Classiﬁ cation of stroke subtype
In the NINDS-SiGN,9 we used two subtyping systems: the 
Causative Classiﬁ cation of Stroke (CCS) system, which is 
a standardised web-based subtype classiﬁ cation system,12 
and the more widely used TOAST subtype classiﬁ cation 
system.11,13 Both of these systems are based on a similar 
conceptual framework but are operationalised  diﬀ erently. 
The TOAST subtyping system is based on the application 
of written rules requiring clinician judgment; patients 
with conﬂ icting potential causes are placed into an 
undetermined category. The CCS subtyping system uses 
two web-based algorithms that classify patients 
with conﬂ icting potential causes. Causative (CCSc) 
categorisation uses historical examination and test data 
from each ischaemic stroke subject to assign the most 
probable cause in the presence of competing aetiologies, 
while phenotypic (CCSp) categorisation uses abnormal 
test ﬁ ndings to assign each case into one or more major 
groups without using rules to determine the most likely 
aetiology. In addition to the generation of both CCSc and 
CCSp subtype categories, the advantages of the CCS 
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system are improved inter-observer and intra-observer 
reliability12,14,15 and the ability to capture and store individual 
data elements from the clinical evaluation of the subject.
In the ﬁ rst stage of our study, each site assigned stroke 
subtypes with the CCS system (appendix). All of the CCS 
data were collected, subjected to quality control, and 
analysed centrally. Most sites had previously generated 
TOAST subtype classiﬁ cations. In the second stage, we 
identiﬁ ed additional sites that had GWAS data for subtyped 
stroke cases. Because we included all available CCS-
classiﬁ ed cases in the ﬁ rst stage, we used the corresponding 
subtype categories from TOAST in the second stage.
For both CCS and TOAST, each case was assigned to 
one of ﬁ ve ischaemic stroke subtypes: cardioembolic, 
large artery atherosclerosis, small artery occlusion, 
undetermined, and other. Although the classiﬁ cation of 
other was available, we did not analyse it because of 
low sample counts and insuﬃ  cient power. In CCS, the 
classiﬁ cation undetermined was used to refer to 
cryptogenic cases in which no cause was identiﬁ ed after 
adequate assessment, whereas in TOAST, undetermined 
cases were those with incomplete assessment, more 
than one possible cause, and cryptogenic.
Quality control
Full details of the genotyping and quality control 
processes are provided in the appendix (p 4). Brieﬂ y, 
newly genotyped cases and about 1150 controls were 
genotyped on the Illumina 5M array (Illumina, 
San Diego, CA, USA) so we could include them in the 
analyses for the ﬁ rst stage. All other cases had been 
previously genotyped on various Illumina platforms 
(appendix). We selected publicly available external 
controls to match cases on the basis of ancestral 
background and genotyping array.
The cases and controls that were newly genotyped 
formed separate analysis groups (Krakow, Poland, and 
Leuven, Belgium; table 1). The remaining cases and 
controls were matched based on cohort, geographic region 
of the sample collection site, and genotyping platform 
(table 1). We assigned matched cases and controls into 
ancestry-speciﬁ c analysis strata in two steps (appendix). 
We projected samples onto HapMap 316 data using 
principal component analysis to establish a group of 
European ancestry samples. Then, we implemented a 
hyper-ellipsoid clustering technique based on principal 
components within self-reported groups of non-Hispanic 
black and Asian participants. We used the hyper-ellipsoid 
analysis to establish a group of non-Hispanic black 
(African ancestry) participants and a group of participants 
of Asian ancestry. Samples that were not grouped as 
European, African, or Asian ancestry formed the Hispanic 
stratum. We excluded samples of Asian ancestry from 
further analysis because of the small number. After 
establishing the ancestry-based composite groups, we did 
principal component analysis again to conﬁ rm the 
ancestral homogeneity within each case-control stratum. 




Ancestry groups Cases Controls
First stage
Case-control group 1
BRAINS UK 650Q European 267 ··
MGH-GASROS USA 610 European 111 ··
ISGS USA 610 European 351 ··
SWISS USA 610 European 25 ··
HABC USA 1M European ·· 1586
Case-control group 2
EDIN UK 660 European 566 ··
MUNICH UK 660 European 1131 ··
OXVASC UK 660 European 457 ··
STGEORGE UK 660 European 418 ··
KORA Germany 550 European ·· 804
WTCCC UK 660 European ·· 5150
Case-control group 3
GEOS USA 1M African, European 843 880
Case-control group 4
BRAINS UK 5M European, Hispanic 110 ··
MGH-GASROS USA 5M African, European, Hispanic 456 ··
GCNKSS USA 5M African, European, Hispanic 482 ··
ISGS USA 5M African, European, Hispanic 178 ··
MCISS USA 5M African, European, Hispanic 619 ··
MIAMISR USA 5M African, European, Hispanic 294 ··
NHS USA 5M European, Hispanic 314 ··
NOMAS USA 5M African, European, Hispanic 358 ··
REGARDS USA 5M African, European, Hispanic 304 ··
SPS3 The Americas, Spain 5M African, European, Hispanic 949 ··
SWISS USA 5M African, European, Hispanic 181 ··
WHI USA 5M African, European, Hispanic 454 ··
WUSTL USA 5M African, European, Hispanic 449 ··
HRS USA 2·5M African, European, Hispanic ·· 11 174
OAI USA 2·5M African, European ·· 3882
HCHS/SOL USA 2·5M Hispanic ·· 1214
Case-control group 5
Krakow Poland 5M European, Hispanic 880 717
Case-control group 6
Leuven Belgium 5M European, Hispanic 460 453
Case-control group 7
BASICMAR Spain 5M European, Hispanic 890 ··
ADHD Spain 1M European ·· 411
INMA Spain 1M European ·· 807
Case-control group 8
GRAZ Austria 610 European ·· 815
GRAZ Austria 5M European 609 ··
Case-control group 9
SAHLSIS Sweden 5M European, Hispanic 783 ··
LUND Sweden 5M European, Hispanic 613 ··
MDC* Sweden 610 European, Hispanic 211 1362
Case-control group 10
ASGC Australia 610 European 1109 1200
Case-control group 11
VISP USA, Canada, UK 1M African, European 1979 ··
(Table 1 continues on next page)
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Case-control strata then underwent extensive quality 
control (appendix). Finally, each stratum was prephased17 
and imputed. We imputed samples of European ancestry 
using a merged reference panel that included the 
1000 Genomes Project Phase I18 and the Genome of the 
Netherlands.19 We imputed samples in the African and 
Hispanic groups using the 1000 Genomes Project Phase I 
reference panel only. We added summary-level imputed 
data from an additional cohort (Vitamin Intervention for 
Stroke Prevention) to the ﬁ rst stage meta-analysis.
First stage genome-wide association analysis
After quality control and imputation, 16 851 cases and 
32 473 controls from 15 ancestry-speciﬁ c groups were 
available for genome-wide testing (table 1, appendix). 
Within each stratum, we analysed all ischaemic stroke 
phenotypes and the four main subtypes (cardioembolism, 
large artery atherosclerosis, small artery occlusion, and 
undetermined) as established with CCSc, CCSp, and 
TOAST, which were available for 12 612 (74·8%) cases. All 
GWAS were adjusted for sex and the top ten principal 
components; genome-wide testing was not corrected for 
age, because age information was missing for most of the 
controls.
After the GWAS, we removed SNPs with frequency of 
less than 1% because they showed excessive genomic 
inﬂ ation. We checked the frequencies of imputed SNPs 
for consistency with the continental populations repre-
sented in the 1000 Genomes Project Phase I, and we 
removed SNPs with a diﬀ erence in frequency of more 
than 30%. After quality control, 9·3 million to 
15·4 million SNPs were available in the study strata for 
the meta-analysis. We did inverse variance-weighted 
ﬁ xed-eﬀ ects meta-analysis across the 15 ancestry-speciﬁ c 
strata using MANTEL20 in each of the 15 traits. The 
genomic inﬂ ation factor λ of the 15 meta-analyses for 
each trait ranged from 0·936 to 1·005 (appendix pp 5–8).
Second stage analysis
In the second stage, we performed in-silico lookups 
of association results in 18 independent studies 
that contained 20 941 TOAST-subtyped cases and 
364 736 controls, using the nominally signiﬁ cant SNPs 
identiﬁ ed in the ﬁ rst stage (table 1 and appendix p 51). The 
SNPs selected for the second stage for each subtype were 
aggregated such that, for example, SNPs with p<1 × 10–⁶ 
from the three cardioembolism GWAS (CCSc, CCSp, and 
TOAST) were all selected for lookup in the independent 
TOAST cardioembolism cases and matched controls. This 
process was repeated for the other subtypes.
Joint analysis
We did a meta-analysis of the results from the in-silico 
lookups from the second stage and the results from the 
ﬁ rst stage. We set the threshold for genome-wide 
signiﬁ cance in the joint analysis at p<1 × 10–⁸, after 
correction for testing of the ﬁ ve phenotypes (all stroke, 




Ancestry groups Cases Controls
(Continued from previous page)
Melanoma 
Study
USA 1M European ·· 1047
HANDLs USA 1M African ·· 971
Total ·· ·· ·· 16 851 32 473
Second stage
ARIC USA Aﬀ y 6.0 African 263 2466
CADISP† Multi-cohort Illumina 610 European 555 9259
CHARGE† Multi-cohort Multi-chip European 3100 75 530
CHS USA Illumina Omni 1M African 110 623
deCODE Iceland Multi-chip European 5291 228 512
Glasgow UK ImmunoChip European 599 1775
HVH USA Illumina 370CNV European 577 1330
INTERSTROKE† Multi-cohort Cardio-
metabochip
African, East Asian, 
European, Hispanic
1771 2103
LUND Sweden 635 European 546 528
MDC Sweden 5M European 1304 3504
METASTROKE† Multi-cohort Multi-chip European 1729 7925
RACE Pakistan 660 South Asian 2385 5193
SAHLSIS Sweden 750 European 299 596
SIFAP Germany 2·5M European 981 1825
SIGNET-REGARDS USA Aﬀ y 6.0 African 258 2094
SWISS/ISGS USA Illumina 610 or 
660
African 173 389
UTRECHT The Netherlands ImmunoChip European 556 1145
VHIR-FMT-
BARCELONA
Spain HumanCore and 
ExomeChip
European 545 320
WGHS‡ USA Human Hap300 
and custom array
European 440 22 725
Total ·· ·· ·· 21 482 367 842
Joint
Total ·· ·· ·· 38 333 400 315
Case cohorts in the ﬁ rst stage were matched to external controls based on genotyping array, cohort, ancestry, and location 
of sample collection. Case-control groups were constructed for the ﬁ rst stage analyses from contributing cohorts, which 
were mainly case-only or control-only cohorts. Hispanic samples were an exception and are not shown as a separate group 
here, because the small number of samples required that we pool all available Hispanic samples into a single analysis 
stratum. The second stage consisted of in-silico SNP lookups of summary-level results in previously analysed case-control 
sets. Totals represent the number of unique samples, accounting for partial sample overlap between two sites (CHARGE and 
WGHS). NINDS-SiGN=National Institute of Neurological Disorders and Stroke Stroke Genetics Network. 
BRAINS=Biorepository of DNA in Stroke. MGH-GASROS=Massachusetts General Hospital—Genes Aﬀ ecting Stroke Risk and 
Outcome Study. ISGS=Ischemic Stroke Genetics Study. SWISS=Siblings with Ischemic Stroke Study. HABC=Health ABC. 
EDIN=Edinburgh Stroke Stoke. OXVASC=Oxford Vascular Study. STGEORGE=St George’s Hospital. KORA=MONICA/KORA 
Ausburg Study. WTCCC=Wellcome Trust Case Control Consortium. GEOS=Genetics of Early Onset Stroke. GCNKSS=Greater 
Cincinnati/Northern Kentucky Stroke Study. MCISS=Middlesex County Ischemic Stroke Study. MIAMISR=Miami Stroke 
Registry and Biorepository. NHS=Nurses’ Health Study. NOMAS=Northern Manhattan Study. REGARDS=Reasons for 
Geographic and Racial Diﬀ erences in Stroke. SPS3=Secondary Prevention of Small Subcortical Strokes. WHI=Women’s 
Health Initiative. WUSTL=Washington University St Louis. HRS=Health and Retirement Study. OAI=Osteoarthritis Initiative. 
HCHS/SOL=The Hispanic Community Health Study/Study of Latinos. LEUVEN=Leuven Stroke Genetics Study. 
BASICMAR=Base de Datos de Ictus del Hospital del Mar. ADHD=Attention-deﬁ cit Hyperactivity Disorder. INMA=Infancia y 
medio ambiente. SAHLSIS=Sahlgrenska Academy Study of Ischemic Stroke. LUND=Lund Stroke Registry. MDC=Malmo Diet 
and Cancer Study. ASGC=Australian Stroke Genetics Collaborative. VISP=Vitamin Intervention for Stroke Prevention. 
HANDLs=Health/Aging in Neighborhoods of Diversity across the Lifespan Study. ARIC=Atherosclerosis Risk in Communities 
Study. CADISP=Cervical Artery Dissection and Ischemic Stroke Patients. CHARGE=Cohorts for Aging and Research in Genetic 
Epidemiology. CHS=Cardiovascular Health Study. HVH=Heart and Vascular Health Study. GLASGOW=Glasgow ImmunoChip 
Study. RACE=Risk Assessment of Cardiovascular Events. SIFAP=Stroke in Young Fabry Patients. SIGNET=The Sea Island 
Genetics Network. UTRECHT=Utrecht ImmunoChip Study/PROMISe Study. WGHS=Women’s Genome Health Study. *Only 
TOAST subtypes available for the ﬁ rst stage. †Contributing cohorts are described in the appendix. ‡Not included in the 
ischaemic stroke and cerebroembolism analyses because of overlap with CHARGE.
Table 1: Case and control cohorts in NINDS-SiGN 
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cardioembolic, large artery atherosclerosis, small artery 
occlusion, and undetermined). λ in the ischaemic stroke 
joint analysis was 1·005 and ranged from 0·936 to 0·998 
in the subtype analyses (appendix pp 9–12).
Role of the funding source
The funder participated in the design of the study. The 
study investigators were solely responsible for the data 
collection, analysis, and interpretation. An employee of 
NINDS (KG) was a member of the writing committee 
The analysis team had full access to all data included in 
the study. The steering committee had ﬁ nal responsibility 
for the decision to submit the report for publication.
Results
After data quality control (appendix p 4 and pp 114–26), 
we included 16 851 stroke cases and 32 473 controls in the 
ﬁ rst stage of our analyses. The ﬁ rst stage GWAS revealed 
1372 SNPs in 268 loci associated with ischaemic stroke or 
a speciﬁ c subtype in any of the CCS or TOAST traits at 
p<1 × 10–⁶. We included an additional independent set of 
20 941 cases and 364 736 controls in the second stage, 
which enabled the joint analysis of 37 893 cases and 
397 209 controls across ﬁ ve primary independent traits 
(ischaemic stroke and the four subtypes).
Genome-wide Z scores (SNP β values divided by their 
respective SE) from the CCSc, CCSp, and TOAST 
GWAS were checked for correlation (Pearson’s r) 
between each possible pair of traits. The analysis 
revealed moderate to strong genetic correlation (ﬁ gure 1) 
between the standardised SNP eﬀ ects in CCSc, CCSp, 
and TOAST, despite the modest phenotypic correlation 
noted previously.21 The moderate to strong genetic 
correlation between CCS and TOAST within subtype-
speciﬁ c clusters suggested that TOAST subtyping was 
appro priate for inclusion in the second stage of the 
analysis. Phenotypic correlations were also strong 
within subtype-speciﬁ c clusters (ﬁ gure 1).
In the joint analysis of CCS (ﬁ rst stage) and TOAST 
(second stage) results, SNPs in two novel loci exceeded 
genome-wide signiﬁ cance. Four common SNPs in 
linkage disequilibrium (r²>0·57 in the 1000 Genomes 
Project samples of European ancestry) near the TSPAN2 
locus on chromosome 1 were associated at genome-wide 
signiﬁ cance with large artery atherosclerosis. The lead 
SNP in the associated locus was rs12122341 (odds ratio 
[OR] for the G allele 1·19, 95% CI 1·12–1·26, p=1·3 × 10–⁹; 
ﬁ gure 2, table 2). 
A second locus emerged as having a genome-wide 
signiﬁ cant association with ischaemic stroke, but only in 
samples of African ancestry. In view of the small sample 
size in which it was identiﬁ ed, the association must be 
interpreted with caution. rs74475935 in ABCC1 on 
chromosome 16 was associated with the undetermined 
phenotype (table 2, appendix p 14), driven by a variant 
with rare frequency (minor allele frequency [MAF] about 
0·01%) in European-ancestry samples and low frequency 
(MAF about 1·5%) in African-ancestry samples.
We also identiﬁ ed associations for the previously 
reported loci PITX24 and ZFHX35 for cardioembolic 
stroke, and HDAC96 for large artery atherosclerotic 
stroke, all of which exceeded genome-wide signiﬁ cance 
in our samples (table 2). The 12q24.12 locus near ALDH2, 
previously reported to be associated with all ischaemic 
stroke, but not with any speciﬁ c subtype,7 exceeded 
genome-wide signiﬁ cance in the joint analysis of all 
ischaemic stroke (OR for the T allele 1·07, 95% CI 
1·5–1·09, p=4·20 × 10–⁹). However, the association was 
even stronger for small artery occlusion in the joint 
analysis of CCSp in the ﬁ rst stage and TOAST in the 
second stage (OR 1·17, 95% CI 1·11–1·23, p=2·92 × 10–⁹); 
the association was not genome-wide signiﬁ cant in the 
joint analysis of CCSc (ﬁ rst stage) and TOAST (second 
stage; OR 1·16, 95% CI 1·10–1·22, p=2·77 × 10–⁸). 
Evidence of associations with other subtypes was reduced 
in our study (OR<1·1 and p>4 × 10–³ for cardioembolism, 
large artery atherosclerosis, and undetermined in the 
combined CCSp and TOAST analysis; appendix p 15). 
Systematic testing that accounted for shared controls 
(appendix p 15) showed a signiﬁ cant diﬀ erence in the 
magnitude of ORs between small artery occlusion and 
the combined non-small artery occlusion subtypes 
(p=0·048, appendix p 15), suggesting that the eﬀ ect of 
12q24.12 might be speciﬁ c for small artery occlusion.
By contrast, we did not ﬁ nd any evidence for the 
previously reported association between ischaemic stroke 
and NINJ2 (rs34166160, OR for the A allele 1·20, 95% CI 
0·96–1·48, p=0·106; table 2), even though our sample 
size had 100% power to detect an association (p<0·05) at 
this locus. In the full ﬁ rst stage analysis, evidence 
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Figure 1: Genetic and phenotypic correlation between subtyping methods in the ﬁ rst stage analysis
All cases with an available CCS subtype were included in the ﬁ rst stage analyses. Genome-wide Z scores from the 
CCSc, CCSp, and TOAST GWAS were checked for correlation between each possible pair of traits. Pearson’s 
r correlation coeﬃ  cient (mathematically equivalent in this scenario to the Lin’s concordance correlation coeﬃ  cient) 
within each square shows genetic correlation. Cohen’s κ within each square shows phenotypic agreement. CCSc1 
includes all undetermined strokes; CCSc2 includes all incomplete and unclassiﬁ ed strokes; and CCSc3 includes all 
cryptogenic and cardioembolic minor strokes. The CCSc2 and CCSc3 classiﬁ cations are mutually exclusive. 
CCS=Causative Classiﬁ cation of Stroke. CCSc=CCS causative. CCSp=CCS phenotypic. TOAST=Trial of Org 10172 in 
Acute Stroke Treatment classiﬁ cation system. GWAS=genome-wide association study. 
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CDKN2B-AS123 loci in large artery atherosclerosis, and 
for the ABO24 locus in all ischaemic stroke, large artery 
atherosclerosis, and cardioembolism (table 2). When we 
restricted our analysis to only the samples not used for 
the initial discovery (appendix p 52), CDKN2B-AS1 was 
associated with large artery atherosclerosis (OR for the 
G allele 1·09, 95% CI 1·02–1·17, p=0·009) and ABO was 
associated with all ischaemic stroke (OR for the C allele 
1·07, 95% CI 1·03–1·10, p=2·5 × 10–⁴), large artery 
atherosclerosis (OR 1·15, 95% CI 1·07–1·24, p=2·5 × 10–⁴), 
and cardioembolism (OR 1·09, 95% CI 1·02–1·16, 
p=0·007). For 6p21, however, we detected no evidence for 
any association with large artery atherosclerosis (OR for 
the T allele 1·04, 95% CI 0·96–1·12, p=0·304).
Discussion
Our results show a novel association between a genetic 
locus and large artery atherosclerosis. The lead SNP, 
rs12122341, is located in an intergenic region 23·6 kb 
upstream of TSPAN2, the gene encoding tetraspanin-2 
(ﬁ gure 2) This SNP is in linkage disequilibrium with 
intronic and untranslated region variants in TSPAN2 
(r²>0·3 in 1000 Genomes Project samples of European 
ancestry), but is located in a DNA sequence immediately 
adjacent to TSPAN2 that can be bound by several 
transcription factor proteins, including CTCF. This 
sequence is a promotor and enhancer site that is marked 
by histone modiﬁ cation and DNase hypersensitivity 
according to experimental data from ENDCODE and 
ROADMAP Epigenomics (appendix p 16),25,26 suggesting 
a potential role for rs12122341 in gene regulation. An 
intergenic SNP near rs12122341 has been reported to be 
associated with migraine,27 but the two SNPs are not in 
linkage disequilibrium (r²=0·03 in 1000 Genomes 
Project samples of European ancestry).
TSPAN2, the gene closest to rs12122341, is a member of 
the transmembrane 4 (tetraspanin) superfamily. This 
family of proteins can mediate signal transduction to 
regulate cell development, activation, growth, and motility. 
TSPAN2 knock-out mice have increased neuroinﬂ am-
mation, shown by activation of microglia and astrocytes 
with no eﬀ ect on myelination and axon integrity.28 Notably, 
TSPAN2 is highly expressed in artery tissue and whole 
blood cells (appendix p 16), which accords with the 
association we detected between TSPAN2 with large artery 
atherosclerosis stroke. Whether the association of 
rs12122341 is caused by the locus’ regulation of TSPAN2 or 
other nearby genes will need further functional assessment.
The additional locus that we identiﬁ ed as being 
associated with undetermined stroke (rs74475935) is in a 
gene-rich region with linkage-disequilibrium-paired 
SNPs (r²>0·1 in 1000 Genomes Project samples of 
African ancestry) of up to 4 Mb. Because of the small 
sample size for rs74475935 (610 cases) and the shortage 
of samples from people with African ancestry, studies 
with large samples from people of African descent will 
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Figure 2: Forest plot (A) and regional association plot (B) of rs12122341
Plot of eﬀ ect size of the association of rs12122341 with large artery atherosclerosis-related stroke across the 
case–control groups included in the ﬁ st and second stage analyses (A). Association of rs12122341 and other 
SNPs in the region with large artery atherosclerosis-related stroke (B). Point shading shows linkage 
disequilibrium (r²) to rs12122341 as calculated in 1000 Genomes Project Phase I European samples. Purple lines 
show recombination rate. EUR=European ancestry. AFR=African ancestry. HIS=Hispanic samples. EAS=east Asian 
ancestry. SAS=south Asian ancestry. 
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So far, only four loci—PITX2,4 ZFHX3,5 HDAC9,6 and 
12q24.127—have been repeatedly identiﬁ ed in GWAS of 
ischaemic stroke, all of which are subtype speciﬁ c except 
for 12q24.12. Although the 12q locus association was 
originally identiﬁ ed for all ischaemic stroke, our analysis 
suggests that it is probably speciﬁ c to small artery occlusion. 
These ﬁ ndings suggest that ischaemic stroke subtypes 
have distinct genetic signatures. Our analysis of genetic 
correlation across the traits also showed that the subtypes 
share subtle genetic associations (appendix p 17 and p 53). 
This ﬁ nding is supported by the results of another study, 
which identiﬁ ed genetic overlap between the large artery 
atherosclerosis and small artery occlusion subtypes.29 
Future eﬀ orts will help to clarify both the shared and 
unique genetic architectures within and between subtypes.
Until now, GWAS of ischaemic stroke subtypes have 
used far smaller sample sizes than studies of other 
complex traits. The SiGN study, the largest GWAS of 
ischaemic stroke so far, was well powered (75·1%) to 
detect common SNP subtype-speciﬁ c associations of 
larger eﬀ ect (MAF 25% and OR 1·2 in 3000 cases and 
30 000 controls) but was substantially less powered to 
identify lower frequency or lower eﬀ ect SNPs (13·8% 
power for MAF 10% and OR 1·2; 1·1% power for MAF 
25% and OR 1·1). Because of the almost linear relation 
that exists between sample size and discovered loci,30 and 
because large-scale GWAS in other complex traits have 
yielded hundreds of SNP-disease associations,31–33 
studying ischaemic stroke subtypes in larger samples 
will probably yield additional associated common 
variants. Furthermore, the implementation of whole 
genome sequencing studies of stroke will begin to test 
whether rare alleles in the population account for a 
substantial proportion of disease heritability.
The SiGN study has several other limitations. First, 
sample inclusion was heavily biased towards individuals of 
European descent; inclusion of non-European populations 
will improve power for locus discovery34 and will be 
especially informative for future ﬁ ne-mapping eﬀ orts.35 
Second, the inclusion of TOAST-based classiﬁ cation for 
samples in the second stage probably added phenotypic 
heterogeneity (ﬁ gure 1, appendix p 53), which potentially 
reduced power.21 Third, many of the participating studies 
within SiGN (especially the publicly available controls) had 
little or no stroke-speciﬁ c risk factor data available. Such 
data are key to disentangling potential gene–environment 
interactions. Future genetic studies of stroke will continue 
to face challenges related to the disease phenotype, 
including high prevalence of the disease (lifetime risk 
about 20%), its late onset (mainly in individuals >65 years), 
the contribution of other cardiovascular diseases and 
environment as causative factors, and diﬃ  culties of 
subtyping (in SiGN 12·6–22·3% of all cases analysed were 
ultimately classiﬁ ed as undetermined by CCS or TOAST).
Our use of CCS enabled identiﬁ cation of candidate SNPs 
that were not signiﬁ cant for the second stage follow-up in 
TOAST, including those SNPs at the TSPAN2 locus. This 
reﬁ nement might represent a reduction in phenotypic 
heterogeneity that CCS introduces through its capture of 
clinical stroke features, completeness of diagnostic 
investigations, and, where possible, classiﬁ cation of cases 
with diﬀ erent potential causes into the most probable 
causes. The association signal of the TSPAN2 locus 
identiﬁ ed with CCS was, however, improved by the 
inclusion of TOAST-classiﬁ ed samples, suggesting that 
making use of the genetic correlation underlying the 
subtyping methods and allowing for broader inclusion of 
cases, regardless of subtyping system, can lead to the 
discovery of more susceptibility loci. Further studies will 
help to establish whether the rich repository of 
individual-level data created through the use of the CCS 
will help to uncover novel phenotypes and thus reveal 
biological mechanisms and broaden the understanding of 
the genetic architecture in patients with stroke.
NINDS Stroke Genetics Network (SiGN) and International Stroke Genetics 
Consortium (ISGC) 
Sara L Pulit*, Patrick F McArdle*, Quenna Wong*, Rainer Malik*, Katrina 
Gwinn, Sefanja Achterberg, Ale Algra, Philippe Amouyel, Christopher D 
Anderson, Donna K Arnett, Ethem Murat Arsava, John Attia, Hakan Ay, 
Traci M Bartz, Thomas Battey, Oscar R Benavente, Steve Bevan, 
Alessandro Biﬃ  , Joshua C Bis, Susan H Blanton, Giorgio B Boncoraglio, 
Robert D Brown Jr, Annette I Burgess, Caty Carrera, Sherita N Chapman 
Smith, Daniel I Chasman, Ganesh Chauhan, Wei-Min Chen, Yu-Ching 
Cheng, Michael Chong, Lisa K Cloonan, John W Cole, Ioana Cotlarciuc, 
Carlos Cruchaga, Elisa Cuadrado-Godia, Tushar Dave, Jesse Dawson, 
Stéphanie Debette, Hossein Delavaran, Cameron A Dell, 
Martin Dichgans, Kimberly F Doheny, Chuanhui Dong, David J Duggan, 
Gunnar Engström, Michele K Evans, Xavier Estivill Pallejà, Jessica D Faul, 
Israel Fernández-Cadenas, Myriam Fornage, Philippe M Frossard, 
Karen Furie, Dale M Gamble, Christian Gieger, Anne-Katrin Giese, 
Eva Giralt-Steinhauer, Hector M González, An Goris, 
Solveig Gretarsdottir, Raji P Grewal, Ulrike Grittner, Stefan Gustafsson, 
Buhm Han, Graeme J Hankey, Laura Heitsch, Peter Higgins, 
Marc C Hochberg, Elizabeth Holliday, Jemma C Hopewell, 
Richard B Horenstein, George Howard, M Arfan Ikram, Andreea Ilinca, 
Erik Ingelsson, Marguerite R Irvin, Rebecca D Jackson, Christina Jern, 
Jordi Jiménez Conde, Julie A Johnson, Katarina Jood, 
Muhammad S Kahn, Robert Kaplan, L Jaap Kappelle, Sharon L R Kardia, 
Keith L Keene, Brett M Kissela, Dawn O Kleindorfer, Simon Koblar, 
Daniel Labovitz, Lenore J Launer, Cathy C Laurie, Cecelia A Laurie, 
Cue Hyunkyu Lee, Jin-Moo Lee, Manuel Lehm, Robin Lemmens, 
Christopher Levi, Didier Leys, Arne Lindgren, W T Longstreth Jr, 
Jane Maguire, Ani Manichaikul, Hugh S Markus, Leslie A McClure, 
Caitrin W McDonough, Christa Meisinger, Olle Melander, 
James F Meschia, Marina Mola-Caminal, Joan Montaner, 
Thomas H Mosley, Martina Müller-Nurasyid, Mike A Nalls, 
Jeﬀ rey R O’Connell, Martin O’Donnell, Ángel Ois, George J Papanicolaou, 
Guillaume Paré, Leema Reddy Peddareddygari, Annie Pedersén, 
Joanna Pera, Annette Peters, Deborah Poole, Bruce M Psaty, 
Raquel Rabionet, Miriam R Raﬀ eld, Kristiina Rannikmäe, Asif Rasheed, 
Petra Redfors, Alex P Reiner, Kathryn Rexrode, Marta Ribasés, 
Stephen S Rich, Wim Robberecht, Ana Rodriguez-Campello, Arndt Rolfs, 
Jaume Roquer, Lynda M Rose, Daniel Rosenbaum, Natalia S Rost, 
Peter M Rothwell, Tatjana Rundek, Kathleen A Ryan, Ralph L Sacco, 
Michèle M Sale, Danish Saleheen, Veikko Salomaa, 
Cristina Sánchez-Mora, Carsten Oliver Schmidt, Helena Schmidt, 
Reinhold Schmidt, Markus Schürks, Rodney Scott, Helen C Segal, 
Stephan Seiler, Sudha Seshadri, Pankaj Sharma, Alan R Shuldiner, 
Brian Silver, Agnieszka Slowik, Jennifer A Smith, Martin Söderholm, 
Carolina Soriano, Mary J Sparks, Tara Stanne, Kari Stefansson, 
O Colin Stine, Konstantin Strauch, Jonathan Sturm, Cathie LM Sudlow, 
Salman M Tajuddin, Robert L Talbert, Turgut Tatlisumak, Vincent Thijs, 
Gudmar Thorleifsson, Unnur Thorsteindottir, Steﬀ en Tiedt, 
Matthew Traylor, Stella Trompet, Valerie Valant, Melanie Waldenberger, 
Articles
184 www.thelancet.com/neurology   Vol 15   February 2016
Matthew Walters, Liyong Wang, Sylvia Wassertheil-Smoller, David R Weir, 
Kerri L Wiggins, Stephen R Williams, Dorota Wloch-Kopec, Daniel Woo, 
Rebecca Woodﬁ eld, Ona Wu, Huichun Xu, Alan B Zonderman, 
Australian Stroke Genetics Consortium, Cervical Artery Dissection and 
Ischemic Stroke Patients (CADISP) study, Cohorts of Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortium, Consortium 
of Minority Population genome-wide Association Studies of Stroke 
(COMPASS), METASTROKE consortium, Wellcome Trust Case-Control 
Consortium, Bradford B Worrall*, Paul IW de Bakker*, Steven J Kittner*, 
Braxton D Mitchell*, Jonathan Rosand*. *Contributed equally.
NINDS Stroke Genetics Network (SiGN) and International Stroke Genetics 
Consortium Writing committee Jonathan Rosand (chair), Braxton D Mitchell 
(co-chair), Hakan Ay, Paul I W de Bakker, Katrina Gwinn, Steven J Kittner, 
Arne Lindgren, James F Meschia, Sara L Pulit, Cathie L M Sudlow, 
Vincent Thijs, Daniel Woo, Bradford B Worrall. Steering committee 
Donna K Arnett, Oscar Benavente, John W Cole, Martin Dichgans, 
Raji P Grewal, Christina Jern, Jordi Jiménez Conde, Julie A Johnson, 
Steven J Kittner, Jin-Moo Lee, Christopher Levi, Arne Lindgren, 
Hugh S Markus, Olle Melander, James F Meschia, Kathryn Rexrode, 
Jonathan Rosand, Peter M Rothwell, Tatjana Rundek, Ralph L Sacco, 
Reinhold Schmidt, Pankaj Sharma, Agnieszka Slowik, Cathie L M Sudlow, 
Vincent Thijs, Sylvia Wasssertheil-Smoller, Daniel Woo, Bradford B Worrall.
Contributors
JR, BDM, HA, PIWdB, SJK, AL, JFM, SLP, CLMS, VT, DW, and BBW 
contributed to data collection and provided critical review of the 
manuscript. JR, BDM, HA, PIWdB, KG, SJK, AL, SLP, CLMS, VT, DW, 
and BBW made critical decisions regarding study design and conduct. JR, 
BDM, HA, PIWdB, KG, SJK, AL, SLP, CLMS, VT, DW, and BBW 
participated in literature search and writing of the paper. BDM, PIWdB, 
and SLP did the statistical analysis and data interpretation.
Declaration of interests
KG is an employee of NINDS. The other members of the writing 
committee declare no competing interests.
Acknowledgments
The SiGN study was funded by a cooperative agreement grant from the 
US National Institute of Neurological Disorders and Stroke, National 
Institutes of Health (U01 NS069208). The information about funding for 
each collection is reported in the appendix (pp 159–70).
References
1 World Health Organization. The top 10 causes of death. May 2014. 
http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed 
April 23, 2015).
2 Mozaﬀ arian D, Benjamin EJ, Go AS, et al. Heart disease and stroke 
statistics—2015 update: a report from the American Heart 
Association. Circulation 2014; 131: e29–322.
3 Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the 
primary prevention of stroke: a statement for healthcare 
professionals from the American Heart Association/American 
Stroke Association. Stroke 2014; 45: 3754–832.
4 Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants 
for atrial ﬁ brillation on chromosome 4q25 associate with ischemic 
stroke. Ann Neurol 2008; 64: 402–09.
5 Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence 
variant in ZFHX3 on 16q22 associates with atrial ﬁ brillation and 
ischemic stroke. Nat Genet 2009; 41: 876–78.
6 Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide 
association study identiﬁ es a variant in HDAC9 associated with 
large vessel ischemic stroke. Nat Genet 2012; 44: 328–33.
7 Kilarski LL, Achterberg S, Devan WJ, et al. Meta-analysis in more 
than 17,900 cases of ischemic stroke reveals a novel association at 
12q24.12. Neurology 2014; 83: 678–85.
8 Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of 
ischemic stroke and the contribution of previously reported candidate 
gene and genomewide associations. Stroke 2012; 43: 3161–67.
9 Meschia JF, Arnett DK, Ay H, et al. Stroke Genetics Network (SiGN) 
study: design and rationale for a genome-wide association study of 
ischemic stroke subtypes. Stroke 2013; 44: 2694–702.
10 Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more 
eﬃ  cient than replication-based analysis for two-stage genome-wide 
association studies. Nat Genet 2006; 38: 209–13.
11 Adams H, Bendixen B, Kappelle L, et al. Classiﬁ cation of subtype of 
acute ischemic stroke. Deﬁ nitions for use in a multicenter clinical 
trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 
1993; 24: 35–41.
12 Ay H, Benner T, Arsava EM, et al. A computerized algorithm for 
etiologic classiﬁ cation of ischemic stroke: the causative 
classiﬁ cation of stroke system. Stroke 2007; 38: 2979–84.
13 Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, 
Heuschmann PU. Epidemiology of ischemic stroke subtypes 
according to TOAST criteria: incidence, recurrence, and long-term 
survival in ischemic stroke subtypes: a population-based study. 
Stroke 2001; 32: 2735–40.
14 Arsava EM, Ballabio E, Benner T, et al. The causative classiﬁ cation 
of stroke system: an international reliability and optimization study. 
Neurology 2010; 75: 1277–84.
15 Ay H, Arsava EM, Andsberg G, et al. Pathogenic ischemic stroke 
phenotypes in the NINDS-Stroke Genetics Network. Stroke 2014; 
45: 3589–96.
16 Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, 
Reich D. Principal components analysis corrects for stratiﬁ cation in 
genome-wide association studies. Nat Genet 2006; 38: 904–09.
17 Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. 
Fast and accurate genotype imputation in genome-wide association 
studies through pre-phasing. Nat Genet 2012; 44: 955–59.
18 Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic 
variation from 1,092 human genomes. Nature 2012; 491: 56–65.
19 Francioli LC, Menelaou A, Pulit SL, et al. Whole-genome sequence 
variation, population structure and demographic history of the 
Dutch population. Nat Genet 2014; 46: 818–25.
20 de Bakker PIW, Ferreira MAR, Jia X, Neale BM, Raychaudhuri S, 
Voight BF. Practical aspects of imputation-driven meta-analysis of 
genome-wide association studies. Hum Mol Genet 2008; 17: R122–28.
21 McArdle PF, Kittner SJ, Ay H, et al. Agreement between TOAST 
and CCS ischemic stroke classiﬁ cation: the NINDS SiGN study. 
Neurology 2014; 83: 1653–60.
22 Holliday EG, Maguire JM, Evans T-J, et al. Common variants at 
6p21.1 are associated with large artery atherosclerotic stroke. 
Nat Genet 2012; 44: 1147–51.
23 Smith JG, Melander O, Lövkvist H, et al. Common genetic variants 
on chromosome 9p21 confers risk of ischemic stroke a large-scale 
genetic association study. Circ Cardiovasc Genet 2009; 2: 159–64.
24 Williams FMK, Carter AM, Hysi PG, et al. Ischemic stroke is 
associated with the ABO locus: the EuroCLOT study. 
Ann Neurol 2013; 73: 16–31.
25 Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, 
et al. Integrative analysis of 111 reference human epigenomes. 
Nature 2015; 518: 317–30.
26 Ward LD, Kellis M. HaploReg: a resource for exploring chromatin 
states, conservation, and regulatory motif alterations within sets of 
genetically linked variants. Nucleic Acids Res 2012; 40: D930–34.
27 Esserlind AL, Christensen AF, Le H, et al. Replication and 
meta-analysis of common variants identiﬁ es a genome-wide 
signiﬁ cant locus in migraine. Eur J Neurol 2013; 20: 765–72.
28 de Monasterio-Schrader P, Patzig J, Möbius W, et al. Uncoupling of 
neuroinﬂ ammation from axonal degeneration in mice lacking the 
myelin protein tetraspanin-2. Glia 2013; 61: 1832–47.
29 Holliday EG, Traylor M, Malik R, et al. Genetic overlap between 
diagnostic subtypes of ischemic stroke. Stroke 2015; 46: 615–19.
30 Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of 
GWAS discovery. Am J Hum Genet 2012; 90: 7–24.
31 Ripke S, Neale BM, Corvin A, et al. Biological insights from 
108 schizophrenia-associated genetic loci. Nature 2014; 511: 421–27.
32 Wood AR, Esko T, Yang J, et al. Deﬁ ning the role of common 
variation in the genomic and biological architecture of adult human 
height. Nat Genet 2014; 46: 1173–86.
33 Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and reﬁ nement 
of loci associated with lipid levels. Nat Genet 2013; 45: 1274–83.
34 Pulit SL, Voight BF, de Bakker PIW. Multiethnic genetic association 
studies improve power for locus discovery. PLoS One 2010; 5: e12600.
35 Zaitlen N, Paşaniuc B, Gur T, Ziv E, Halperin E. Leveraging genetic 
variability across populations for the identiﬁ cation of causal 












with  infarct volume or stroke etiology nor affected after neuronal  injury  in vitro or  in  two 
different  experimental  stroke models. When  used  to  discriminate  between  patients with 
acute IS and HCs this combination of miRNAs showed an unprecedented diagnostic utility for 
a blood‐based biomarker and outperformed multimodal CT in our sample. 






atherosclerosis‐related  stroke.  Four  previously  identified  loci,  HDAC9  for  large  artery 
atherosclerosis‐related  stroke, PITX2 and ZFHX3  for  cardioembolic  stroke, and 12q24 near 
ALDH2 for small‐artery stroke were confirmed. 






The number of studies  investigating blood‐based biomarkers  for  IS has grown 10‐fold over 




A  literature  search  in PubMed was queried on September 28, 2017, using  the  search  terms  “blood 
AND biomarker AND stroke”. 
A number of prerequisites have been  identified  for  the  implementation of  a blood‐based 
biomarker  test  into  clinical  routine.  The  concept  of  unmet  clinical  needs  illustrates  the 
primary  need  to  identify  a missing  or  inadequately  performing  component  in  a  standard 
process of care.53 It includes the recognition of the target group, of the limitations of current 
practice, and of desired outcomes as well as exclusion of alternatives such as optimization of 
current  practice.53  Identification  of  desirable  clinical  performance  criteria  such  as  clinical 
validity  and  diagnostic  accuracy will  guide  the  design  of  the  study  including  appropriate 
validation.54 The selection process for a biomarker (set) should then integrate understanding 
of  the biological processes  leading  to higher clinical performance and effectiveness of  the 
selected biomarker. Clinical  implementation also requires sufficient analytical performance 
of the biomarker test system including but not limited to limit of detection and quantitation, 




In  RNA‐Seq  Identifies  Circulating  miR‐125a‐5p,  miR‐125b‐5p  and  miR‐143‐3p  as  Potential 
Biomarkers  for  Acute  Ischemic  Stroke  we  primarily  aimed  at  identifying  biomarkers  to 




design  in  a  three‐step  approach with  independent  validation  and  replication  samples, we 
identified  three  platelet‐derived miRNAs, which  have  also  been  linked  to  phenotype  and 
function  of  vascular  smooth  muscle  cells56  and  endothelial  cells57  as  well  as  to 
angiogenesis.58,59  The  clinical  performance  of  the  set  of  these  three  miRNAs  was 
unprecedented for a blood‐based biomarker when differentiating patients with IS from HCs. 
The  diagnostic  utility  for  the  differentiation  of  patients with  IS  and  patients with  TIA,  an 
important differential diagnosis to IS at hospital arrival, was lower and may not be sufficient 
for answering  this question  in clinical  routine.  In  this study, we used qRT‐PCR,  the current 
gold  standard  for  quantifying miRNA  expression  levels. However,  using  different  isolation 
techniques,60 primer designs,61 and qPCR machines may  lead  to different  results between 
laboratories.  Due  to  the  confounding  effects  of  medication62  and  comorbidities63  our 
analysis included multivariate adjustment, which is difficult to accomplish in a clinical setting. 
Also,  to  date,  the  process  of  RNA  isolation  from  platelet‐poor  plasma  samples,  cDNA 
synthesis  and qPCR  takes  a minimum of  five hours  and  is  almost  always performed on  a 
group‐  and  not  individual‐based  level.  Emerging  other  techniques  include  the  single 
molecule array platform SIMOA, employing single detection of magnetic beads coupled  to 
miRNA  detection  probes,64  TORNADO,  a  technology  based  on  electrocatalytic  platinum 
nanoparticles,65  a  microchip‐based  double‐strand  ligation  assay,66  and  base‐stacking 
isothermal  amplification.67  All  four  approaches  quantify  miRNAs  levels  directly,  thereby 
saving time by skipping RNA isolation and cDNA synthesis, but are still in the developmental 
phase and have not been shown to be applicable in a clinical context. Hence, the identified 
miRNAs  are  biologically  linked  to  IS  and  show  a  promising  clinical  performance  for  an 
important clinical question with an existing gap in diagnostics. However, many confounders 




Correct  etiological  classification  of  patients  with  IS  leads  to  more  accurate  secondary 
prophylactic treatment and counsel. The widely used TOAST classification system categorizes 
approximately 30 % of patients with  IS  as  “undetermined”.15  Initial data on CCS not only 
suggested  its use as a web‐based research  tool, but also showed a promising reduction of 




and  sensitive  clinical  findings  and  technical  studies  is  not  sufficient  to  provide  accurate 
etiological classification eventually guiding secondary prophylactic treatment.  
To  date,  genetic  testing  is  only  performed  in  IS  patients with  suspected  rare mutations 
causing Mendelian  diseases  like  Fabry’s  disease.  Being  eligible  for  enzyme  replacement 
therapy,71 the  identification of these patients by genetic testing  leads to specific treatment 
and  improves their  longterm outcome. In contrast,  it remains unclear, which consequences 
should be drawn from the knowledge about an individual’s genetic polymorphisms. Whether 
assessing  the  genotype  could  assist  in  therapeutic  decisions  has  probably  best  been 
investigated for the question whether genotype‐guided compared to clinically guided dosing 
of warfarin  improves  patients’  safety  outcomes. Whereas  initial  studies  investigating  the 
outcome  parameter  time  within  therapeutic  range72,73  were  controversial,  a  recent 
multicenter  randomized  trial  revealed  results  in  favor  of  genotype‐guided  dosing.74  The 
identification  of  IS  subgroup‐specific  loci  has  not  led  to  the  implementation  of  genetic 
testing  in  a  broader  population  of  patients with  IS  yet.  Although  sequencing  costs  have 
dropped  significantly  in  recent  years,  the effect  sizes  for  subtype‐associations  appear  too 
small,  to  base  risk  stratification  or  etiological  classification  solely  on  polymorphisms. 
However,  the  identification  of  these  loci  has  also  prompted  experimental  studies 




tests  in stroke care.  In the  following paragraphs  I will present a selection of biomarkers to 
90  Discussion 
address  these  questions  combined  with  necessary  question‐specific  performance 
parameters, e.g. sensitivity and specificity, but also duration to result. 
Shortening the time between symptom onset and initiation of thrombolysis in patients with 
IS  is  associated  with  better  outcome.76  Currently,  neuroimaging  to  rule  out  intracranial 
bleeding  is the only technical study that  is required  in patients otherwise eligible  for rt‐PA 
administration.  Although  a  CT‐equipped  mobile  stroke  treatment  unit  has  been 
implemented  in  some  metropolitan  areas,77  its  application  in  rural  areas  is  unlikely.78 
Optimization of in‐hospital stroke care including hospital prenotification, premixing of rt‐PA 
and  reduced  door‐to‐imaging,  door‐to‐needle  time  can  be  reduced  to  a  median  of  20 
minutes.79  Enabling  thrombolysis  prior  to  hospital  arrival  by  means  of  a  blood‐based 
biomarker  test  that  differentiates  between  IS  and  HS  in  the  pre‐hospital  setting  would 
reduce the symptom‐to‐needle time even further. Applying point‐of‐care testing would lead 
to  immediate  output  of  results  and  simple  use. Given  the  risks  of  applying  thrombolytic 
treatment  in  patients  with  HS,  this  test  needs  to  exclude  all  patients  with  HS  (100  % 
sensitivity  for HS,  specificity  for  IS,  positive‐predictive  value  for  IS,  or  negative‐predictive 
value for HS) and identify a high proportion of patients with IS (high sensitivity for IS). Most, 
if not all studies have  focused on how to exclude patients with HS and  investigated serum 
levels  of  GFAP,  a marker  of  astrocytic  injury,  increasing  very  early  after  HS.21  However, 
shortly after symptom onset, when the benefit  from  thrombolysis  is  largest, or  in patients 
with smaller hemorrhage, serum  levels of GFAP are  low. Accordingly, applying a cut‐off  to 
rule out all patients with HS (100 % sensitivity for HS) leads to very low specificity for HS and 
sensitivity for IS.23 More favorable cut‐offs may be achieved using ultra‐sensitive assays like 
SIMOA  or by  combining GFAP with other  astrocytic markers  like  the  glutamate  aspartate 
transporter,  glutamine  synthetase,  aquaporin  4  or  ALDH1L1.80  Also,  combining  the  HS 
marker GFAP with  a marker  for  IS  could  yield  higher  sensitivity  for  IS  along with  100 % 
specificity  for  IS.  Early  biomarkers  of  IS  could  include  markers  of  platelet  aggregation, 
thrombus  formation,  or  hypoxia. With  improving  door‐to‐needle  and  symptom‐onset‐to‐




In patients with occlusions of  large  cerebral  arteries, MT has over  a  short period of  time 
become a mainstay in these patients’ care.7 Outcome is influenced by numerous parameters 




for  faster  potential  MT  and  accepting  delayed  thrombolytic  therapy  depends  on  these 
parameters but  also  on  the  early  identification  of  these  patients.81,82 However,  currently, 
there  is  no  predictor  of  occlusions  of  arteries  of  the  proximal  cerebral  circulation  in  the 
preclinical  setting.  In  this  context, blood‐based biomarkers  could be of value as  surrogate 
markers for thrombus size,  indicating  large vessel occlusions, and for the extent of  lost and 













associated  miRNAs  being  elevated  in  the  acute  phase  of  IS.  Future  analyses  will  show 
whether  these or other platelet‐enriched miRNAs, e.g. miR‐223‐3p or miR‐126‐3p,62,87 are 
associated with large vessel occlusion in patients with IS.  
IS  is  one  of many  causes  of  acute  neurological  dysfunction.  In  addition  to HS,  these  also 
include  so‐called  stroke  mimics  and  include  migraine,  epileptic  seizures,  and  infections 







mimics). Given  the heterogeneity of diseases mimicking  stroke,  the  selection of a unifying 
biomarker for stroke mimics may be more challenging compared to the definition of a lower 
threshold of  a marker  for  IS. Accordingly, patients missing  this  lower  threshold would be 
excluded from thrombolytic treatment. The biomarker could  involve circulating endothelial 
cells89,90 or  any of  the already  specified markers  for  cerebral damage, oxidative  stress, or 
platelet activation. 
Although  IS  can  be  caused  by many  different  etiologies  categorized within  classification 
systems  like  TOAST  and  CCS,  the  clinically  most  relevant  question  with  therapeutic 
consequences  to  date  is  to  identify  patients  with  AF  as  they  benefit  from  oral 
anticoagulation. In contrast, patients with IS categorized as large vessel stroke, small‐artery 
occlusion,  and  undetermined  etiology  benefit  from  secondary  prevention  with  the 
antiplatelet  agent  acetylsalicylic  acid.91  Ongoing multicentric  randomized  trials,  RESPECT‐
ESUS, NAVIGATE‐ESUS,  and  ATTICUS  now  investigate whether  the  anticoagulating  agents 
Dabigatran, Rivaroxaban, or Apixaban, respectively,  in comparison to the antiplatelet agent 
acetylsalicylic  acid  show  longer  time  to  first  recurrent  stroke  also  in  patients with  recent 
embolic  stroke of unknown  source  (ESUS).  ESUS  is defined  as  a non‐lacunar brain  infarct 
without proximal arterial stenosis or cardioembolic sources92 and represents a subgroup of 
patients  formerly  classified  as  undetermined.  The  results  of  these  trials will  enhance  our 
understanding  about  the  potential  source  of  thromboembolism  in  the  individual  patient 
based  upon  which  patient  subgroup  benefits  from  anticoagulation  and  which  not.  The 
integration of  these  findings with new pathophysiological  concepts  like  the  thrombogenic 
atrial  substrate93  may  lead  to  new  approaches  using  blood‐based  biomarkers  to  define 
etiological subgroups of IS.  





lists  and  tables  of  numbers.  The  achievement  to monitor  heart  rate  and  blood  pressure 
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